This document contains information that is confidential and proprietary to ERYTECH Pharma. This information is being 
provided to you solely for the purpose of evaluating and/or conducting a clinical trial for ERYTECH Pharma. You may disclose 
the contents of this protocol only to study personnel under your supervision, your Independent Ethics Committe e/Institutional 
Review Board, or duly authorized representatives of regulatory agencies. The foregoing shall not apply to disclosure required by [CONTACT_17140]; however, you will give prompt notice to ERYTECH Pharma of any such disclosure.   
Eryaspase 
Protocol GRASPANC 2018-01 
A Randomized, Phase 3 Study of Eryaspase in Combination with 
Chemotherapy versus Chemotherapy Alone as Second -Line 
Treatment in Patients with Pancreatic Adenocarcinoma  
TRYbeCA -1 – TRial of erYaspase in pancreatic CAncer 
Protocol Number:  GRASPANC [ADDRESS_395051] Number:  2018 -000572- 15 
IND Number: 018886 
Coordinating Investigator s: Pascal Hammel, MD , PhD 
Hôpi[INVESTIGATOR_57055] – Clichy, Paris, [LOCATION_009]  
E-mail: [EMAIL_6271]  
Phone: +33 (0)1 40 87 56 14 
Manuel Hidalgo, MD, PhD  
W
eill Cornell Medicine – [LOCATION_001], NY, [LOCATION_003]  
Email: [EMAIL_6272]  
Phone: +[PHONE_6694]  
Sponsor:  ERYTECH Pharma  
60 avenue Rockefeller , [ZIP_CODE] Lyon, [LOCATION_009]  
Phone: [PHONE_6698] 44 38 
Version Number:  2.0 (Amended protocol), 14 December 2020 
Sponsor Contacts:  Linda Grummer  
Study Team Leader  
Email: [EMAIL_6273]  
Phone: +[PHONE_6695] 
Sophie Salesse  
S
tudy Team Leader  
Email: [EMAIL_6274]  
Phone: [PHONE_6699] 26 89  
Sponsor Medical Officer:  Iman El Hariry  
Chief Medical Officer  
Email: [EMAIL_6275]  
Phone: [PHONE_6700] [ADDRESS_395052]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395053] OF FIGURES  ....................................................................................................................... 9  
SPONSOR SIGNATURES  .......................................................................................................... 10  
COORDINATING INVESTIGATOR [INVESTIGATOR_320145]  ............................................................... 11  
INVESTIGATOR’S AGREEMENT  ........................................................................................... 12  
SYNOPSIS  ................................................................................................................................... 13  
SCHEDULE OF EVENTS .......................................................................................................... 24  
ABBREVIATIONS  ..................................................................................................................... 29  
1 INTRODUCTION  ........................................................................................................... 33  
1.1 Background ................................................................................................................... 33  
1.1.1  Pancreatic Cancer  ....................................................................................................... 33  
1.1.2  Tumor Cell Metabolism  ............................................................................................. 33  
1.1.3  Asparaginase .............................................................................................................. 34  
1.2 Clinical Experience with Eryaspase  .............................................................................. 35  
1.3 Eryaspase in the Treatment of Pancreatic Cancer  ......................................................... 35  
1.4 Study Rationale ............................................................................................................. 41  
1.5 Risk/Benefit Assessment  .............................................................................................. 41  
1.5.1  Known Potential Risks ............................................................................................... 41  
1.5.2  Known Potential Benefits .......................................................................................... 42  
1.5.3  Assessment of Potential Risks and Benefits  .............................................................. 43  
2 OBJECTIVES AND ENDPOINTS  ................................................................................. 44  
2.1 Primary Objective  ......................................................................................................... 44  
2.2 Secondary Objectives  .................................................................................................... 44  
2.3 Endpoints: ..................................................................................................................... 44  
3 STUDY DESIGN ............................................................................................................. 46  
3.1 Overall Design  .............................................................................................................. 46  
3.2 Number of Patients  ....................................................................................................... 49  
3.3 Scient ific Rationale for Study Design  ........................................................................... 49  
3.3.1  Choice of Chemotherapy (Control) ........................................................................... [ADDRESS_395054]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 3 of 119  3.5 End of Study Definition  ................................................................................................ 50  
4 STUDY POPULATION  .................................................................................................. 51  
4.1 Inclusion Criteria  .......................................................................................................... 51  
4.2 Exclusion Criteria  ......................................................................................................... 53  
4.3 Screen Failures  .............................................................................................................. 54  
5 STUDY TREATMENTS ................................................................................................. 56  
5.1 Descriptio n of Study Drugs .......................................................................................... 56  
5.1.1  Eryaspase  ................................................................................................................... 56  
5.1.2  Gemcitabine and Abraxane ........................................................................................ 56  
5.1.3  Irinotecan and 5-FU/Leucovorin ................................................................................ 56  
5.2 Dosage and Administration........................................................................................... 57  
5.2.1  Eryaspase  ................................................................................................................... 57  
5.2.2  Gemcitabine and Abraxane ........................................................................................ 57  
5.2.3  Irinotecan and 5-FU/Leucovorin ................................................................................ 58  
5.2.4  Guidelines for Treatment Discontinuation and Dose Modification  ........................... 58  
[IP_ADDRESS]  Dose Modification for Eryaspase ............................................................................ 59  
[IP_ADDRESS]  Dose Modifications for Chemotherapy (with or w ithout Eryaspase)  ..................... [ADDRESS_395055]  ................................................................. 69  
[IP_ADDRESS]  Management of Hypersensitivity Reactions with Eryaspase or Other Agents  ....... 69  
[IP_ADDRESS]  Management of Infusion/Transfusion Reactions  .................................................... 70  
[IP_ADDRESS]  Management of Diarrhea  ........................................................................................ 72  
5.3 Eryaspase Preparation/Handling/Storage/Accountability  ............................................. 73  
5.3.1  Acquisition and Accountability  ................................................................................. 73  
[IP_ADDRESS]  Acquisition .............................................................................................................. 73  
[IP_ADDRESS]  Accountability ......................................................................................................... 74  
5.3.2  Form ulation, Appearance, Packaging, and Labeling ................................................. 74  
5.3.3  Preparation  ................................................................................................................. 74  
5.4 Measures to Minimize Bias: Randomization and Blinding  .......................................... [ADDRESS_395056]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395057] to Follow- Up ......................................................................................................... 78  
6.4 Study Termination ........................................................................................................ 78  
7 STUDY ASSESSMENTS AND PROCEDURES  ........................................................... 80  
7.1 Screening Assessments and Procedures........................................................................ 80  
7.2 Randomization .............................................................................................................. 83  
7.3 Treatment Phase Assessments and Procedures  ............................................................. 83  
7.3.1  Assessments prior to Initiation of Treatment on Cycle  1 Day  1 ................................ 83  
7.3.2  Efficacy Assessments During the Treatment Phase ................................................... 84  
[IP_ADDRESS]  Radiological Disease Assessments  ......................................................................... 84  
[IP_ADDRESS]  Health Outcomes  ..................................................................................................... 84  
[IP_ADDRESS]  Pharmacokinetic and Pharmacodynamic Assessments  ........................................... 84  
[IP_ADDRESS]  Immunogenicity  ...................................................................................................... 84  
[IP_ADDRESS]  Biomarker Assessments  .......................................................................................... [ADDRESS_395058]-Study Subsequent Cancer Therapy .................................................................... 86  
7.5.2  Survival Follow- Up ................................................................................................... 86  
7.6 Efficacy Assessments  .................................................................................................... 86  
7.6.1  Radiological Disease Assessment and Evaluation of Response  ................................ 86  
[IP_ADDRESS]  Key Definitions ....................................................................................................... 87  
[IP_ADDRESS]  Other Considerations .............................................................................................. 89  
[IP_ADDRESS]  Measurement of Small Lesions on Follow -Up Scans ............................................. 89  
[IP_ADDRESS]  Response Criteria  .................................................................................................... 89  
[IP_ADDRESS]  Determination of Radiological Best Overall Response .......................................... [ADDRESS_395059]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 5 of 119  7.6.2  Health Outcomes  ........................................................................................................ 90  
7.6.3  Pharmacokinetic and Pharmacodynamic Assessments  .............................................. 91  
7.6.4  Immunogenicity  ......................................................................................................... 92  
7.6.5  Biomarker Assessments  ............................................................................................. 92  
[IP_ADDRESS]  Analysis of Tumor Tissues ..................................................................................... 92  
[IP_ADDRESS]  Analysis of Plasma Samples  ................................................................................... 92  
[IP_ADDRESS]  Pharmacogenetic Analysis  ...................................................................................... 93  
[IP_ADDRESS]  Sample Collection, Storage, and Shippi[INVESTIGATOR_007] ............................................................. 93  
[IP_ADDRESS]  Bioanalysis .............................................................................................................. 93  
[IP_ADDRESS]  Storage of Biological Samples for Potential Future Analysis  ................................ 93  
7.7 Adverse Events and Serious Adverse Events ............................................................... 94  
7.7.1  Definition of Adverse Events ..................................................................................... 94  
7.7.2  Definition of Serious Adverse Events  ........................................................................ 94  
7.7.3  Classification of Adverse Events  ............................................................................... 94  
[IP_ADDRESS]  Severity Grading ..................................................................................................... 94  
[IP_ADDRESS]  Causality Assessment .............................................................................................. 95  
[IP_ADDRESS]  Expectedness ........................................................................................................... 96  
7.7.4  Time Period and Frequency for Adverse Event Assessment and Follow -Up ........... 96  
7.7.5  Recording Adverse Events and Serious Adverse Events ........................................... 96  
7.7.6  Serious Adverse Event Reporting .............................................................................. 97  
[IP_ADDRESS]  Investigator Reporting Responsibilities for Serious Adverse Events ..................... 97  
[IP_ADDRESS]  Expedited Reporting and Investigator Safety Reports ............................................ [ADDRESS_395060]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 6 of 119  8 STATISTICAL CONSIDERATIONS........................................................................... 102  
8.1 Statistical Hypotheses  ................................................................................................. 102  
8.2 Sample Size Determination  ......................................................................................... 102  
8.3 Analysis populations ................................................................................................... 103  
8.4 Statistical Analyses  ..................................................................................................... 103  
8.4.1  Analysis of the Primary Efficacy Endpoint ............................................................. 103  
8.4.2  Analysis of the Secondary Endpoints ...................................................................... 103  
8.4.3  Other Aspects of the Efficacy Analyses .................................................................. 104  
8.4.4  Planned Interim Analyses  ........................................................................................ 104  
8.4.5  Subgroup Analyses .................................................................................................. 104  
8.4.6  Independent Data Monitoring Committee (IDMC) ................................................. [ADDRESS_395061] Keepi[INVESTIGATOR_007] ........................................................................ 111  
[IP_ADDRESS]  Data Collection and Management Responsibilities .............................................. 111  
[IP_ADDRESS]  Study Record Retention ........................................................................................ [ADDRESS_395062]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395063]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395064] 10% of Patients by [CONTACT_320177] - Safety Population ....... [ADDRESS_395065] 5% of Patients 
by [CONTACT_320177] – Safety Population ............................................... 40  
Table 5  ............ Overview of AEs Affecting >10% of Patients in the Pooled Safety Population . [ADDRESS_395066] of Laboratory Assessments  ........................................................................... 81  
Table 11  .......... EORTC QLQ- 30 Scales and Items [43]  .............................................................. [ADDRESS_395067]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395068] OF FIGURES  
Figure 1  ........... GRASPANC 2013-03: OS Kaplan -Meier Curves – Full ITT Population  ........... 38  
Figure 2  ........... GRASPANC 2013- 03: Best Response – Waterfall Plot (Percent Change from 
Baseline)  (Eryaspase + Chemotherapy)  ............................................................... 39  
Figure 3  ........... GRASPANC 2013 03: Best Response – Waterfall Plot (Percent Change from 
Baseline) (Chemotherapy  Alone) ........................................................................ [ADDRESS_395069]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 10 of 119  SPONSOR S IGNATURES  
 
Protocol ID:  GRASPANC 2018 -01 
Protocol Title:  A Randomized, Phase 3 Study of Eryaspase in Combination 
with Chemotherapy versus Chemotherapy Alone as Second- Line Treatment in Patients with Pancreatic 
Adenocarcinoma 
Protocol Version and Date:  Version 2.0 (Amended protocol), [ADDRESS_395070]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 11 of 119  COORDINATING  INVESTIGATOR  [INVESTIGATOR_12844] S 
 
Protocol ID:  GRASPANC 2018 -01 
Protocol Title:  A Randomized, Phase 3 Study of Eryaspase in Combination 
with Chemotherapy versus Chemotherapy Alone as Second- Line Treatment in Patients with Pancreatic 
Adenocarcinoma 
Protocol Version and Date:  Version 2.0 (Amended protocol), 14
th December  2020 
 
This amended  clinical study protocol has been reviewed and approved by: 
 
    
[CONTACT_320178], MD , PhD 
Coordinating Investigator  [INVESTIGATOR_320146], MD, PhD Coordinating Investigator  [INVESTIGATOR_320147] [ADDRESS_395071]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 12 of 119  INVESTIGATOR’S  AGREEMENT  
 
Protocol ID: GRASPANC 2018 -01 
Protocol Title:  A Randomized, Phase 3 Study of Eryaspase in Combination 
with Chemotherapy versus Chemotherapy Alone as Second- Line Treatment in Patients with Pancreatic 
Adenocarcinoma 
Protocol Version and Date: Version 2.0 (Amended protocol), [ADDRESS_395072] read the Protocol GRASPANC 2018-01, Version  2.0 (Amended protocol), 14th 
December  2020. I agree to abide by [CONTACT_125211]. I will conduct the study as 
outlined herein, in accordance with Good Clinical Practice (GCP) and the Declaration of Helsinki, and will comply with the obligations and requirements of clinical investigators and all 
other requirements listed in the International Council for  Harmonization (ICH) guideline for 
GCP.  
I agree to comply with all regulations regarding clinical research that apply in the country where I am based. I agree to comply with all legislatio n regarding protection of privacy that applies in 
the country where I am based. I understand that all information concerning eryaspase and this protocol is confidential, and I agree to not use this information for any purpose other than the evaluation and conduct of the clinical investigation without the prior written consent of ERYTECH Pharma.  
I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments. 
 
 
   
Signature   [CONTACT_320227]:  
   
 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395073]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 13 of 119  SYNOPSIS  
Study No.:  GRASPANC 2018 -01 
Title of Study: A Randomized, Phase  3 Study of Eryaspase in Combination with 
Chemotherapy versus Chemotherapy Alone as Second- Line Treatment in Patients with 
Pancreatic Adenocarcinoma  
Number of Study Centers:  approximately 100 study centers 
Phase of Development: 3 
Objectives:  
Primary Objective:  
To determine whether the addition of eryaspase to chemotherapy improves overall survival 
(OS) in second -line treatment of pancreatic adenocarcinoma compared to chemotherapy alone.  
Secondary Objectives:  
• To compare progression- free survival (PFS) between the two treatment arms.  
• To compare the objective response rate (ORR) and duration of response (DoR) between the two treatment arms.  
• To compare the disease control rate (DCR) between the two  treatment arms.  
• To evaluate the safety and tolerability of eryaspase in combination with chemotherapy 
versus chemotherapy alone .  
• To assess the effect of eryaspase on quality of life using the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire -Core 30 ( EORTC 
QLQ- C30). 
• To determine the pharmacokinetics of eryaspase.  
• To assess the immunogenicity of eryaspase in terms of the induction of anti-
asparaginase (ASNase) antibodies and neutralizing antibodies. 
• To evaluate the relationship of clinical outcome with relevant biomarkers and genetic changes present in tumor tissues and blood and/or serum samples.  
• To investigate the predictive relationship between the patient’s deoxyribonucleic acid 
(DNA) sequence variation, e.g. exploratory single nucleotide polymorphism [SNP] genotypi[INVESTIGATOR_320148] , and their response to combination treatment in 
terms of safety and tolerability (pharmacogenetics [PGx]).  
Endpoints : 
Primary Endpoint : 
Overall Survival (OS) in the ITT population.  
Secondary Endpoints : 
• Progression- free Survival (PFS),  
• Objective Response Rate (ORR)  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395074]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 14 of 119  • Duration of Response (DoR)  
• Disease Control R ate (DCR)  
• Pharmacokinetics and Pharmacodynamics 
• Anti- ASNase  antibodies 
• Adverse events AEs  
• Quality of life (QoL)  
• Biomarkers   
Trial Design/Methodology: 
This is an open -label, multicenter, randomized, P hase [ADDRESS_395075] measurable disease as defined by [CONTACT_320179] (RECIST  1.1) criteria. After provision of informed 
consent and conduct of screening assessments, patients who meet all inclusion and no exclusion criteria will be randomized in a 1:1 ratio to one of the following treatment arms  (see 
figure below ): 
• Arm A (investigational arm): eryaspase in combination with either 
gemcitabine/ Abraxane or irinotecan -based therapy ( FOLFIRI  [FOLinic acid -
Fluorouracil- IRInotecan regimen ] or Onivyde®/5- fluorouracil/leucovorin),  
• Arm B (control arm): gemcitabine/Abraxane or irinotecan -based therapy ( FOLFIRI or 
Onivyde/5-fluorouracil/leucovorin). 
 
 
The study will be divided into the following phases: 
• Screening Phase:  Screening assessments should occur within 3  weeks of 
randomization for assessment of the patient ’s overall eligibility.  
• Randomization Phase:  Randomization will occur after the patient has been 
determined to be eligible . 

ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395076]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 15 of 119  • Treatment Phase:  The first dose of chemotherapy will be administered within 3 days 
after randomization. Treatment will continue until objective disease progression, 
unacceptable toxicity , or the patient ’s withdrawal of consent. Unacceptable toxicity  is 
determined at inves tigator’s discretion, but as a guidance, unacceptable toxicity could 
consist of  prolonged Grade 3 or 4 toxicity lasting more than 2 weeks.  
• In the investigational treatment arm (Arm A), eryaspase will be administered on Day  1 
and Day  15 of each 4- week cycle in combination with chemotherapy. Eryaspase will 
be administered by [CONTACT_33980] (IV) infusion over approximately [ADDRESS_395077] and then followed by [CONTACT_320180]. 
• Chemotherapy will be one of the following two  treatm ent regimens:  
− Gemcitabine and Abraxane combination chemotherapy or 
− Irinotecan -based therapy : FOLFIRI (FOLinic acid -Fluorouracil-IRInotecan 
regimen) or Onivyde/5-fluorouracil (5- FU)/leucovorin (LV). 
• The choice of the chemotherapy regimen for a particular pa tient will be determined by 
[CONTACT_320181]-line setting. Thus: 
− If a patient received prior gemcitabine/A braxane in the first -line setting, then on 
disease progression, the patient will be assigned to FOLFIRI (or 
Onivyde/5- FU/LV) in the current study.  
− If a patient received prior irinotecan -based therapy ( FOLinic acid -Fluorouracil-
IRInotecan -Oxaliplatin; FOLFIRINOX), then  on disease progression,  the patient 
will be assigned to gemcitabine/Abraxane in the current study. 
• Follow-u p Phase:  Patients will be monitored for survival at 8 -week intervals. Patients 
who discontinue treatment for reasons other than disease progression will continue to 
be assessed radiologically every 8  weeks until disease progression , or until withdrawal 
from the study , or death. 
Randomization will occur through an interactive web response system (IWRS). Patients will be randomized in a 1:1 ratio to chemotherapy with or without eryaspase. Randomization will be stratified according to  the following factors:  
• Eastern Cooperative Oncology Group ( ECOG) performance status (0 or 1),  
• Chemotherapy regimen in this study (gemcitabine/A braxane or irinotecan -based 
treatment [FOLFIRI or its equivalent Onivyde/5- FU/LV ]), and 
• Time interval since initial diagnosis of advanced disease to date of randomization in 
the study ( <6 months or ≥6 months ). 
An Independent Data Monitoring Committee ( IDMC ) will be established to review safety and 
efficacy data at regular intervals, including the interim and final analyses.  
In addition, the safety of eryaspase in combination with irinotecan-based therapy or 
gemcitabine /Abraxane regimen will be reviewed by [CONTACT_320182] [ADDRESS_395078]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 16 of 119   
Safety and Efficacy Evaluations  
Assessments and timing of data collection are detailed in the Schedule of Events ( Table  1). 
Safety Evaluations 
Clinical and labor atory parameters and adverse events  will be assessed in all patients to 
evaluate disease status and toxicity. Patients will have safety assessments (laboratory tests, 
physical exams, vital sign s including temperature, heart rate, and blood pressure, 
electrocardiograms  [ECGs; to be performed  during screening and then as clinically indicated ], 
and performance status score) performed on Day  [ADDRESS_395079] dose of study treatment, or until start of a new anti -cancer treatment whichever is sooner . 
Efficacy Evaluations  
Tumor assessments utilizing thoraco-abdominal computed tomography (CT)/magnetic resonance imaging (MRI) scans will be repeated every [ADDRESS_395080] be collected in a de -identified manner, quality controlled, stored, 
and available for future review , including independent radiological review as necessary. 
Survival information will be collected by [CONTACT_648], follow- up visit, or medic al records review  
every 8 weeks  from the date of the EOT visit until the patient ’s death, until the patient is lost 
to follow-up, or until study closure. Survival follow- up information will include collection of 
any subsequent anticancer therapy received after discontinuation from study medication. 
Quality of life (QoL ) assessment ( EORTC QLQ -C30) will be performed, at  Day  1 of each 
cycle prior to dosing, at the end of treatment visit  and every 8 weeks during survival follow 
up. Pharmacokinetics, Pharmacodynamics, and Translational Research  
Where possible, blood and plasma samples will be collected in the eryaspase arm for 
pharmacokinetic ( PK) (ASNase  activity) and pharmacodynamic determination, and for 
immunogenicity evaluation. 
Blood/plasma samples for PK and pharmacodynamic assessments will be collected at the 
following time points of Cycles 1 and 3 of study treatment: Day [ADDRESS_395081]-infusion (at the 
Investigator’s d iscretion), and at Day  [ADDRESS_395082]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 17 of 119  and plasma concentration s of ASNase and amino acids . The sparse PK data will be combined 
with previous data as part of a Population PK (POP  PK) analysis.  
Samples for assessment of anti -L-ASNase antibodies and neutralizing antibodies will be 
collected pre-dose at Cycle 1 Day  1 and Day 15, at Day 1 of every second cycle thereafter,  
upon determination of disease progression and at the End of Treatment (EOT) visit, as 
specified in the Schedule of Events ( Table  1). 
Exploratory biomarker analyses will examine potential predictive biomarkers correlating with eryaspase acti vity. Tissue s ample s will be collected at study start. In addition,  blood/plasma 
samples for biomarker analysis will be collected from all patients at Cycle  1 Day  1 and 
Day 15, at Day  1 of every second cycle thereafter, upon determination of disease progression, 
and at the EOT  visit. 
A blood sample for pharmacogenetic (PGx) analysis will be obtained once during the study, preferably during the screening phase, for patients who consent to this optional procedure. 
Number of Patients : The target sample size is 482  patients.  
Criteria for Inclusion:  
A patient will be eligible for the study if all the following criteria are met: 
1. Must be [ADDRESS_395083] Stage III or  IV disease (see APPENDIX 1).  
4. Must have received one  line of systemic chemotherapy in the advanced setting with or 
without t argeted agents, immunotherapy, or radiotherapy for treatment of advanced 
pancreatic adenocarcinoma.  NOTE: patients whose disease progresses on, or within 3 
months of neo(adjuvant) chemotherapy may be considered eligible 
5. Must have radiological evidence of disease progression following most recent prior treatment, defined as a ppearance of any new lesion or increase of >20% of one or more 
existing lesions. 
6. Must have measurable lesion(s) per RECIST version  1.[ADDRESS_395084] (or 
MRI, if the patient is allergic to CT contrast media).  
• Measurable disease may be in the field of prior irradiation; however, at least 
[ADDRESS_395085] elapsed between the completion of radiation therapy and the 
baseline scan documenting disease status.  
• Bone disease is considered radiologically measurable only  if there is at least a 50% 
lytic component. 
NOTE:  Bone disease consisting of blastic lesion only is not measurable.  
7. Archival or fresh tumor tissue  must be available  for evaluating relevant biomarkers. 
Formalin -fixed paraffin -embedded [FFPE] block preferred, or a minimum of 
10 unstained FFPE slides of one archived block is required.  NOTE: if archival tissue is unavailable and an elective biopsy can’t be scheduled due to COVID, this will be waived. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395086]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 18 of 119  NOTE : Cytology samples from fine needle aspi[INVESTIGATOR_320149].  
8. Must have adequate performance status (see APPENDIX 2 and APPENDIX 3): 
a. ECOG Performance Status (PS) score of 0, or  
b. ECOG PS score one and score ≥80 on Karnofsky Performance Status (KPS) scale.  
NOTE:  Must have body mass index (BMI) ≥18.5  kg/m2 (obtained <[ADDRESS_395087] life expectancy of >12 weeks according to the investigator’s clinical 
judgment. 
10. Females of childbearing potential must have a negative pregnancy test at screening and 
additional negative pregnancy test prior to first dose . Males and females of 
childbearing potential must agree to use a highly effective method of contraception  
during treatment and for at least [ADDRESS_395088] dose of study treatment. These 
include, but not limited to: 
a. combined (es trogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation: 
i. intravaginal 
ii. transdermal  
b. progestogen-only hormonal contraception associated with inhibition of ovulation: i. injectable  
ii. implantable  
c. intrauterine device (IUD)  
d. bilateral tubal occlusion  
e. vasectomised partner  
f. sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments)  is intended . The true 
abstinence is  when this is in line with the  preferred and usual lifestyle of the 
patient. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception] 
g. males with partners of childbearing potential must agree to u se condoms  
NOTE:  Since an indirect interaction between components of the oral contraceptives  
and ASNase  cannot be ruled out, oral contraceptives are not considered acceptable as 
contraceptive methods in the current clinical trial.  A method other than oral 
contraception should be used in women of childbearing potential. 
NOTE:  All chemotherapeutic agents may be teratogenic and excreted in breast milk. 
Patients who are breast feeding should consider alternative methods. 
11. Must have adequate laboratory parameters at baseline (obtained <14  days prior to 
randomization). Laboratory parameters outside of th ese ranges that are deemed 
clinically insignificant should be discussed with the medical monitor: 
a. Absolute neutrophil count ≥1.5  x 109/L. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395089]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 19 of 119  b. Hemoglobin ≥9  g/dL . Patients with a baseline Hemoglobin ≥13 g/dL should be 
discussed with the medical monitor. 
c. Platelet count ≥100,000/mm3 (100 x 109/L). 
d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
≤2.5 x upper limit of normal (ULN) (≤[ADDRESS_395090] in presence of liver metastases ). 
e. Total bilirubin ≤  1.[ADDRESS_395091] . 
f. Serum creatinine within normal limits or calculated clearance >60  mL/min/1.73 m2 
for patients with serum creatinine levels above or below the institutional normal range.  
g. Acceptable coagulation parameters: plasma antithrombin  III >70% and fibrinogen 
≥1.5 g/L. 
h. Serum albumin ≥3.0 g/dL.  
12. Patients requiring biliary stent placement must have the  biliary stent placed >[ADDRESS_395092] read and understood the consent form and provided written informed consent. 
Criteria for Exclusion:  
A patient is not eligible to participate in the study if any of the following criteria are met:  
1. Resectable or borderline resectable pancreatic adenocarcinoma at the time of signing the informed consent. 
2. Histology other than pancreatic adenocarcinoma (for example, but not inclusive: neuroendocrine, adenosquamous, etc.). 
3. More than one  line of prior treatment in advanced or metastatic setting.  
4. Patient has experienced medically significant acute decline in clinical status including  
a. Decline in ECOG PS to >1 (or KPS <70) between baseline visit and within 72 hours prior to randomization. 
b. Weight loss of ≥10% during screening. 
5. Presence of active or symptomatic untreated central nervous system (CNS) metastases.  
NOTE:  Patients with asymptomatic or stable CNS metastases are eligible, provided 
that the CNS metastases are radiologically and clinica lly stable, and the patient is off 
high- dose steroid treatment for at least one  month prior to randomization.  
6. Prior radiotherapy to the only area of measurable disease.  
NOTE:  Patients must have completed treatment and recovered from all acute 
treatment- related toxicities prior to administration of the first dose of eryaspase or 
chemotherapy. 
7. Bone  as the only site of metastatic disease from pancreatic cancer (bone -only disease).  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395093]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 20 of 119  8. History of recent clinical pancreatitis, according to revised Atlanta criteria, within 
3 months of randomization. 
NOTE:  The revised Atlanta classification [1] requires that two or more of the 
following criteria be met for the diagnosis of acute pancreatitis: (a) abdominal pain 
suggestive of pancreatitis, (b) serum amylase or lipase level ≥[ADDRESS_395094], or (c) 
characteristic imaging findings using CT or MRI. 
9. Neurosen sory neuropathy > Grade  2 at baseline.  
10. Pregnancy or breastfeeding. 
11. History of infection with human immunodeficiency virus (HIV) and/or active infection 
with hepatitis  B or hepatitis C.  
NOTE:  Patients with unknown status of hepatitis B or C must be tested and declared 
negative before randomization . 
12. Hypersensitivity to any of the components of the chemotherapy or ASNase . 
NOTE:  Patients known to be homozygous for UGT1A1*[ADDRESS_395095] be 
screened for UGT1A1*[ADDRESS_395096] the initial irinotecan dose reduced if demonstrated t o be homozygous for the UGT1A1*28 allele. 
NOTE:  Patients assigned to the irinotecan/[ADDRESS_395097] 
dihydropyridine dehydrogenase deficiency (DPD). Patients whose DPD status is unknown at time of screening should be tested before enr ollment in the 
irinotecan/[ADDRESS_395098] received live or live attenuated vaccines within 3  weeks of 
randomization. 
14. History of other malignancies  
NOTE:  Adequately treated non- melanoma skin cancer or curatively treated in -situ 
cancer of the cervix may be eligible.  
NOTE:  Patients successfully  treated for other malignancies and are disease- free for at 
least 5 years  may be eligible . 
15. Any other severe acute or chronic condition /treatments  that may increase the risk of 
study participation including:  
a. History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra -
abdominal abscess within 6 months prior to randomization.  
b. Current or history within 6  months prior to randomization o f medically  significant 
cardiovascular disease including symptomatic congestive heart failure >[LOCATION_001] Heart Association (NYHA) Class II, unstable angina pectoris, clinically significant cardiac arrhythmia. 
c. Patients with pre -existing coagulopathy (e.g. hemophilia).  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395099]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 21 of 119  d. Psychiatric illness /social situations or any other serious uncontrolled medical 
disorders in the opi[INVESTIGATOR_2511] I nvestigator  that would limit compliance with study 
requirements.  
Investigational Product, Dosage and Mode of Administration:  
Eryaspase is a dispersion for infusion of homologous (allogeneic) erythrocytes encapsulating 
recombinant E.  coli L--ASNase , in a saline preservative solution. 
The dose of eryaspase is 100  U/Kg administered every two weeks (Day  1 and Day 15) until 
disease progression, unacceptable toxicity, or the patient’s withdrawal of consent.  
Eryaspase will be administered intravenously over approximately [ADDRESS_395100]  Chemo therapy  dose and mode of administration:  
Gemcitabine plus A braxane (albumin- bound paclitaxel)  administered on Days 1, 8, and 15 
of each 4 -week cycle as follows:  
• Abraxane (125 mg/m2) IV over 30- 40 minutes followed by 
• Gemcitabine (1000 mg/m2) IV over 30 minutes. 
Onivyde (irinotecan nanoliposomal) + 5 -FU/leucovorin  administered on Days  1 and 15 of 
each 4 -week cycle as follows:  
• Onivyde 70 mg/m2 IV over 90 minutes (recommended starting dose of Onivyde in 
patients homozygous for UGT1A1*28 is 50 mg/m2), 
NOTE:  The approved dose of Onivyde is based on the NAPOLI -1[36] trial, in which 
Onivyde was given at a dose of 80 mg/m2 (i.e. equivalent of 70 mg/m2 of irinotecan 
free base).  
• Leucovorin 400 mg/m2 IV over 30 minutes, and  
NOTE: Modifications to the leucovorin dose per sites standard administration protocol may be allowed in the study following approval from the medical monitor. 
• 5-FU 2400 mg/m
2 over 46 hours. 
FOLFIRI (irinotecan, 5 -FU, and leucovorin)  administered on Days  1 and 15 of each 4- week 
cycle as follows:  
• Irinotecan 180  mg/m2 IV infusion over 90 minutes  (recommended starting dose of 
irinotecan in patients homozygous for UGT1A1*28 is 150 mg/m2), 
• Leucovorin 400 mg/m² IV infusion over two  hours, 
NOTE:  Modifications to the leucovorin dose per sites standard administration protocol 
may be allowed in the study following approval from the medical monitor. 
• 5-FU 400 mg/m² IV bolus injection over 2-4 minutes, immediately following leucovorin infusion, and 
• 5-FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5-FU (Days  1 and 2, and Days 15 and 16). 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395101]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 22 of 119  Rationale for Sample Size Estimation:  
With a power of 88.4% and an overall one-sided type I error of 2.5% , and including one 
interim analysis  for efficacy with an O’Brien -Fleming -type stoppi[INVESTIGATOR_1877], a total of [ADDRESS_395102] once 261 (67%) 
events have been observed .  
Assuming a recruitment period of 26 months, a median overall survival in the control group of 
6.0 months , a 10% probability of droppi[INVESTIGATOR_320150], and a minimum 
follow -up of 9 months, the study size will be based on the recruitment of 482 patients.  
 
Analysis Populations:  
Intent to Treat (ITT) population: All patients randomized, irrespective of whether they 
receive study medication.  
Safety population (SP):  All randomized patients who receive at least one dose of study 
medication (eryaspase or chemotherapy). 
Per-Protocol (PP) population:  The PP population is a subset of the ITT population, and 
consists of all randomized patients who meet the major inclusion criteria and none of the 
major exclusion criteria and who receive at least one cycle of treatment.  
Interim and Final Analyses:  
This study will have one interim analysis for superiority after 67% of the initial targeted numbers of events are observed .  
Primary Analysis: 
The primary analysis will be the comparison of OS between the two  treatment arms in the ITT 
population using the one -sided stratified log -rank test, stratified for ECOG status, 
chemotherapy regimen, and time from diagnosis of advanced dis ease.  
Key Secondary Analyses:  
Progression- free survival (PFS) will be compared between the two  treatment arms using the 
same method of analysis as for OS.  
The following efficacy analyses will also be performed in the ITT population: 
• ORR, defined as the proportion of patients who achi eve objective tumor response 
(complete response [CR ] or partial response [PR]) per RECIST  1.1. Each patient ’s best 
overall response (BOR) will be summarized (CR, PR, stable disease [ SD], progressive 
disease [ PD], or unknown). 
• DCR (disease control rate), defined as the proportion of patients who achieve CR, PR 
and SD . 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395103]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 23 of 119  • DoR  will be evaluated in patients who achieve CR/PR. It will be measured from the 
time CR/PR (whichever is first recorded) is first met to until the first date that 
recurrence or PD is objectively documented. 
Extensive evaluation of the consistency of treatme nt effect for OS and PFS across the 
population as a whole will be undertaken by [CONTACT_320183], with displays in 
forest plots and p -values for interaction.  
All efficacy analyses will be repeated in the PP population.  
Confirmatory testing for the primary and secondary efficacy endpoints will be performed hierarchically (OS followed by [CONTACT_320184]) in order to account 
for multiplicity. Any statistically significant findings occurring below a non -significant result 
in the hierarchy will be considered as exploratory findings. 
Safety and tolerability of eryaspase in combination with chemotherapy versus chemotherapy 
alone will be assessed by [CONTACT_320185] (incidence, intensity, seriousness, and causal relationship of AEs to  the study drug , action taken following AE ), drug exposure (duration of 
treatment), dosing information/compliance, concomitant medications, clinical laboratory results, ECG findings, vital signs, physical examination, body weight, ECOG PS, and treatment an d study termination status data.  
 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395104]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 24 of 119  SCHEDULE OF EVENTS  
Table 1 Schedule of Events  
Study Procedures  Selection 
period  
(within 
3 weeks of 
Randomizati
on) Up to 
3 days 
prior to 
Cycle  1 
Day 1 Treatment (28 -day/4 -week cycles)  
Cycle 1, 2, 3…  
End of 
Treatment 
Visit  Follow -
Up every 
8 weeks  D1 
(+3 
days)1  
 
 D8 
 
 
  
D15 
(+ 3 
days)1  
 
 
 D21 
 D28 End of 
Cycle 
Evaluation 
(or D1 
subsequent 
cycle)  
Informed consent X         
Eligibility criteria  X  X       
Demography  X         
Medical history  X         
Pancreatic cancer disease history (including 
previous anti -cancer therapi[INVESTIGATOR_014])  X         
Physical exam (including height [screening 
only] and weight)  X  X  X  X X  
Vital signs (temperature, BP, and heart rate)  X  X  X  X X  
Performance status2 X  X  X  X X  
12-Lead ECG3 X  X   
Radiological assessments (CT or MRI)4 X  X (every 8 weeks [±3 days] from time of randomization until disease 
progression, or death)  
Randomization5  X        
QoL assessment (EORTC QLQ -C30)    X     X X6 
AEs/SAEs X (collected from time of informed consent until [ADDRESS_395105] study treatment or start of new anti -
cancer treatment, whichever is sooner)  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395106]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 25 of 119  Table 1 Schedule of Events  
Study Procedures  Selection 
period  
(within 
3 weeks of 
Randomizati
on) Up to 
3 days 
prior to 
Cycle  1 
Day 1 Treatment (28 -day/4 -week cycles)  
Cycle 1, 2, 3…  
End of 
Treatment 
Visit  Follow -
Up every 
8 weeks  D1 
(+3 
days)1  
 
 D8 
 
 
  
D15 
(+ 3 
days)1  
 
 
 D21 
 D28 End of 
Cycle 
Evaluation 
(or D1 
subsequent 
cycle)  
Concomitant medications  X (record all medications taken [ADDRESS_395107] study treatment  or 
start of new anti -cancer treatment, whichever is sooner ) 
Study Drug 
Blood phenotype7 X7         
Prescription with current weight    X8  X8     
Irregular antibody screening test (IAST)  X7  X9  X9     
IAST historical result if available  X         
Pre-eryaspase dose complete compatibility 
test   X10  X10     
Eryaspase administration    X  X     
Chemotherapy    Per standard of care    
Gemcitabine/abraxane    X X X     
Irinotecan -based regimen    X  X     
Biological Exams  
Hematology, biochemistry, and coagulation 
panels; CA19 -[ADDRESS_395108], for patients of childbearing 
potential13 X  X     X  
Tumor tissue (for biomarker analysis, mandatory) X         
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395109]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 26 of 119  Table 1 Schedule of Events  
Study Procedures  Selection 
period  
(within 
3 weeks of 
Randomizati
on) Up to 
3 days 
prior to 
Cycle  1 
Day 1 Treatment (28 -day/4 -week cycles)  
Cycle 1, 2, 3…  
End of 
Treatment 
Visit  Follow -
Up every 
8 weeks  D1 
(+3 
days)1  
 
 D8 
 
 
  
D15 
(+ 3 
days)1  
 
 
 D21 
 D28 End of 
Cycle 
Evaluation 
(or D1 
subsequent 
cycle)  
Pharmacogenetic (PGx) sample (optional)  X (once during the study, preferably during the screening phase)    
Plasma biomarkers  such as ctDNA, 
proteomics, and transcriptomics (central labs)    X18  X14   X  
Pharmacokinetic (ASNase activity) and 
pharmacodynamic (amino acid) sample (eryaspase arm only)   
X
15  X15     
Immunogenicity sample for anti -ASNase 
antibodies and neutralizing antibodies (eryaspase arm only)    
X
18  X14   X  
Survival follow- up         X16 
Subsequent anti -cancer treatments          X 
Abbreviations: D=Day; Rand=Randomization; BP=blood pressure; ECG=electrocardiogram; CT=computed tomography; MRI=magnetic resonance imaging; QoL=quality of life; EORTC QLQ -C30= European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core  30; AE=a dverse 
event; SAE=serious adverse event; IAST=irregular antibody screening test; CA19- 9=cancer antigen 19 -9; ctDNA=circulating tumor deoxyribonucleic acid; 
ASNase=asparaginase.  
1. There must be a minimum of 10 days between 2 eryaspase injections . 
2. Per Eastern Cooperative Oncology Group (ECOG)  /Karnofsky scales  (KPS (if required per ECOG score) only during screening and at Cycle 1 Day 1) 
(See APPENDIX 2  and APPENDIX 3). 
3. Performed during screening, and then as clinically indicated.  
4. Radiological assessment to be completed within 3  weeks of randomization and then every 8 weeks (±3  days) from time of randomization until disease 
progression , start of subsequent anti -cancer therapy  or until withdrawal from the study, or death, using the same method throughout. Tumor 
assessments will continue in patients, who  start new cancer treatment without evidence of disease progression Every effort should be made to adhere to 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395110]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 27 of 119  the evaluation schedule, irrespective of any treatment delays or modifications.  Bone and/or brain scans are to be repeated every 12 weeks if clinic ally 
indicated.  
5. Randomization performed via interactive web response system (IWRS) within [ADDRESS_395111] chemotherapy dose.  
6. During follow -up, questionnaire  is to be completed every 8 weeks.  
7. A complete RBC phenotype (including D, C, E, c, e,  K  and other  antigens  tested as per site practice), ABO blood group status, and Rhesus factor, all 
assessed on two  separate samples (can be collected on the same day), to be done as soon as possible but preferably at least [ADDRESS_395112] (IMP) Manual.   Historical results of IAST can be used 
at screening if known and available.  
8. Prescription form indicating the patient’s identifiers as well as his/her most r ecently collected weight, the Investigator recipi[INVESTIGATOR_320151], and the 
place and time of the delivery must be sent as soon as possible once the eryaspase infusion is scheduled, and at the latest [ADDRESS_395113] be completed within 72 hours prior to each eryaspase administration.  The results (of the previous infusion) will be provided to the Sponsor 
along with the prescription form prior to subsequent eryaspase infusion.  
10. In case of incompatibility, collection of an additional blood sample will be required for further investigation.  
11. Laboratory tests to be performed at local laboratory as follows:  
Hematology: Complete blood count with differential (hemoglobin, hematocrit, RBC count, white blood cell (WBC) count, neutroph ils, lymphocytes, 
monocytes, eosinophils, basophils, and platelet count).  
Biochemistry: Sodium, potassium, bicarbonate, calcium, ch loride, creatinine, albumin, ammonia, total bilirubin, alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, gamma glutamyl transferase, lactate dehydrogenase, glucose, urea, triglycerides, total cholesterol, amylase, 
lipase and uric acid; Coagulation parameters – fibrinogen, antithrombin III.  
Tumor marker: CA19 -[ADDRESS_395114] -infusion, and on Day  15 pre -dose.  
16. Survival  follow to be conducted  8 weeks after the patient’s End of  Treatment visit  by [CONTACT_648], visit, or medical records review every 8  weeks (±3  days) 
from  the date of the EOT visi t (or date of last dose of study medication  if patient is unable to come in due to declining health)  until patient’s death, los t 
to follow up, or study closure. Subsequent therapy should be collected during this follow -up.  
17. For patients under eryaspase arm, in addition to regular evaluation of liver function tests before treatment administration, patients will be monitored on weekly basis in the event of occurrence of ≥Grade 2 elevation of liver enzymes and bilirubin levels.  
18. Performed pre -dose Cycle  1 Day 1 and then pre -dose Day  1 of every second cycle thereafter i.e., Cycle 3 Day  1, Cycle  5 Day  1, upon determination of 
disease progression, or EOT, whichever is sooner.as clinically indicated.  
** Additional lab tests may be required (e.g., weekly monitoring per standard practice or label requirements should be followed)  and should be reported in 
the electronic Case Report Form (eCRF) if clinically significant.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395115]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395116]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395117] Term  Explanation  
AE Adverse event  
ALL  Acute lymphoblastic leukemia  
ALT  Alanine aminotransferase  
AML  Acute myeloid leukemia  
ANC  Absolute neutrophil count  
ANSM  Agence nationale de sécurité du médicament et des 
produits de santé  
ASCO  American Society for Cooperative Oncology  
ASN  Asparagine  
ASNase  Asparaginase  
ASNS  Asparagine synthetase  
ASNS  0/1+ Subgroup of patients with patients with low or no 
ASNS expression  
ASNS  2+/3+  Subgroup of patients with high ASNS expression  
AST  Aspartate amino transferase  
AT III Antithrombin  III 
BP Blood pressure  
BMI  Body Mass Index  
BOR  Best overall response  
CA19-[ADDRESS_395118]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395119]  
IB Investigator ’s Brochure  
ICF Inform ed Consent Form  
ICH International Council for  Harmonization  
ID Identification  
IDMC  Independent Data Monitoring Committee  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395120]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395121]  Lower limit of normal  
LV Leucovorin  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
mL Milliliter  
MRI  Magnetic resonance imaging  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
ND No disease  
NE Non-evaluable  
NYHA  [LOCATION_001] Heart Association  (classification)  
OR Objective response  
ORR  Objective response rate  
OS Overall survival  
PD Progressive disease  
PAC  Pancreatic adenocarcinoma  
PFS Progression -free survival  
PGx Pharmacogenetics  
PK Pharmacokinetic  
POP PK Population pharmacokinetic  
PP Per Protocol  
PR Partial response  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395122]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395123] Term  Explanation  
PS Performance status  
PVC  Polyvinyl chloride  
QA Quality assurance  
QC Quality control  
QoL Quality of life  
RBCs  Red blood cells (erythrocytes)  
RECIST  Response Evaluation Criteria in Solid Tumors  
RNA  Ribonucleic acid  
SA Short axis  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SD Stable disease  
SNP Single -nucleotide polymorphism  
SOE  Schedule of Events  
SP Safety population  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
TRALI  Transfusion -related acute lung injury  
TRYbeCA  TRial of erYaspase in pancreatic CAncer  
U Units  
UGT  Uridine 5' -diphosphate glucuronosyltransferase  
ULN  Upper limit of normal  
US [LOCATION_002]  
WBC  White blood cell  
5-FU 5-fluorouracil  
 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395124]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 33 of 119  1 INTRODUCTION  
1.1 BACKGROUND  
1.1.1 Pancreatic Cancer 
Pancreatic adenocarcinoma ( PAC) is one of the most aggressive and fatal malignancies, and is 
ranked as the seventh leading cause of cancer death. [2] The overall prognosis for PAC is poor, 
with a 5 -year survival rate of 7%. [3] This is attributable to the difficulty of diagnosing pancreatic 
cancer in the ear ly stages, poor tumor resectability, and poor response to chemotherapy.[4] 
Indeed, most patients with pancreatic cancer progress to either metastatic or locally advanced 
disease in the asymptomatic phase. [5] 
Current treatment strategies for non -resectable, metastatic disease focus on conventional 
cytotoxic therapi[INVESTIGATOR_014]. Established first -line treatment options include gemcitabine -based 
chemotherapy, either alone or in combination with nab- paclitaxel, or the FOLFIRINOX regimen 
(a combination of leucovorin [LV], 5- fluorouracil [5- FU], irinotecan , and oxaliplatin). [5] 
Gemcitabine treatment results in only modest improvements in overall survival (OS) and quality of life (QoL). [6] While the FOLFIRINOX regimen has demonstrated a robust clinical benefit 
compared with gemcitabine,[7] this regimen should only be considered for patients with good performance status (East ern Cooperative Oncology Group Performance Status [ECOG PS] 0 or 
1) due to considerable toxicity.[5 8] 
In the second- line setting, there remains a lack of consensus regarding the standard of care. 
Treatment options are dependent on the risk- benefit balance for the patient and the treatment 
received in the first line. [5] In 2017, treatment guidelines were updated to recommend that the 
combination of nanoliposomal irinotecan (Onivyde®) with fluoropyrimidine regimens (i.e., 
5-FU with LV) can be considered an active and tolerable treatment option in fit patients (ECOG 
PS ≥2) previously treated with gemcitabine -based therapy. [8 9]  This combination extended 
survival by 1.9 months compared with patients treated with 5-FU in combination with LV.[10] 
No formal recommendations are available for patients who have progressed on first- line 
FOLFIRINOX; although gemcitabine is widely used in this setting, disease control is only achieved in one in 5 patients. [11] The limited efficacy provided by [CONTACT_320186][INVESTIGATOR_320152]. [4] 
1.1.2 T
 umor Cell Metabolism  
Targeting tumor cell metabolism is one of the prospective therapeutic approaches.[12]  PAC is 
characterized by [CONTACT_320187], which enables tumor cells to 
proliferate in a nutrient-poor, hypoxic microenvironment. The acquisition of activating mutations in the oncogenic KRAS ( Kirsten rat sarcoma virus) gene, which are o bserved in more than 90% 
of PACs, is central to this process. [13] Mutations in KRAS mediate the reprogramming of 
metabolic pathways that allow continued cellular proliferation in the absence of nutrients required by [CONTACT_182815].[14 15] However, such reprogramming leads to dependence on  
metabolites that are utilized through non-canonical metabolic pathways, distinguishing these cells from normal cells. One such dependency is on the amino acid glutamine, which fuels anabolic metabolism and maintains redox balance with PAC cells. [16 17] Glutamine deprivation 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395125]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395126] results in 
suppression of PAC growth.[16] 
KRAS also regulates expression of amino acid transporters, which provide most of the biomass for growing cells.[18] This is despi[INVESTIGATOR_320153], which indicates that KRAS -mediated regulation of amino acid transporters is vital for tumor 
growth. In pancreatic cancer, KRAS has been shown to regulate macropi[INVESTIGATOR_320154], yielding amino acids including glutamine and asparagine that may then enter the tricarboxylic acid cycle.[19]  
Although glutamine is important for many cellular processes, including anaplerosis and lipid/nucleotide synthesis through its catabolism to glutamate, asparagine is the only amino acid that requires glutamine for de novo synthesis. A non- essential amino acid, asparagine is 
synthesized from glutamine and aspartic acid by [CONTACT_182816] (ASNS). [20] 
Enhanced ASNS expression is a mechanism through which PAC cells adapt to hypoxia and glucose deprivation.[21] ASNS protects PAC cells from apoptosis induced by [CONTACT_320188]/SAPK activation. [21] 
Further more , it has also been demonstrated that KRAS, t hrough ATF4  regulation, adapts amino 
acid uptake and asparagine biosynthesis.[22]  As KRAS activation increases dependency on 
glutamine, knock-down of KRAS in low glutamine conditions results in poor clinical outcome. [22] Expression of ASNS – a target of ATF4 – has been identified as a key regulator of 
cancer cell proliferation , and contributes to apoptotic suppression, protein biosynthesis, and 
mTOR pathway activation.[22] Together, the modulation of glutamine and of asparagine levels leads to  a critical vulnerability of PAC  cells, which may be exploited in cancer therapeutic s. 
1.1.3 A
 sparaginase 
Asparaginase is a key component of multi-agent chemotherapy used in the treatment of childhood acute lymphoblastic leukemia (ALL). In ALL, as leukemic cells lack ASNS, ASNase exerts its anti -tumor effect through depletion of serum asparagin e by [CONTACT_320189]. [20] This starves susceptible cells of asparagine required for 
protein synthesis, which results in cell cycle arrest and, ultimately, apoptosis.[20 23] As glutamine also acts as a substrate for the enzyme,[24] ASNase treatment also  depletes serum 
glutamine levels, contributing further  to cell growth inhibition. [20] 
Several in vitro  studies have demonstrated that reductions in both aspara gine and glutamine 
levels are associated with inhibition of the mTOR pathway , which results in suppression of 
ribosomal protein synthesis.[25]  Early experiments utilizing pancreatic cell lines demonstrated 
that inhibition of protein synthesis by [CONTACT_320190].[26] More recently, in cell lines expressing high levels of ASNS, glutamine was demonstrated to maintain  the viability of cells in  asparagine-deprived 
medium. [27] This suggests that glutaminase activity is an important component of the anti -tumor 
effect of ASNase , especially agai nst tumors with high ASNS expression.[27] 
Despi[INVESTIGATOR_320155], clinical studies in solid tumors have been limited due to the 
challenge of a narrow therapeutic index for ASNase. Excessive toxicity of native and pegylated ASNase (peg -ASNase) formulations has been observed in clinical studies of solid tumors 
(pancreatic, ovarian) and multiple myeloma. [28-30] Indeed, a recent phase [ADDRESS_395127]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 35 of 119  peg-ASNase in combination with gemcitabine in patients with metastatic solid tumors and 
lymphoma was terminated early due to toxicity. [31] 
1.2 CLINICAL EXPERIENCE WITH ERYASPASE  
Encapsulation of ASNase within RBC s through a proprietary process is a novel approach to the 
delivery of ASNase at biologically effective doses with reduced propensity for toxic effects. The 
encapsulated ASNase remains bi ologically active , with a half- life of approximately two 
weeks.[32] It has been demonstrated that encapsulation has no effect on the permeability of RBCs to asparagine. [33] Thus, asparagine is actively transported across a concentration gradient 
into the RBC where it is de -aminated into aspartic acid and ammonia, depleting the serum of 
asparagine. It is postulated that the same process occurs with glutamine.  
Encapsulation prevents the rapid degradation of ASNase in the blood, thus prolonging activity, and limits exposure to the immune system, thus impeding its intrinsic immunogenicity, and in 
particular hypersensitivity reactions. [32] 
To date, five clinical tria ls have been conducted with eryaspase in pediatric and adult patients 
with ALL and acute myeloid leukemia (AML), and two  clinical trials have been conducted in 
pancreatic cancer. The total number of patients treated thus far in the eryaspase clinical trial  
program is 307, as of a cut -off date of [ADDRESS_395128] two  prior lines of therapy. Twelve patients received a single administration of 
eryaspase as mono therapy (25, 50, 100, or 150 U/Kg ). No  dose- limiting toxicity was reported. 
The recommended P hase two dose was determined to be 100 U/Kg  every two  weeks.[34]  [35] 
GRASPANC 2013 -03, a phase 2 trial in advanced PAC, was completed in 2017. This was a 
multicenter, open -label study investigating eryaspase in combination with gemcitabine or 
mFOLFOX6 (modified FOLinic acid-Fluorouracil- Oxaliplatin -6 regimen) as second -line 
treatment in patients with metastatic PAC. Patients were randomized in a 2:1 ratio to either 
eryaspase plus chemotherapy or chemotherapy alone, and were stratified according to chemotherapy regimen. The co-primary endpoints were progression- free survival (PFS) and 
overall survival (OS) in patients with low or no ASNS expression (ASNS  0/1+). Secondary 
endpoints included PFS and OS in the Intent to Treat (ITT) and high- ASNS expression 
(ASNS  2+/3+) populations, objective response, and toxicity. It should be noted that t he study 
was not powered for the co-primary endpoints of PFS and OS. The conclusions regarding the 
efficacy of eryaspase when used in combination with gemcitabine or mFOLFOX6  chemotherapy 
in relation to these endpoints was to be based  on observed hazard ratio (HR), with the study 
being considered positive if the HR for OS or f or PFS was <0.85. 
A total of 141  patients were randomized , 95 to eryaspase plus chemotherapy and 46 to 
chemotherapy alone. The majority of patients (~90%) received gemcitabine during the study. Baseline demographics and disease characteristics were general ly well -balanced between 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395129]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 36 of 119  treatment arms. Median age (range) was 63  years (37 –84) in the eryaspase arm compared with 
63 years (43 –80) with chemotherapy alone. 
Both co-primary endpoints were met in the ASNS 0/1+ subgroup ( eryaspase, n = 66; control, 
n = 32), with HRs  of 0.67 for PFS and 0.63 for OS , Table 2. 
Table 2 Key Efficacy Outcomes in the ITT Population and ASNS Subpopulations 
in GRASPANC 2013 -03 
 Overall Survival (OS)  
 ITT ASNS 0/1+  ASNS 2+/3+  
 Eryaspase 
+ Chemo -
therapy  
(95) Chemo -
therapy 
Alone  
(46) Eryaspase 
+ Chemo -
therapy  
(66) Chemo -
therapy 
Alone  
(32) Eryaspase + 
Chemo -
therapy  
(29) Chemo -
therapy 
Alone  
(14) 
Event rate, N (%)  82 (86.3)  42  (91.3)  55 (83.3)  28 (87.5)  27 (93.1)  14 (100.0) 
OS (weeks), 
Median (95%  CI)  26.1 
(
21.0, 28.9)  19.0 
(13.0, 21.7)  27.0 
(22.3, 31.1)  21.3 
(13.0, 31.0)  21.0 
(14.9, 29.4)  11.9 
(6.9, 19.7) 
HR (95%  CI) 0.60 (0.41, 0.87)  0. 63 (0.39, 1.01)  0.52 (0.26, 1.04)  
Log-Rank p -value  0.008  0. 056 0.063  
OS rate at 
24 weeks  56.2%  3 5.8%  59.8%  46.0%  48.1%  14.3%  
 
 Progression -Free Survival (PFS)  
 ITT ASNS 0/1+  ASNS 2+/3+  
 Eryaspase 
+ Chemo -
therapy  
(95) Chemo -
therapy 
Alone  
(46) Eryaspase 
+ Chemo -
therapy  
(66) Chemo -
therapy 
Alone  
(32) Eryaspase + 
Chemo -
therapy  
(29) Chemo -
therapy 
Alone  
(14) 
Event rate, N (%)  70 (73.7)  36  (78.3)  50 (75.8)  23 (71.9)  20 (69.0)  13 (92.9)  
PFS (weeks), 
Median (95%  CI) 8.6 
(
7.6, 14.6) 6.9 
(6.0, 7.6)  8.6 
(7.6, 14.6) 7.6 
(6.1, 16.3) 8.0 
(7.0, 14.9) 6.0 
(4.4, 6.9)  
HR (95%  CI) 0.56 (0.37, 0.84)  0. 67 (0.40, 1.12)  0.38 (0.18, 0.83)  
p-value  0.005  0. 127 0.015  
PFS rate at 
24 weeks  18.7%  5. 8% 20.4%  9.0%  14.3 0% 
 
 Objective Response Rate (ORR)  
 ITT ASNS 0/1+  ASNS 2+/3+  
 Eryaspase 
+ Chemo -
therapy  
(95) Chemo -
therapy 
Alone  
(46) Eryaspase 
+ Chemo -
therapy  
(66) Chemo -
therapy 
Alone  
(32) Eryaspase + 
Chemo -
therapy  
(29) Chemo -
therapy 
Alone  
(14) 
Response rate, % 
(95%  CI) 12 (12.6)  
(
6.7, 21.0) 3 (6.5) 
(1.4, 17.9) 10 (15.2)  
(7.5, 26.1) 3 (9.4) 
(2.0, 25.0) 2 (6.9)  
(0.8, 22.8) 0 
(0.0, 23.2) 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395130]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 37 of 119  Table 2 Key Efficacy Outcomes in the ITT Population and ASNS Subpopulations 
in GRASPANC 2013 -03 
SD 34 (35.8)  8 (17.4)  21 (31.8)  7 (21.9)  13 (44.8)  1 (7.1) 
PD 42 (44.2)  31  (67.4)  32 (48.5)  18 (56.3)  10 (34.5)  13 (92.9)  
NE 7 (7.4) 4  (8.7) 3 (4.5) 4 (12.5)  4 (13.8)  0 
 
 Disease Control Rate (DCR) 
 ITT ASNS 0/1+  ASNS 2+/3+  
 Eryaspase 
+ Chemo -
therapy  
(95) Chemo -
therapy 
Alone  
(46) Eryaspase 
+ Chemo -
therapy  
(66) Chemo -
therapy 
Alone  
(32) Eryaspase + 
Chemo -
therapy  
(29) Chemo -
therapy 
Alone  
(14) 
DCR 
(CR+PR+SD), % 
(95%  CI) 46 (48.4)  
(
38.0, 58.9)  11 (23.9)  
(12.6, 38.8)  31 (47.0)  
(34.6, 59.7)  10 (31.3)  
(16.1, 50.0)  15 (51.7)  
(32.5, 70.6)  1 (7.1) 
(0.2, 33.9) 
OS: overall survival; ITT: Intent to Treat; ASNS: asparagine synthetase; CI: confidence interval; HR: hazard 
ratio; PFS: progression -free survival; ORR: objective tumor response rate; SD: stable disease; PD: progressive 
disease; NE: Non -evaluable (no follo w-up scans [4 consent withdrawal; 4 randomized but not treated; 1 fatal 
event; 1 target lesions unassessed; 1 treated but discontinued treatment before follow -up scans]; NE was similar 
between Investigator  and independent review); DCR: disease control rate ; CR: complete response; PR: partial 
response.  
Response was determined per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria, based on 
independent radiological review.  
In the ITT population, OS was statistically significantly longer in the eryaspase arm compared to the chemotherapy arm alone. M edian OS  improved from 19.0 weeks in the control arm to 
26.1 weeks in the eryaspase arm , with an HR of 0.60 (95% CI:  0.41, 0.87; stratified log rank 
p = 0.008), Table [ADDRESS_395131]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 38 of 119   
Figure 1 GRASPANC 2013-03: OS Kaplan- Meier Curves – Full ITT Population 
The objective response rate was also higher in the eryaspase arm (12.6%) compared to the 
control arm (6.5%), as assessed by [CONTACT_320191]. Notably, there was one 
patient who achieved complete response in the eryaspase arm, Figure 2 and Figure 3 . Similarly, 
the disease control rate ( DCR) was also higher in the eryaspase arm (48.4% compared with 
23.9% in the control arm). 

ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395132]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 39 of 119   
Figure 2 GRASPANC 2013- 03: Best Response – Waterfall Plot (Percent Change from 
Baseline) (Eryaspase + Chemotherapy)  
 
Figure 3 GRASPANC 2013 03: Best Response – Waterfall Plot (Percent Change from 
Baseline) (Chemotherapy Alone)  

ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395133]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 40 of 119   
Adverse events (AEs , Table 3) and serious adverse events ( SAEs, Table 4) were slightly more 
frequent in the eryaspase arm; however, AEs resulting in treatment discontinuation  and fatal 
outcomes were less frequent  in the eryaspase arm. The safety profile of eryaspase added to 
chemotherapy revealed no unexpected findings, and eryaspase did not appear to add to the 
toxicity of chemotherapy. 
Table [ADDRESS_395134] 10% of Patients by [CONTACT_320177] - Safety Populatio n 
Preferred Term  Eryaspase +Chemotherapy  
(N = 93)  Chemotherapy Alone  
(N = 44)  
Patients with at least one 
Adverse Event, n  (%) 86 (92.5)  42 (95.5)  
Asthenia  44 (47.3)  24 (54.5)  
Nausea  40 (43.0)  20 (45.5)  
Thrombocytopenia  40 (43.0)  16 (36.4)  
Anemia  30 (32.3)  16 (36.4)  
Vomiting  30 (32.3)  10 (22.7)  
Diarrhea  20 (21.5)  11 (25.0)  
Neutropenia  23 (24.7)  7 (15.9)  
Decreased appetite 11 (11.8)  13 (29.5)  
Pyrexia  15 (16.1)  9 (20.5)  
Fatigue  10 (10.8)  5 (11.4)  
Stomatitis  12 (12.9)  3 (6.8)  
Positive IAST 14 (15.1)  0 
MedDRA: Medical Dictionary for Regulatory Activities; IAST: Irregular antibody screening test.  
The Safety population includes all randomized patients who received at least [ADDRESS_395135] 5% of 
Patients by [CONTACT_320177] – Safety Population  
Preferred Term  Eryaspase + Chemotherapy  
(N = 93)  Chemotherapy Alone  
(N = 44)  
Patients with at least one SAE, 
n (%) 42 (45.2)  22 (50.0)  
General physical health 
deterioration 7 (7.5)  4 (9.1)  
Abdominal pain 4 (4.3)  1 (2.3)  
Gastrointestinal hemorrhage 2 (1.1)  3 (6.8)  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395136]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 41 of 119  Jaundice  3 (3.2)  1 (2.3)  
MedDRA: Medical Dictionary for Regulatory Activities: SAE: Serious adverse event.  
The Safety population includes all randomized patients who received at least one dose of study drug.  
1.4 STUDY RATIONALE  
PAC is characterized by [CONTACT_320192], su ch as constitutive activation of KRAS 
signaling, that utilize asparagine and glutamine to circumvent the hypoxic and nutrient-poor 
tumor microenvironment. Perturbation of these pathways through deprivation of glutamine and asparagine results in loss of cel l viability.  
The potential benefit of ASNase therapy in PAC has been explored  previously; however, these 
studies were stopped early due to the excessive toxicity of the ASNase. [28] 
In the P hase 2 GRASPANC 2013 -03 study, eryaspase demonstrated clinical benefits in terms of 
OS, PFS, and objective response rate ( ORR) in the second- line treatment of metastatic PAC. The 
study met its primary endpoints, and the benefits of eryaspase (in terms of OS an d PFS) reached 
statistical significance in the ITT population.  
Given the results of this  Phase 2, proof-of-concept study, eryaspase has the potential to add to the 
limited treatment options available for  second -line PAC. 
1.5 RISK/BENEFIT ASSESSMENT  
1.5.1 Known  Potential Risks  
Eryaspase is a combination of two recognized products, RBCs and ASNase, whose safety profiles are well documented. Thus, the potential toxicity of eryaspase may arise from 3  main 
mechanisms: ASNase, RBCs, or a combination of the two components. 
Please refer to the investigator’s Brochure  (IB)  for additional details. 
To date, there have been [ADDRESS_395137] been conducted in PAC, with eryaspase administered to 
104 pa tients. Table 5 shows the adverse events reported in >10% of patients in the combined 
eryaspase-treated populations ( ALL, AML, PAC), regardless of severity or attribution to 
treatment.  
In the P hase 2 GRASPANC 2013 -03 study, the safety profile of eryaspase added to 
chemotherapy revealed no unexpected findings, and eryaspase did not appear to add to the toxicity of chemotherapy. 
Table 5 Overview of AEs Affecting >10% of Patients in the Pooled Safety 
Population 
Preferred Term  All Patients  
N = [ADDRESS_395138] one AE, n (%)  303 (98.7)  
Thrombocytopenia  168 (54.7)  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395139]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 42 of 119  Table 5 Overview of AEs Affecting >10% of Patients in the Pooled Safety 
Population 
Preferred Term  All Patients  
N = 307  
Anemia  131 (42.7)  
Neutropenia  119 (38.8)  
Asthenia  116 (37.8)  
Leukopenia  100 (32.6)  
Pyrexia  92 (30.0)  
Stomatitis  90 (29.3)  
Nausea  89 (29.0)  
Transaminases increased  84 (27.4)  
Lymphopenia  72 (23.5)  
Diarrhea  71 (23.1)  
Hypokalemia 68 (22.1)  
Febrile bone marrow aplasia 67 (21.8)  
Abdominal pain 66 (21.5)  
Vomiting  63 (20.5)  
Antithrombin III decreased  62 (20.2)  
Gamma -glutamyl transferase (GGT) increased  62 (20.2)  
Hypoalbuminemia  62 (20.2)  
Musculoskeletal pain  61 (19.9)  
Hyperbilirubinemia 54 (17.6)  
Hyperglycemia 52 (16.9)  
Constipation  48 (15.6)  
Lipase increased  45 (14.7)  
Hyponatremia  41 (13.4)  
Decreased appetite 40 (13.0)  
Drug hypersensitivity  39 (12.7)  
Edema  35 (11.4)  
General physical health deterioration  34 (11.1)  
Febrile neutropenia  32 (10.4)  
Headache  30 (9.8)  
Peripheral neuropathy  30 (9.8)  
 
1.5.[ADDRESS_395140]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 43 of 119  The potential benefit for patients can be measured in terms of improvements in quality of life 
(QoL), OS , and PFS, factors associated with improved tumor control. The GRASPANC 2013-03 
study evaluated eryaspase in combination with chemotherapy in the second- line treatment of 
PAC. This study demonstrated improved OS and PFS in the ITT population, with an accept able 
tolerability profile.  
1.5.3 A ssessment of Potential R isks and B enefits  
The potential benefit of ASNase therapy in PAC has been explored  previously; however, these 
studies were stopped early due to the excessive toxicity of the ASNase. [28] 
In the P hase [ADDRESS_395141]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 44 of 119  2 OBJECTIVES AND ENDPOINTS  
2.1 PRIMARY OBJECTIVE 
The primary objective of this study is to determine whether the addition of eryaspase to 
chemotherapy improves overall survival (OS) in second -line treatment of p ancreatic 
adenocarcinoma compared to chemotherapy alone.  
2.2 SECONDARY OBJECTIVES  
The secondary objectives of this study are: 
• To compare progression- free survival (PFS) between the two treatment arms.  
• To compare the objective response rate (ORR) and duration of response (DoR) between the two  treatment arms.  
• To compare the disease control rate (DCR) between the two  treatment arms.  
• To evaluate the safety and tolerability of eryaspase in combination with chemotherapy versus chemotherapy alone   
• To assess the effect  of eryaspase on quality of life using the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire -Core  30 (EORTC 
QLQ- C30). 
• To determine the pharmacokinetics of eryaspase.  
• To assess the immunogenicity of eryaspase in terms of the induction of anti- ASNase  
antibodies and neutralizing antibodies. 
• To evaluate the relationship of clinical outcome with relevant biomarkers and genetic changes present in tumor tissues and blood and/or serum samples.  
• To investigate the predictive relationship between the patient’s DNA sequence variation , 
e.g. exploratory SNP genotypi[INVESTIGATOR_320156]  (pharmacogenetics [PGx]). 
 
2.3 ENDPOINTS : 
Primary Endpoint:  
Overall Survival (OS) in the ITT population. 
 
Secondary Endpoints : 
• Progression- free Survival (PFS),  
• Objective Response R ate (ORR)  
• Duration of Response (DoR) 
• Disease Control rate (DCR)  
• Pharmacokinetics and pharmacodynamics 
• Anti- ASNase  antibodies 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395142]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 45 of 119  • Adverse events AEs  
• Quality of life (QoL)  
• Biomarkers  
 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395143]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395144] measurable disease as defined by [CONTACT_107330] (RECIST  1.1) criteria. After provision of informed consent and conduct of screening 
assessments, patients who meet all inclusion and no exclusion criteria will be randomized in a 1:1 ratio to one of the following treatment arms, Table 4: 
• Arm A (investigational arm): eryaspase in combination with either gemcitabine/Abraxane 
or irinotecan -based therapy ( FOLFIRI [ FOLinic acid -Fluorouracil- IRInotecan regimen ] 
or Onivyde/5- fluorouracil/leucovorin),  
• Arm B (control arm): gemcitabine/Abraxane, or irinotecan -based therapy ( FOLFIRI or 
Onivyde/5-fluorouracil/leucovorin). 
 
 
Figure 4 Study Schema   
The study will be divided into the following phases: 
Screeni ng Phase:  Screening assessments should occur within 3  weeks of randomization for 
assessment of the patient’s  overall eligibility.  
Randomization Phase:  Randomization will occur after the patient has been determined to be 
eligible . 
Treatment Phase: The first dose of chemotherapy will be administered within 3 days  after 
randomization. Treatment will continue until objective disease progression, unacceptable 
toxicity , or the patient ’s withdrawal of consent. Unacceptable toxicity is determined at 
investigator’s discretion, but as a guidance, unacceptable toxicity could consist of prolonged Grade  [ADDRESS_395145]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 47 of 119  In the investigational treatment arm (Arm A), eryaspase will be administered on Day  1 and 
Day 15 of 4-week cycle in combination with chemotherapy. Eryaspase will be administered by 
[CONTACT_33980] (IV) infusion over approximately [ADDRESS_395146] of one of the following two treatment regimens:  
− Gemcitabine and Abraxane combination chemotherapy 
− Irinotecan -based therapy : FOLFIRI (FOLinic acid -Fluorouracil-IRInotecan regimen) 
or Onivyde/5- fluorouracil (5- FU)/leucovorin (LV) 
The choice of the chemotherapy regimen for a particular patient will be determined by [CONTACT_320193]- line setting. Thus:  
− If a patient received prior gemcitabine/A braxane in the first -line setting, then on 
disease progression, the patient will be assigned to FOLFIRI (or Onivyde/5- FU/LV) 
in the current study . 
− If a patient received prior irinotecan -based therapy (FOLFIRINOX), then on disease 
progression, the patient will be assigned  to gemcitabine/Abraxane in the current 
study. 
Follo w-up Phase:  Patients will be monitored for survival at 8 -week intervals. Patients who 
discontinue treatment for reasons other than disease progression will continue to be assessed radiologically every 8 weeks until disease progression , or until withdrawal from the study , or 
death . 
Randomization will occur through an interactive web response system (IWRS). Patients will be randomized in a 1:1 ratio to chemotherapy with or without eryaspase. Randomization will be stratified according to  the following factors:  
• ECOG Performance Status (PS) score  (0 or 1), 
• Chemotherapy regimen in this study (gemcitabine/A braxane or irinotecan -based 
treatment [FOLFIRI or its equivalent Onivyde/5- FU/LV ]), and 
• Time interval since initial diagnosis of advanced disease to randomization date 
(<6 months or ≥6 months ). 
An Independent Data Monitoring Committee (IDMC) will be established to review safety and efficacy data at regular intervals, including the interim and final analyses.  
In addition, the safety of eryaspase in combination with irinotecan -based therapy or 
gemcitabine /Abraxane regimen will be reviewed by [CONTACT_320182] [ADDRESS_395147] safety assessments (labor atory tests, physical 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395148]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 48 of 119  exam s, vital signs including temperature, heart rate, and blood pressure, electrocardiogram s 
[ECGs performed during screening and then as clinically indicated ], and performance status 
score performed on Day  [ADDRESS_395149] dose of study treatment or until start of new anti-cancer treatment, whichever is sooner. 
Efficacy Evaluations  
Tumor assessments utilizing computed tomography (CT)/magnetic resonance imaging (MRI) 
scans will be repeated every [ADDRESS_395150] be collected in a de-identified manner, quality controlled, stored, and available for future 
review , including independent radiological review as necessary . 
Survival information will be collected by [CONTACT_648], follow- up visit, or medical records review every 
8 weeks from the date of the EOT visit  until the patient ’s death, until the patient is lost to 
follow -up, or until study closure. Survival follow -up information will include collection of any 
subsequent anticancer therapy received after discontinuation from study medication. 
QoL (EORTC QLQ- C30) assessment will be performed , at Day  1 of each cycle prior to dosing, 
at the End of Treatment visit, and every 8 weeks during survival follow up. 
Blood and plasma samples will be collected in the eryaspase arm for pharmacokinetic ( PK) and 
pharmacodynamic determination and for immunogenicity evaluation. Pharmacokinetics, Pharmacodynamics, and Translational Research  
Where possible, blood/plasma samples for PK  and pharmacodynamic assessment s will be 
collected at the following time points of Cycles 1 and 3 of study treatment: Day [ADDRESS_395151]- infusion (at 
the Investigator’s discretion), and at Day 15 pre-dose. Samples will be anal yzed for whole blood 
and plasma concentration s of ASNase  and amino acids. The sparse PK data will be combined 
with previous data as part of a Population PK (POP  PK) analysis. 
Samples for assessment of anti -ASNase  antibodies and neutralizing antibodies will  be collected 
pre-dose at Cycle 1 Day  1 and Day 15, at Day  1 of every second cycle thereafter, upon 
determination of disease progression, and at the End of Treatment (EOT) visit, as specified in the Schedule of Events ( Table 1). 
Exploratory biomarker analyses will examine potential predictive biomarkers correlating with eryaspase activity. Tissue samples will be collected at study start. In addition, blood/plasma samples for biomarker analysis will be collected from all patients at Cycle  [ADDRESS_395152]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 49 of 119  at Day  1 of every second  cycle thereafter, upon determination of disease progression, and at the 
End of Treatment ( EOT ) visit, as specified in  the Schedule of Events (Table 1) . 
A blood sample for pharmacogenetic (PGx) analysis will be obtained once during the study, 
preferably during the screening phase, for patients who consent to this optional procedure. 
An effective contraception must be used by [CONTACT_320194] [ADDRESS_395153] interaction 
between components of the oral contraception and free ASNase cannot be ruled out (potential 
increase in the risk of a change in coagulation parameters and thrombosis), oral contraceptives are not considered sufficiently reliable when co -administered with ASNase products.  A method 
other than oral contraception should be used in women of childbearing potential. 
3.2 NUMBER OF PATIENTS  
The target sample size is 482  patients.  
3.3 SCIENTIFIC RATIONALE FOR STUDY DESIGN 
3.3.1 Choice of Chemotherapy ( Control) 
There is currently no standard of c are for locally advanced or metastatic pancreatic cancer that 
has progressed following either FOLFIRINOX or a gemcitabine- based regimen. While there are 
potential options, there is no proven benefit for any regimen, and treatment choice is generally an extrapolation from front -line studies. Based on systematic reviews and National Comprehensive 
Cancer Network ( NCCN) guidelines, gemcitabine- based therapy can be given to those 
previously treated with fluoropyrimidine-based chemotherapy. Fluoropyrimidine- based 
chemotherapy regimens are acceptable second -line options for patients who received prior 
gemcitabine -based therapy. Based the recent P hase 3 NAPOLI -1 trial [36] , Onivyde was 
approved by [CONTACT_2165] ( FDA) and European Medicines Agency ( EMA ) 
in combination with 5- FU/leucovorin for use following gemcitabine- based therapy. Therefore, 
the choices of chemotherapy as the backbone of treatment in both treatment arms are  justified.  
3.4 JUSTIFICATION FOR DO SE 
The choice of dose and schedule for eryaspase (100 U/Kg  given on Day s 1 and 15 of each  4-
week cycle ) is based on safety and tolerability data from the phase 1 monotherapy study in PAC 
patients  [37] . This dose and schedule were  evaluated in Study GRASPANC [ADDRESS_395154]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395155] patient’s  last visit.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395156]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 51 of 119  4 STUDY POPULATION 
Eligibility will be reviewed and documented by [CONTACT_209191] ’s team before patients are enrolled.  
4.1 INCLUSION CRITERIA 
A patient will be eligible for the study if all the following criteria are met: 
1. Must be [ADDRESS_395157] Stage III or  IV disease (see APPENDIX 1).  
4. Must have received one  line of systemic chemotherapy in advanced setting with or 
without targeted agents, immunotherapy, or radiotherapy for treatment of advanced pancreatic adenocarcinoma.    
NOTE:  patients whose disease progresses on, or within 3 months of neo(adjuvant) 
chemotherapy may be considered eligible 
5. Must have radiological evidence of disease progression following most recent prior treatment, defined as a ppearance of any new lesion or increase of >20% of one or more 
existing lesions. 
6. Must have measurable lesion(s) per RECIST version  1.[ADDRESS_395158] (or 
MRI, if the patient is allergic to CT contrast media).  
• Measurable disease may be in the field of prior irradiation; however, at least [ADDRESS_395159] elapsed between the completion of radiation therapy and the baseline scan documenting disease status.  
• Bone disease is considered radiologically measurable only if there is at least a 50% lytic component. 
NOTE:  Bone disease consisting of blastic lesion only is not measurable.  
7. Archival or fresh tumor tissue  must be available  for evaluating relevant biomarkers. 
Formalin -fixed paraffin -embedded [FFPE] block preferred, or a minimum of 
10 unstained FFPE slides of one archived block is required.
   
NOTE:  if archival tissue is unavailable and an elective biopsy can’t be scheduled due to 
COVID, this will be waived.  
NOTE: C ytology samples from fine needle aspi[INVESTIGATOR_320149].  
8. Must have adequat e performance status (see APPENDIX 2 and APPENDIX 3): 
a. ECOG Performance Status (PS) score of 0, or  
b. ECOG PS score one and score ≥80 on Karnofsky Performance Status (KPS) scale.  
NOTE:  Must have body mass index (BMI) ≥18.5  kg/m2 (obtained <[ADDRESS_395160] life expectancy of >12 weeks according to the investigator’s clinical 
judgment. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395161]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395162] dose of study treatment. These include, but not 
limited to:  
a. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: i. intravaginal 
ii. transdermal  
b. progestogen-only hormonal contraception associated with inhibition of ovulation: i. injectable  
ii. implantable  
c. intrauterine device (IUD)  
d. bilateral tubal occlusion  
e. vasectomised partner  
f. sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments)  is intended . The true 
abstinence is  when this is in line with the  preferred and usual lifestyle of the patient. 
[Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception] 
g. males with partners of childbearing potential must agree to u se condoms  
NOTE:  Since an indirect interaction between components of the oral contraceptives  and 
ASNase  cannot be ruled out, oral contraceptives are not considered acceptable as 
contraceptive methods in the current clinical trial.  A method other than oral contraception 
should be used in women of childbearing potential. 
NOTE:  All chemotherapeutic agents may be teratogenic and excreted in breast milk. 
Patients who are breast feeding should consider alternative methods. 
11. Must have adequate laboratory parameters at baseline (obtained <14  days prior to 
randomization). Laboratory parameters outside of th ese ranges that are deemed clinically 
insignificant should be discussed with the medical monitor: a. Absolute neutrophil count ≥1.5 x 10
9/L. 
b. Hemoglobin ≥9  g/dL . Patients with a baseline Hemoglobin ≥13 g/dL should be 
discussed with the medical monitor  
c. Platelet count ≥100,000/mm3 (100 x 109/L). 
d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper 
limit of normal (ULN) (≤[ADDRESS_395163] in pre sence of liver metastases ). 
e. Total bilirubin ≤  1.[ADDRESS_395164] . 
f. Serum creatinine within normal limits or calculated clearance >60  mL/min/1.73 m2 
for patients with serum creatinine levels above or below the institutional normal range.  
g. Acceptable coagulation parameters: plasma antithrombin  III >70% and fibrinogen 
≥1.5 g/L. 
h. Serum albumin ≥3.0 g/dL.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395165]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395166] the  biliary stent placed >[ADDRESS_395167] read and understood the consent form and provided written informed consent.  
4.2 EXCLUSION CRITERIA  
A patient is not eligible to participate in the study if any of the following criteria are met:  
1. Resectable or borderline resectable pancreatic adenocarcinoma at the time of signing the informed consent. 
2. Histology other than pancreatic ad enocarcinoma (for example, but not inclusive: 
neuroendocrine, adenosquamous, etc.). 
3. More than one  line of prior treatment in advanced or metastatic setting.  
4. Patient has experienced medically significant acute decline in clinical status including  
a. Decline in ECOG PS to >1 (or KPS <70) between baseline visit and within 72 hours prior to randomization.  
b. Weight loss of ≥10% during screening. 
5. Presence of active or symptomatic untreated central nervous system (CNS) metastases.  
NOTE:  Patients with asymptom atic or stable CNS metastases are eligible, provided that 
the CNS metastases are radiologically and clinically stable, and the patient is off high -
dose steroid treatment for at least one  month prior to randomization. 
6. Prior radiotherapy to the only area of measurable disease.  
NOTE:  Patients must have completed treatment and recovered from all acute treatment-
related toxicities prior to administration of the first dose of eryaspase or chemotherapy . 
7. Bone as the only site of metastatic disease from pancreatic cancer (bone- only disease).  
8. History of recent clinical pancreatitis, according to revised Atlanta criteria, within 3 months of randomization. 
NOTE:  The revised Atlanta classification [1] requires that two or more of the following 
criteria be met for the diagnosis of acute pancreatitis: (a) abdominal pain suggestive of 
pancreatitis, (b) serum amylase or lipase level ≥[ADDRESS_395168], or (c) characteristic imaging findings using CT or MRI. 
9. Neurosen sory neuropathy > Grade  2 at baseline.  
10. Pregnancy or breastfeeding. 
11. History of infection with human immunodeficiency virus (HIV) and/or active infection 
with hepatitis  B or hepatitis C.  
NOTE:  Patients with unknown status of hepatitis B or C must be tested and declared 
negative before randomization . 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395169]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 54 of 119  12. Hypersensitivity to any of the components of the chemotherapy or ASNase . 
NOTE:  Patients known to be homozygous for UGT1A1*[ADDRESS_395170] be screened for 
UGT1A1*[ADDRESS_395171] the initial irinotecan dose reduced if demonstrated to be homozygous for the UGT1A1*28 allele. 
NOTE:  Patients assigne d to the irinotecan/[ADDRESS_395172] 
dihydropyridine dehydrogenase deficiency (DPD). Patients whose DPD status is 
unknown at time of screening should be tested before enrollment in the irinotecan/5- FU 
arm unless they have previously t olerated full doses of [ADDRESS_395173] received live or live attenuated vaccines within 3  weeks of 
randomization. 
14. History of other malignancies  
NOTE:  Adequately treated non- melanoma skin cancer or curatively treated in -situ cancer 
of the cervix may be eligible.  
NOTE:  Patients successfully  treated for other malignancies and are disease- free for at 
least 5 years  may be eligible . 
15. Any other severe acute or chronic condition /treatments  that may increase the risk of study 
participation including:  
a. History  of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra -
abdominal abscess within 6 months prior to randomization.  
b. Current or history within 6  months prior to randomizat ion of medically  significant 
cardiovascular disease including symptomatic congestive heart failure >[LOCATION_001] Heart Association (NYHA) Class II, unstable angina pectoris, clinically significant cardiac arrhythmia. 
c. Patients with pre -existing coagulopathy (e.g. hemophilia). 
d. Psychiatric illness /social situations or any other serious uncontrolled medical 
disorders in the opi[INVESTIGATOR_2511] I nvestigator  that would limit compliance with study 
requirements.  
4.3 SCREEN FAILURES  
Screen failures are defined as patients who consent to partici pate in the study but are not 
subsequently randomized. A minimal set of screen failure information is required to ensure transparent reporting of screen failure patients , in order  to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publication requirements and to respond to queries from 
regulatory authorities.  
This m inimal information includes demography  and reason for screen failure.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395174]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395175]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 56 of 119  5 STUDY TREATMENTS  
5.1 DESCRIPTION OF STUDY DRUGS  
The study drugs include all chemotherapy agents used in both treatment arms, as well as t he 
investigational drug which  is eryaspase (Investigational Medicinal Product). 
The chemotherapy agents used in this study (gemcitabine, A braxane, irinotecan, and 
5-FU/leucovorin) are commercially available and are being used in accordance with approved 
labeling. 
5.1.[ADDRESS_395176]. 
5.1.2 Ge mcitabine  and Abraxane  
Gemcitabine is an antineoplastic agent. It is commercially available as a lyophilized powder for 
solution for IV use. Gemcitabine will be reconstituted/used as per the manufacturer’s suggestions 
and will be administered as per institutional procedure.  
Abra xane (protein -bound paclitaxel) is a microtubule inhibitor. It is commercially available as a 
lyophilized powder in a single -use vial for reconstitution for IV use. Abraxane will be 
reconstituted/used as per the manufacturer’s suggestions and will be admin istered as per 
institutional procedure.  
Gemcitabine and A braxane will be sourced locally.  Investigators are responsible for ensuring 
that patients receive supplies of gemcitabine and Abraxane for the entire duration of the study 
treatment, except in countries where regulatory authorities mandate that the Sponsor must supply 
all medications required for study participation.  
5.1.3 I rinotecan and 5-FU/Leucovorin 
Irinotecan is an antineoplastic agent of the topoisomerase  I inhibitor class. It is commercially 
availabl e as an aqueous solution intended for dilution prior to IV infusion. Irinotecan will be 
reconstituted/used as per the manufacturer’s suggestions and will be administered as per 
institutional procedure.  
Onivyde (liposomal irinotecan) is a topoisomerase  I inhibitor. It is commercially available as an 
opaque liposomal dispersion in a single-dose vial for IV infusion. Onivyde will be reconstituted/used as per the manufacturer’s suggestions and will be administered as per 
institutional procedure.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395177]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 57 of 119  5-FU is an anti neoplastic antimetabolite agent. It is commercially available as an injectable 
solution for IV use. 5-FU will be administered as per institutional procedure.  
Leucovorin is folinic acid (the active metabolite of folic acid). It is an essential coenzyme for 
nucleic acid synthesis and is used to enhance the cytotoxicity of 5-FU. It is commercially 
available as a powder for reconstitution for IV use. Leucovorin will be administered as per institutional procedure.  
Irinotecan or Onivyde and 5- FU/leucovorin will b e sourced locally. investigators are responsible 
for ensuring that patients receive supplies for the entire duration of the study treatment, except in countries where regulatory authorities mandate that the Sponsor must supply all medications required for study participation. 
5.[ADDRESS_395178] been completed and the results reviewed  and after  it has been confirmed that 
the patient meets all eligibility criteria.  
The dose of eryaspase is 100  U/Kg , to be administered at Days 1 and 15 of each 4- week cycle 
until disease progression, unacceptable toxicity , or withdrawal of consent. 
Eryaspase is administered over approximately 60  minutes per bag, depending on the volume of 
the bag(s) . The entire content of each bag is to be administered, unless otherwise specified . 
Eryaspase administration must be completed before the expi[INVESTIGATOR_320157].  
Date of administration, exact start and end time s of infusion, and volume administered will be 
recorded on the Shipment and Administration Form (SAF) as described in the Investigational Medicinal Product ( IMP) Manual  and noted in the patient’s electronic Cas e Report Form 
(eCRF ). 
Detailed instructions related to eryaspase administration and contact [CONTACT_320195] . 
5.2.2 Ge
 mcitabine  and Abraxane  
Gemcitabine and Abraxane are to be administere d on Days 1, 8, and 15 of each 4- week cycle as 
follows:  
− Abraxane: 125 mg/m2 IV over 30- 40 minutes, followed by 
− Gemcitabine: 1000 mg /m2 IV over [ADDRESS_395179]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 58 of 119  5.2.3 I rinotecan and 5-FU/Leucovorin 
Onivyde  (irinotecan nanoliposomal) + 5- FU/leucovorin  are to be administered  on Days 1 and 
15 of each 4 -week cycle as follows:  
• Onivyde 70 mg/m2 IV over 90 minutes (recommended starting dose of Onivyde in 
patients homozygous for UGT1A1*28 is 50 mg/m2), 
NOTE:  The approved dose of Onivyde is based on the NAPOLI -1[36] trial, in which 
Onivyde was given at a dose of 80 mg/m2 (i.e. equivalent of 70 mg/m2 of irinotecan free 
base).  
• Leucovorin 400 mg/m2 IV over 30 minutes , and  
NOTE: Modifications to the leucovorin dose per sites standard administration protocol 
may be allowed in the study following approval from the medical monitor . 
• 5-FU 2400 mg/m2 over 46 hours. 
 
FOLFIRI (irinotecan, 5- FU, and leucovorin)  is to be administered every 2 weeks on Day  1 
and Day  15 of each 4 -week cycle as follows:  
• Irinotecan 180  mg/m2 IV infusion over 90 minutes  (recommended starting dose of 
irinotecan in patients homozygous for UGT1A1*28 is 150 mg/m2) 
• Leucovorin 400 mg /m² IV infusion over 2 hours  
NOTE: Modifications to the leucovorin dose per sites standard administration protocol may be allowed in the study following approval from the medical monitor. 
• 5-FU 400 mg /m² IV bolus injection over 2-4 minutes , immediately following leucovorin 
infusion, and  
• 5-FU 2400 mg/m² IV  continuous infusion over 46 hours, immediately following bolus 
5-FU. 
5.2.4 G
 uidelines for Treatment Discontinuation and Dose Modification  
Patients will be treated until disease progression, unacceptable toxicity  as determined by [CONTACT_3786], or withdrawal of consent. Each patient will be evaluated for drug- related toxicity. If 
a patient experiences unacceptable toxicity  for more than two  weeks, then such patients should 
be withdrawn from study treatment.  Unacceptable toxicity will be determined at the 
investigator’s discretion; however, as a guidance, unacceptable toxicity could consist of prolonged Grade [ADDRESS_395180]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 59 of 119  [IP_ADDRESS] DOSE MODIFICATION FOR ERYASPASE 
One 25% dose reduction of eryaspase is permitted at the first occurrence of an eryaspase- related 
toxicity . Additional dose reduction to 50% is allowed on second instance. If further dose 
reductions are necessary, then eryaspase should be discontinued.  
Table 6 presents  guidelines for carrying out eryaspase dose reductions  when deemed appropriate . 
Dose reduction approach will depend on whether the drug is at site and ready for infusion 
(during a cycl e) or is planned for a subsequent cycle. Dose reduction during a cycle will follow 
an empi[INVESTIGATOR_320158]. Dose reduction in subsequent cycles will be reflected in the prescription form and will therefore be carried out by [CONTACT_320196](s). 
Table 6 Pre-Specified Dose Reductions for Adverse Events Related to Eryaspase 
Dose level  After manufacturing (during cycle)  Before manufacturing (subsequent 
cycle)  
0 100 U/Kg (full bag)  100 U/Kg  
-1 75% of the bag volume  75 U/Kg  
-2 50% of the bag volume  50 U/Kg  
 
After a dose reduction, the dose of eryaspase may be re- escalated to the previous higher dose 
level , provided that toxicity resolves to at Grade 1 (or 2  where specified ). 
Treatment with eryaspase may be delayed for up to [ADDRESS_395181] instance  of an eryaspase -
related  toxicity  to allow for resolution of toxicity, defined as a return to ≤ Grade  2, where 
indicated. The sponsor’s Medical Monitor must be consulted if any patient requires further treatment delays or dose modification s. If eryaspase- related adverse events do not resolve after a 
period of 2 weeks, the patient should discontinue eryaspase and should then complete the EOT 
visit and Follow-up visits per the Schedule of Events ( Table 1). 
[IP_ADDRESS] DOSE MODIFICATIONS FOR CHEMOTHERAPY (WITH OR WITHOUT ERYASPASE)  
The product labeling information and local institutional practice should be referred to regarding hematological and non- hemato logical AEs attributable to the individual chemotherapy agents 
used in this study. In addition, it is recommended that patients receive pre -medication according 
to respective product labeling information. In case of Abraxane and Onivyde, pre-medication standard doses of dexamethasone (or an equivalent corticosteroid) together with a 5-hydroxytryptamine 3 (5- HT3) antagonist (or other antiemetic) at least 30  minutes prior to start of 
chemotherapy infusion. 
[IP_ADDRESS].1 DOSE MODIFICATIONS FOR GEMCITABINE AND ABRAXANE 
Table 7  presents a summary of dose modifications for gemcitabine, A braxane, and eryaspase.  
Patients who experience adverse events will be re- evaluated weekly, or more often according to 
the Investigator’s discretion. Dose delays or reduction for gemcitabine or Abraxane follow the 
respective prescribing information,  and are provided in the table below for ensuring consistency  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395182]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395183], for adverse events and serious adverse events. Th ereafter, the 
patient will be followed for radiological disease assessment and survival until withdrawal from 
study or death. 
Table 7 Dose Modifications for Gemcitabine, Abraxane, and Eryaspase  
 Abraxane  Gemcitabine  Eryaspase  
Hypersensitivity Reactions:  
Grade  1: transient 
flushing/rash, 
intervention not indicated  Maintain original dose level 
 Maintain original dose 
level Maintain original dose level 
Grade  2: intervention/ 
infusion interruption indicated; responds promptly to symptomatic treatment Maintain original dose level Maintain original dose level During cycle  
interrupt for transient period and then resume
(1) 
Subsequent cycles   
Maintain dose level 
Grade 3: Prolonged 
recurrence of 
symptoms ± clinical 
sequelae, or anaphylaxis (symptomatic bronchospasm, 
edema/angioedema, 
hypotension, parenteral intervention required) infusion interruption indicated; responds promptly to symptomatic treatment During cycle   delay 
dose until resolved to 
≤Grade 2, then full 
dose During cycle   delay 
dose until resolved to 
≤Grade 2, then full 
dose 
During cycle  delay 
until resolved ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Grade  4: Systemic 
allergi c reaction or 
anaphylaxis  Discontinue  Discontinue  Discontinue  
Pancreatitis:  
Grade 2: enzyme 
(lipase/amylase) elevation >3.[ADDRESS_395184], or 
Radiological findings only Maintain original dose level Maintain original dose level Maintain original dose 
level 
Grade 3: Symptomatic 
pancreatitis [Severe pain, vomiting; Lipase /amylase elevation During cycle   delay 
dose until resolved to ≤Grade 2, then full dose During cycle   delay 
dose until resolved to ≤Grade 2,  then full 
dose 
During cycle  Delay 
until resolved to ≤Grade 2, then ↓ to 75% of dose  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395185]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 61 of 119  Table 7 Dose Modifications for Gemcitabine, Abraxane, and Eryaspase  
 Abraxane  Gemcitabine  Eryaspase  
>3.[ADDRESS_395186] for >3  days; 
Medical intervention 
needed  Subsequent cycles  
75 U/Kg  
Grade 4: Symptomatic 
pancreatitis, life-threatening  Discontinue  Discontinue  Discontinue  
Hepatic toxicity:  
No Hepatic metastasis  
Grade  1: ALT/AST 
>3.[ADDRESS_395187], and total 
bilirubin ≤1.[ADDRESS_395188] Maintain original dose level Maintain original dose level Maintain original dose level 
Grade 2: ALT/AST 
≤5.[ADDRESS_395189] and total 
bilirubin ≤1.[ADDRESS_395190] Maintain original dose level Maintain original dose 
level During cycle  ↓ to 
75% of dose  
Subsequent cycles    
100 U/Kg  
Grade 3: ALT/AST 
>5.[ADDRESS_395191], and total 
bilirubin >[ADDRESS_395192]  During cycle  delay  
dose until resolved to ≤Grade 2, then ↓ to 100 mg/m
2 
Subsequent cycles   
100 mg/m2  During cycle  delay  
dose until resolved to ≤Grade 2, then ↓ to 800 mg/m
2 
Subsequent cycles   
800 mg/m2 During cycle  Delay 
until resolved to ≤Grade 2, then ↓ to 75% of dose  
Subsequent cycles   
75 U/Kg  
Grade  4: ALT/AST 
>20.[ADDRESS_395193], or total 
bilirubin >[ADDRESS_395194]  Discontinue  Discontinue  Discontinue  
Hepatic metastasis 
ALT/AST >5.[ADDRESS_395195] 
- ≤10.[ADDRESS_395196]  
and total bilirubin ≤1.[ADDRESS_395197] Maintain original dose 
level Maintain original dose level Maintain original dose level 
ALT/AST >10.[ADDRESS_395198], and total 
bilirubin ≤1.[ADDRESS_395199] During cycle  delay  
until resolved to ≤10.0, then ↓ to 100  mg/m
2 
Subsequent cycles   
100 mg/m2 During cycle  delay  
dose until resolved to 
ALT/AST <10.[ADDRESS_395200], then ↓ to 
800 mg/m
2 
Subsequent cycles   
800 mg/m2 During cycle  delay 
until resolved to ≤10.0, then ↓ to 50% of dose  
Subsequent cycles   
50 U/Kg  
ALT/AST >20.[ADDRESS_395201] and total 
bilirubin ≤1.[ADDRESS_395202] Discontinue  Discontinue  Discontinue  
Total bilirubin >2.[ADDRESS_395203]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 62 of 119  Table 7 Dose Modifications for Gemcitabine, Abraxane, and Eryaspase  
 Abraxane  Gemcitabine  Eryaspase  
Motor or Sensory Ne uropathy  
Grade  1 or Grade  2 Maintain original dose 
level Maintain original dose level Maintain original dose level 
Grade  3 or Grade  4 
 During cycle  delay 
until resolved to ≤Grade 2, then ↓ to 100 mg/m
2 
Subsequent cycles   
100 mg/m2 During cycle  delay 
until resolved to ≤Grade 2, then ↓ to 800 mg/m
2 
Subsequent cycles   
800 mg/m2 Maintain original dose 
level 
Hematological Toxicity – Neutropenia (Absolute Neutrophil Count [ANC]):  
Grade 1: <lower limit 
of normal (LLN) to 1.5 x 10
9/L Maintain original dose level Maintain original dose level Maintain original dose level 
Grade 2: <1.5 x 109/L 
- ≥1 x 109/L During cycle   delay 
until resolved  to ≤Grade 1  
then ↓ to 100  mg/m2 
Subsequent cycles   
100 mg/m2 During cycle   delay 
until resolved  to ≤Grade 1 
then  then ↓ to 
800 mg/m2 
Subsequent cycles   
800 mg/m2 Maintain original dose 
level 
Grade  3: <1.0 x 109/L 
- ≥0.5 x 109/L Day 1  delay until 
resolved  
Day 8  ↓ to 
100 mg/m2 
Day 15  ↓ to 
75 mg/m2 Day 1  delay until 
resolved  
Day 8  ↓ to 
800 mg/m2 
Day 15  ↓ to 
600 mg/m2 During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent c ycles  
Maintain original dose 
level 
Grade  4: <0.5 x 109/L 
or 
Febrile neutropenia  Day 1  delay until 
resolved  
Day 8  delay dose 
Day 15  delay dose Day 1  delay until 
resolved  
Day 8  delay dose 
Day 15  delay dose During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Other h ematological toxicities (anemia and thrombocytopenia) follow same guidelines as 
recommended for neutropenia  
Other laboratory investigations  
Any Grade  1 or 
Grade 2   Maintain original dose 
level Maintain original dose 
level Maintain original dose 
level 
Any Grade 3  or 
Grade 4  – not 
clinically significant During cycle  delay 
dose until resolved to ≤Grade 2, then full dose During cycle  delay 
dose until resolved to ≤Grade 2, then full dose During cycle  Delay 
until resolved to ≤Grade 2, then full dose 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395204]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 63 of 119  Table 7 Dose Modifications for Gemcitabine, Abraxane, and Eryaspase  
 Abraxane  Gemcitabine  Eryaspase  
Subsequent cycles  
Maintain original dose 
level Subsequent cycles  
Maintain original dose level Subsequent cycles  
Maintain original dose level 
Any Grade 3  or 
Grade 4  – clinically 
significant  During cycle  delay 
until resolved to ≤Grade 2, then ↓ to 100 mg/m
2 
Subsequent cycles   
100 mg/m2 During cy cle  delay 
until resolved to ≤Grade 2, then ↓ to 800 mg/m
2 
Subsequent cycles   
800 mg/m2 During cycle  Delay 
until resolved to ≤Grade 2, then ↓ to 75% of dose  
Subsequent cycles  
75 U/Kg  
Other non -Hematological Adverse Event: 
Any Grade  1 toxicity  Maintain original dose 
level Maintain original dose 
level Maintain original dose 
level 
Any other Grade 2  
toxicity  Maintain original dose level Maintain original dose level Maintain original dose level 
Any other Grade 3  
toxicity  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
full original dose  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
full original dose  During cycle  delay 
until resolved ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Upper gastro -intestinal 
(GI) peptic ulcer Grades 2 or  3 During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
full original dose  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
full original dose  During cycle  delay 
until resolved to ≤Grade 1, then  use next 
lower dose level   
Subsequent cycles   
next lower dose level   
Any othe r Grade  4 
toxicity  During cycle  delay 
until resolved to ≤Grade 2, then ↓ to 100 mg/m
2 
Subsequent cycles   
100 mg/m2 During cycle  delay 
until resolved to ≤Grade 2, then ↓ to 800 mg/m
2 
Subsequent cycles   
800 mg/m2 During cycle  delay 
until resolved ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Upper gastro -intestinal 
(GI) peptic ulcer Grade 4 , and/or life -
threatening GI bleeding  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
full original dose  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
full original dose  Withdraw  
IMP Incompatibility:  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395205]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395206] result  No actions for the chemotherapy. Repeat eryaspase manufacturing.  
If persists, discontinue.  
(1) Infusion may be resumed at a lower infusion rate, provided that it is within shelf -life and the infusion is 
completed within the 6 -hour window of bringing eryaspase to room temperature.  
[IP_ADDRESS].2 DOSE MODIFICATIONS FOR IRINOTECAN AND 
5-FU/LEUCOVORIN 
Table 8 presents a summary of dose modifications  for irinotecan , Onivyde, and eryaspase. 
Patients who experience adverse events will be re- evaluated weekly, or more often according to 
the Investigator’s discretion. Dose delays or reductions for irinotecan or Onivyde follow the 
respective prescribing inf ormation, and are provided in the table below for consistency across 
sites. If toxicities do not resolve to ≤Grade [ADDRESS_395207] complete an EOT visit and Follow -up 
visits per the Schedule of Events ( Table 1).  
Following 5- FU treatment, mucositis, stomatitis, hand- foot syndrome , and diarrhea occur most 
commonly. Leukopenia is the usual dose -limiting toxicity after IV bolus administration. Patients 
with dihydropyrimidine dehydrogenase deficiency (DPD) are at risk of severe life- threatening  
toxicity with 5 -FU. While severe deficiency is rare, 3 -4% of the population has some degree of 
DPD deficiency. Patients with DPD deficiency cannot be enrolled in the 5-FU arm unless they have tolerated full doses of 5-FU previously. In general, dose modifications and delays follow a similar approach to that used with irinotecan. However, in case of mucositis or stomatitis, only 
5-FU (and not irinotecan or eryaspase) should be withheld during the cycle, and resumed at full 
dose in subsequent cycles. 
Table 8 Dose Modifications for Irinotecan, Onivyde, and Eryaspase 
 Irinotecan(1) Onivyde(2,3) Eryaspase  
Hypersensitivity Reactions:  
Grade 1: transient 
flushing/rash, 
intervention not indicated  Maintain original dose level Maintain original dose level Maintain original dose level 
Grade 2: intervention/ 
infusion interruption indicated; responds promptly to symptomatic treatment Maintain original dose level Maintain original dose level 
During cycle  
interrupt for transient 
period and then 
resume(4) 
Subsequent cycles   
Maintain original dose  
level 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395208]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 65 of 119  Table 8 Dose Modifications for Irinotecan, Onivyde, and Eryaspase 
 Irinotecan(1) Onivyde(2,3) Eryaspase  
Grade  3: Prolonged 
recurrence of 
symptoms ± clinical sequelae, or anaphylaxis 
(symptomatic 
bronchospasm, edema/angioedema, hypotension, parenteral intervention required)  During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 150 mg/m
2 
Subsequent cycles   
180 mg/m2 During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 During cycle  delay 
until resolved ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Grade  4: Systemic 
allergic reaction or anaphylaxis  Discontinue  Discontinue  Discontinue  
Pancreatitis:  
Grade 2: enzyme 
(lipase/amylase) elevation >3.[ADDRESS_395209], 
or Radiological findings only  Maintain original dose level Maintain original dose level Maintain original dose 
level 
Grade 3: Symptomatic 
pancreatitis [Severe 
pain, vomiting; Lipase 
or amylase elevation >3.[ADDRESS_395210] for 
>3 days; and Medical 
intervention needed During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 150 mg/m
2 
Subsequent cycles   
150 mg/m2 During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 During cycle  Delay 
until resolved to ≤Grade 2, then ↓ to 75% of dose  
Subsequent cycles   
75 U/Kg  
Grade 4: Symptomatic 
pancreatitis, life-threatening  Discontinue  Discont inue  Discontinue  
Hepatic toxicity:  
No Hepatic metastasis  
Grade  1: ALT/AST 
>3.[ADDRESS_395211], and total 
bilirubin ≤1.[ADDRESS_395212] Maintain original dose 
level Maintain original dose 
level Maintain original dose 
level 
Grade 2: ALT/AST 
≤5.[ADDRESS_395213] and total 
bilirubin ≤1.[ADDRESS_395214] During cycle  ↓ to 
150 mg/m2 
Subsequent cycles   
Maintain original dose level Maintain original dose level During cycle  ↓ to 
75% of dose  
Subsequent cycles   
Maintain original dose level 
Grade 3: ALT/AST 
>5.[ADDRESS_395215], and total 
bilirubin >[ADDRESS_395216]  Discontinue  Discontinue  During cycle  Delay 
until resolved to ≤Grade 2, then ↓ to 75% of dose  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395217]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 66 of 119  Table 8 Dose Modifications for Irinotecan, Onivyde, and Eryaspase 
 Irinotecan(1) Onivyde(2,3) Eryaspase  
Subsequent cycles  
75 U/Kg  
Grade 4: ALT/AST 
>20.[ADDRESS_395218], or total 
bilirubin >[ADDRESS_395219]  Discontinue  Discontinue   Discontinue  
Hepatic metastasis  
ALT/AST >5.[ADDRESS_395220] 
- ≤10.[ADDRESS_395221]  
and total bilirubin 
≤1.[ADDRESS_395222] Maintain original dose level Maintain original dose level Maintain original dose level 
ALT/AST >10.[ADDRESS_395223], and total 
bilirubin ≤1.[ADDRESS_395224] During cycle  delay 
dose until resolved to ALT/AST <5.[ADDRESS_395225], 
then ↓ to 120  mg/m
2 
Subsequent cycles   
120 mg/m2 During cycle  delay 
dose until resolved to ALT/AST <5.[ADDRESS_395226], 
then ↓ to 50  mg/m
2 
Second occurrence   
43 mg/m2 
Third occurrence   
Discontinue  During cycle  delay 
until resolved to ≤10.0, then ↓ to 50% of dose  
Subsequent cycles   
50 U/Kg  
ALT/AST >20.[ADDRESS_395227] and total 
bilirubin ≤1.[ADDRESS_395228] Discontinue  Discontinue  Discontinue  
Total bilirubin >2.[ADDRESS_395229] Discontinue  Discontinue  Discontinue  
Diarrhea  
Grade 1: 
(2-3 stools/day 
>pretreatment During cycle  delay 
until resolved, then full dose 
Subsequent cycles   
Maintain original dose level During cycle  delay 
until resolved, then full dose 
Subsequent cycles   
Maintain original dose level Maintain original dose level 
Grade  2: 
(4-6 stools/day 
>pretreatment) During cycle  delay 
dose until resolved, then ↓ to 150  mg/m
2 
Subsequent cycles   
180 mg/m2 During cycle  delay 
dose until resolved, then full dose  
Subsequent cycles   
70 mg/m2 Maintain original dose 
level 
Grade 3: 
(7-9 stools/day 
>pretreatment)  During cycle  delay 
dose until resolved, then ↓ to 150  mg/m
2 
Subsequent cycles   
150 mg/m2 During cycle  delay 
dose until resolved to 
≤Grade 2, then ↓ to 
50 mg/m2 
Subsequent cycles   
43 mg/m2 During cycle  delay 
until resolved to 
≤Grade 2, then f ull 
dose 
Subsequent cycles   
Maintain original dose 
level 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395230]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 67 of 119  Table 8 Dose Modifications for Irinotecan, Onivyde, and Eryaspase 
 Irinotecan(1) Onivyde(2,3) Eryaspase  
Grade  4: 
(≥10  stools/day 
>pretreatment) During cycle  delay 
dose until resolved, 
then ↓ to 120  mg/m2 
Subsequent cycles   
120 mg/m2 During cycle delay 
dose until resolved to ≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 
Third occurrence   
Discontinue  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Hematological Toxicity – Neutropenia (Absolute Neutrophil Count [ANC]):  
Grade 1: <LLN to 
1.5 x 109/L Maintain original dose level Maintain original dose level Maintain original dose level 
Grade 2: <1.5 x 109/L 
- ≥1 x 109/L During cycle  ↓ to 
150 mg/m2 
Subsequent cycles   
Maintain original dose level During cycle  delay 
dose until resolved, then full dose  
Subsequent cycles   
70 mg/m2 Maintain original dose level 
Grade 3: <1.0 x 109/L 
- ≥0.5 x 109/L During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ 150 mg/m
2 
Subsequent cycles  
150 mg/m2 During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 
Third occurrence   
Discontinue  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Grade  4: <0.5 x 109/L 
or 
Febrile neutropenia  During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ 120 mg/m
2 
Subsequent cycles   
120 mg/m2 During cycle delay 
dose until resolved to ≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 
Third occurrence   
Discontinue  During cycle  delay 
until resolved to ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Other hematological  toxicities (anemia and thrombocytopenia):  follow same guidelines as 
recommended for neutropenia  
Other laboratory investigations  
Any Grade 1  or 
Grade 2   Maintain original dose level Maintain original dose level Maintain original dose level 
Any Grade 3  or 
Grade 4  – not 
clinically significant During cycle  delay 
dose until resolved to 
≤Grade 2, then ↓ 
150 mg/m2 During cycle  delay 
dose until resolved to 
≤Grade 2, then full 
original dose  During cycle  Delay 
until resolved to 
≤Grade 2, then full 
original dose  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395231]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 68 of 119  Table 8 Dose Modifications for Irinotecan, Onivyde, and Eryaspase 
 Irinotecan(1) Onivyde(2,3) Eryaspase  
Subsequent cycles  
150 mg/m2 Subsequent cycles  
50 mg/m2 
 Subsequent cycles  
Maintain dose level 
Any Grade 3  or 
Grade 4  – clinically 
significant  During cycle  delay 
dose until resolved to 
≤Grade 2, then ↓ 120 mg/m
2 
Subsequent cycles   
120 mg/m2 During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 
Third occurrence   
Discontinue  During cycle  Delay 
until resolved to ≤Grade 2, then then ↓ to 75% dose  
Subsequent cycles   
75 U/Kg  
Other non -Hematological Adverse Event:  
Any Grade  1 toxicity  Maintain original dose level Maintain original dose level Maintain original dose level 
Any other Grade  2 
toxicity  During cycle  delay 
dose until resolved to ≤Grade 1, then ↓ to 150 mg/m
2 
Subsequent cycles   
180 mg/m2 Maintain original dose 
level Maintain original dose 
level 
Any other Grade 3  
toxicity  During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 150 mg/m
2 
Subsequent cycles   
150 mg/m2 During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 
Third occurrence   
Discontinue  During cycle  delay 
until resolved ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Any other Grade  4 
toxicity(5) During cycle  delay 
dose until resolved to ≤Grade 2, then ↓ to 120 mg/m
2 
Subsequent cycles   
120 mg/m2 During cycle  delay 
dose until resolved to 
≤Grade 2, then ↓ to 50 mg/m
2 
Second occurrence   
43 mg/m2 
Third occurrence   
Discontinue  During cycle  delay 
until resolved ≤Grade 2, then full dose 
Subsequent cycles   
Maintain original dose level 
Upper gastro -intestinal 
(GI) peptic ulcer Grades 2 or 3  During cycle  delay 
until resolved to ≤Grade 1, then use next 
lower dose level .  
Subsequent cycles   
next lower dose level  During cycle  delay 
until resolved to ≤Grade 1 , then use next 
lower dose level   
Subsequent cycles   
next lower dose level  During cycle  delay 
until resolved to ≤Grade 1 , then use next 
lower dose level   
Subsequent cycles   
next lower dose level  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395232]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395233] been reported with Abraxane, irinotecan, Onivyde, and 
eryaspase. All patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists as per institution al protocols. 
Eryaspase is an ASNase  encapsulated  into RBCs; therefore, the risk of allergic reactions is 
potentially attributed to one or more of the following causes: a) antibody- mediated clinical 
hypersensitivity reactions; b) non-antibody- mediated infusion reactions attributed to ASNase; 
and/or c) th e RBC component in eryaspase. 
[IP_ADDRESS] MANAGEMENT OF HYPERSENSITIVITY REACTIONS WITH ERYASPASE OR OTHER AGENTS  
Generally, eryaspase does not require premedication for hypersensitivity reactions. However, eryaspase contains E.  coli-derived ASNase,  which  has been associated with hypersensitivity 
reactions. These reactions range from local rash or flush ing to severe systemic reactions with 
features such as urticaria, bronchospasm, angioedema, and severe anaphylactic shock. In the eryaspase program, there had been 15 (4.8%) Grade 3 or 4 allergic reactions  as of 28 Feb  2017. 
The following is guidance for the treatment of hypersensitivity reactions. Treatment should be based on clinical presentation and is at the Investigator ’s discretion. Institution -specific pre-
medica tion and/or treatment plans may also be followed if appropriate . 
Grade  2 Symptoms: 
• Stop administration.  Table 8 Dose Modifications for Irinotecan, Onivyde, and Eryaspase 
 Irinotecan(1) Onivyde(2,3) Eryaspase  
Upper gastro -intestinal 
(GI) peptic ulcer Grade 
4, and/or life -
threatening GI bleeding  Withdraw  Withdraw  Withdraw  
IMP Incompatibility:  
Positive serologic cross-match test result  No actions for the chemotherapy. Repeat eryaspase manufacturing.  
If persists, discontinue.  
(1) For patients starting irinotecan at a reduced dose of 150  mg/m2 due to the presence of UGT1A1*28 
homozygous allele, dose should be reduced to 120 mg/m2 at first occurrence and an additional decrease of 
about 20%  at the second occurrence of toxicity.  
(2) Onivyde dose reductions are presented based on a starting dose of 70 mg/m2 irinotecan free base (equivalent 
to 80  mg/m2 of Onivyde).   
(3) For patients starting Onivyde at a reduced dose of 50  mg/m2 irinotecan free base due to the presence  of 
UGT1A1*28 homozygous allele, dose should be reduced to 43  mg/m2 at first occurrence and to 35  mg/m2 at 
the second occurrence.  
(4) Treatment with eryaspase can be resumed, provided that it is within shelf -life and the infusion is completed 
within the 6-hour window of bringing eryaspase to room temperature.  
(5) For mucositis or stomatitis, decrease only [ADDRESS_395234]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 70 of 119  • Administer IV dexamethasone 10  mg and diphenhydramine hydrochloride (HCL) 25 to 
50 mg . 
• After recovery of symptoms, treatment may be resumed once the pat ient is stable, if the 
product is not expi[INVESTIGATOR_320159] 6 hours. 
• Use premedication for subsequent infusions of eryaspase. 
Grade  3 and 4 Symptoms (such as hypotension, angioedema, or respi[INVESTIGATOR_1506]):  
• Stop a dministration . 
• Administer IV dexamethasone 10  mg and diphenhydramine HCL 25 to 50 mg . 
• Add adrenaline or bronchodilators as indicated. 
• For Grade 4 toxicity, the treatment should be discontinued. 
Example of Infusion Premedication Regimen:  
• Dexamethasone 12 mg  PO and diphenhydramine HCL 25-50 mg PO approximately 6 to 
12 hours prior to the next dose of eryaspase. 
[IP_ADDRESS] MANAGEMENT OF INFUSION/TRANSFUSION REACTIONS  
Allogeneic blood transfusions are associated with immune- related effects in the form of 
alloimmunization due to the exposure to alloantigens, cytokines, or other cellular components. 
Transfusion reactions are typi[INVESTIGATOR_320160] s [38]: i) transfusion -
related lu ng injury (TRALI); ii) volume overload in susceptible patients with cardiovascular 
problems ; iii) bacterial contamination; iv) acute hemolytic reactions, either immune -related with 
ABO incompatibility  or non- immune related (for example , concomitant medica tions causing 
RBC hemolysis, incorrect storage of RBCs, or non- validated administration systems); 
v) non-hemolytic febrile reactions due to cytokines and other allo-proteins; and vi) allergic reactions, mostly related to unidentified allergens in the donor blood. 
Overall, eryaspase-related transfusion/infusion events have been  reported in 25 (8.1%) patients 
enrolled in the combined clinical development program. None of these events were Grade 4 or 
fatal. E ryaspase utilizes leuko -depleted packed RBC s; its manufacturing process additionally 
helps to wash away any remaining leukocytes. Alloimmunization (switch from negative to 
positive anti- erythrocyte irregular antibodies) has been  observed in 14.6% of patients (45 out of 
307) as of 28  Feb 2017. 
Management of transfusion/infusion reactions follow s well -known published guidelines, as 
summarized in these publications [39-41]. I t is recommended that Investigators follow 
institutional and local practice guidelines. Table [ADDRESS_395235]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 71 of 119  Table 9 General Guidelines for Managing Transfusion Reactions  
Reaction  Symptoms  Interventions 
Possible febrile non -
hemolytic reaction Incremental increase <1°C 
above baseline and no other new symptoms • Close observation, frequent vital signs 
measurement.  
• If stable and no other new symptoms, then continue with eryaspase.
 
Possible bacterial 
contamination Incremental increase ≥1°C above baseline, or incremental increase <1°C 
with any other new 
symptoms (chills or rigors, hypotension, nausea, or vomiting)  • Stop eryaspase; keep IV line open, assess patient, check patient ID 
and unit ID and compatibility.  
• Administer antipyretic drug.  
Strongly consider culturing blood 
product if ≥2°C increase in temperature or if high clinical suspi[INVESTIGATOR_320161].  
Possible hemolysis  For consistently febrile patient due to underly ing disease or treatment 
with chemotherapy agents, when possible:  
Delay eryaspase if patient’s temperature is increasing.  
Treat fever with antipyretic drug before starting transfusion.  
Respi[INVESTIGATOR_320162], transfusion -associated 
circulatory overload, septic 
transfusion reaction, or 
transfusion -related acute 
lung injury  Bronchospasm, dyspnea, tachypnea and hypoxemia, copi[INVESTIGATOR_320163]-tinged 
fluid (from endotracheal 
tube)  • Stop eryaspase; keep IV line open, assess patient, check patient ID 
and unit ID and patient 
compatibility.  
• Treat symptoms as indicated (adrenaline, antihistamines, steroids; oxygen and respi[INVESTIGATOR_1413], diuretics; fluid, blood 
pressure, and renal support).  
• Chest radiograph for presence o f 
bilateral interstitial infiltrate, if 
suggestive of transfusion-related acute lung injury (TRALI).  
• Blood cultures (patient and product) if high clinical suspi[INVESTIGATOR_320164].  
• Do not resume eryaspase.  
• Notify blood transfusion 
laboratory; return unit with administration set, plus post-
transfusion patient sample. Associated products can be quarantined.  
All Other Symptoms  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395236]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395237] pain, intravenous site 
pain, cough, dyspnea, 
hypoxia  • Stop eryaspase; keep IV line open, assess unit, check patient ID and unit ID and patient compatibility.  
• Treat symptoms as indicat ed 
(adrenaline, antihistamines, steroids; oxygen and respi[INVESTIGATOR_1413]; diuretics; fluid, blood pressure, and renal support).  
• Blood cultures (patient and product) if high clinical suspi[INVESTIGATOR_320164].  
• Do not resume transfusion.  
• Notify blood transfusion 
laboratory; return unit with 
administration set, plus post-transfusion patient sample. Associated products can be quarantined.  
IV: intravenous; ID: identification; TRALI: transfusion -related acute lung injury.  
[IP_ADDRESS] MANAGEMENT O F DIARRHEA 
Diarrhea is commonly reported with irinotecan and Onivyde, which typi[INVESTIGATOR_320165] 
≤24 hours after starting Onivyde (early onset). A late onset (>24  hours) diarrhea has also been 
reported. When appropriately managed with anti- diarrheal treatment, d iarrhea is generally mild 
to moderate.  
These broad general management principles are provided as a guideline to proactively avoid 
serious complications of diarrhea syndrome. These guidelines do not replace sound clinical judgment. 
In the event of diarrhea, patients should take loperamide at initial [ADDRESS_395238] lapsed without symptoms. Patients should be advised to 
increase fluid intake (water, sports drinks, clear juices, decaffeinated  tea), and modify diet 
(banana, rice, apples and toast) . 
• If mild to moderate diarrhea persists for more than 12  hours, loperamide should be taken 
at a dose of 2  mg every 2 hours 
• If mild to moderate diarrhea persist after 24  hours despi[INVESTIGATOR_320166], a 
cocktail of atropi[INVESTIGATOR_050] -diphenoxylate (Lomotil) and loperamide may be considered. 
Loperamide 2 mg may be alternated with one tablet of Lomotil every 3 hours. 
Loperamide should not be used for more than 48 consecutive hours due to risk of paralytic ileus. Oral antibiotic support (e.g. fluoroquinolone for 7 days) should be also 
considered. If diarrhea persists for more than [ADDRESS_395239]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 73 of 119  For Grade 3 or 4 diarrhea or complicated Grad e 1 or 2 (severe crampi[INVESTIGATOR_007], severe 
nausea/vomiting, decreased performance status, fever, sepsis, Grade 3 or 4 neutropenia, frank 
bleeding, dehydration), IV fluids should be used as appropriate, as well as prophylactic 
antibiotics . 
5.3 ERYASPASE PREPARATION/HANDLING/ STORAGE/ ACCOUNTABILITY  
5.3.1 Acquisition and A ccountability  
[IP_ADDRESS] ACQUISITION 
Eryaspase will be dispatched to the site only after receipt of the required information  in 
accordance with ERYTECH procedures. 
• Information to be provided at study start: RBCs  phenotype (including D, C, E, c, e, K 
and other antigens tested as per site practice ), ABO blood group status, and Rhesus 
factor , all assessed on two  separate samples, which can be collected  on the same day. In 
addition, provide  historical results of an  irregular antibody screening test (IAST), if 
available. This  information  is required at least [ADDRESS_395240] infusion.  
• Prior to Cycle 1 Day 1 and each eryaspase dose: A prescription form indicating patient 
identifiers and body weight should be provided at the latest 5 working days prior to Cycle 
1 Day 1 (for all patients) and each eryaspase infusion  (patients in eryaspase arm) . 
• Information to be provided during the treatment phase:  Results of IAST performed 
for previous eryaspase dose to be provided at the latest 5 working days prior to subsequent eryaspase infusion.  
• The following information is required before eryaspase can be shipped to the site: 
− The name [CONTACT_3669] [CONTACT_182827][INVESTIGATOR_841], who should be the i nvestigator or 
designee.  
− The location for delivery (local pharmacy or blood bank). 
Detailed instructions for completing and providing the phenotype, blood group, and Rhesus 
factor informatio n, the IAST results (from the previous infusion), and the  prescription form are  
provided in the IMP manual. 
Eryaspase will be shipped to the I nvestigator in a qualified container by a specialized carrier, 
who will ensure that the cold chain is maintained b etween +2 -8°C (35-46°F). 
If a temperature excursion outside the range of +2°C to +8°C (35-46°F) occurs, the product 
should be quarantined and ERYTECH Pharma should be contact[CONTACT_182828]. If it is not used immediately after receipt, it is mandatory that  eryaspase be stored at temperatures 
between +2 and +8°C (35-46°F). Eryaspase may be stored at room temperature for up to 6 hours prior to administration, including 
infusion time ; it must not be stored at room temperature for more than [ADDRESS_395241]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 74 of 119  [IP_ADDRESS] ACCOUNTABILITY  
The Investigator or designee is responsible for IMP accountability, reconciliation, and record 
maintenance ( i.e., records of receipt, reconciliation, and final disposition).  
Further guidance and information concerning the final disposition of unused IMP are provided in the IMP Manual.  
5.3.2 Fo
 rmulation, Appearance, Packaging, and Labeling  
Please refer to the IB for details of eryaspase formulation and appearance.  
Eryaspase is packed in medical -grade polyvinyl chloride (PVC) blood bags according to GMP 
requirements and place in a photoprotective pocket . The final volume of the eryaspase bag 
depends on the patient’s weight and the dose prescribed. The volume of the bag ranges from 50 mL to 300 mL depending on the individual patient’s dose (multiple bags may be required to achieve the full dose). 
Three (3) remo vable segment -tubes are attached to the bag for use in  blood compatibility testing 
before administration.  
Label statements are specific to the clinical trial and comply with legal requirements for IMPs . 
The date and time of eryaspase expi[INVESTIGATOR_320167]. In addition, the label 
displays specific information  necessary for traceability of source cell material and medicinal 
product ( blood bank identifier for original RBCs, phenotype, patient identification number, etc.) 
to allow verification o f the patient ’s identity and blood group before administration.  
5.3.[ADDRESS_395242] (cross -match test) 
between the patient’s blood and eryaspase, using  the removable segment tubes, must be 
performed  to confirm compatibility. In case a patient receives multiple bags of eryaspase to 
achieve the intended prescribed dose, separate cross -match  tests must be performed with each 
eryaspase bag to confirm compatibili ty. 
Eryaspase should not be transferred to another container before infusion. Eryaspase should not 
be mixed or administered simultaneously with any other products, solutions, or medicinal products. 
After eryaspase administration, partially administered and  empty bags may be destroyed locally 
under the biomedical waste disposal process as approved by [CONTACT_320197]. However, in 
case of a product defect or quality issue, E RYTECH must be contact[CONTACT_320198]. 
Additional details will be described in the IMP Manual.  
Detailed instructions related to eryaspase administration and contact [CONTACT_320195].  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395243]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 75 of 119  5.4 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  
5.4.1 Blinding  
 The study is an open- label  pi[INVESTIGATOR_16076]. Investigators and patients will be  unblinded to the 
treatment due to the nature of the investigational therapy.  
5.4.2 R andomization 
Patients will be randomized to receive either chemotherapy in combination with eryaspase or 
chemotherapy alone in a 1:1 ratio , using an IWRS.  At screening, the IWRS system will assign a 
unique patient number that will remain constant over the duration of the study. If a patient is rescreened  after initial screen failure , the IWRS will allocat e the same number. T reatment arm  
will be automatically determined by [CONTACT_125070].  Detailed instructions will be provided in 
the IWRS manual.  
Randomization will be stratified by  [CONTACT_41396]: 
• ECOG PS score  (0 or 1), 
• Chemotherapy regimen (g emcitabine plus Abraxane or i rinotecan -based therapy  
[FOLFIRI or Onivyde, 5- FU, and leucovorin]), and  
• Time interval since diagnosis of advanced disease to date of randomization in the study  
(<6 months or ≥6 months ). 
5.5 COMPLIANCE WITH STUDY TREATMENT  
Eryaspase will be  administered by [CONTACT_320199]. 
Compliance with the treatment dose and schedule will be documented in the source documents and recorded in the eCRF. 
5.6 CONCOMITANT T HERAPY  
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly authorized/licensed clinician. All prescription medications, over -the-counter 
medications , and supplements used concomitantly or within [ADDRESS_395244] 
be reported in the eCRF. 
5.6.1 P
 rior Medications  
All treatments received within 14  days prior to Cycle  1 Day  1 will be recorded in  the eCRF, 
including the name [CONTACT_18467], route, indication, star t date, and stop date (if applicable).  In 
addition, any and all  prior therap ies for the treatment of pancreatic cancer (or cancer -related 
events such as bone pain) will also be recorded in  the eCRF.  
5.6.[ADDRESS_395245]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 76 of 119  The following treatments are permitted  during the study:  
• Transfusion of blood products . 
Transfusion of fresh frozen plasma should be minimized, as it provides an exogenous 
source of asparagine. It is preferable to administer antithrombin  III (AT III) concentrates 
in case of a decrease in  AT III following eryaspase administration. Hemoglobin must be 
≥9 g/dL at Cycle  [ADDRESS_395246] be ≥ 8 g/dL before all subsequent doses. If 
hemoglobin is <8  g/dL, then appropriate measures must be taken according to standard 
clinical practice prior to further administration of chemotherapy.  
• Systemic and inhaled s teroid  treatment . 
A standard 3- to 5-day course of dexamethasone following the institutional standard of care is permitted for the prevention of treatment -induced nausea and vomiting. In 
addition, oral glucocorticoids at a daily dose of 1.5  mg dexamethasone (or equivalent) are 
permitted.  
• Palliative radiotherapy (e.g ., for painful bone metastases).  
• Prophylactic granulocyte colony- stimulating factor ( GCSF ) in case of  neutropenia . 
Details and indications for use of GCSF should follow American Society for Cooperative Oncology ( ASCO) guidelines [42]. 
5.6.3 Pr
 ohibited Medications  
During the treatment phase, the following treatments are prohibited: 
• Concomitant vaccination with live vaccines , due to increased  risk of serious infection . 
Immunization with live or live -attenuated vaccines should take place no earlier than 
3 months after completion of eryaspase treatment.  
• Other L- ASNase  products . 
• Highly hemolytic agents  that may lead to RBC hemolysis: acetanilide, antipyrine 
(phenazone ), and chloroquine and derivatives. 
• Prophylactic phenytoin. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395247]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 77 of 119  6 DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT 
WITHDRAWAL FROM THE STUDY  
6.1 DISCONTINUATION OF STUDY TREATMENT  
Discontinuation from eryaspase and/or chemotherapy treatment does not imply  discontinuation 
from the study, and remaining study procedures should be completed as indicated by [CONTACT_17143]. 
If a clinically significant finding is identified after enrollment, the investigator or qual ified 
designee will determine whether any change in patient manag ement is needed. Any new 
clinically relevant finding will be reported as an adverse event (AE).  
A patient may be withdrawn from treatment for any of the following reasons: 
• Unacceptable toxici ty. 
• Objective disease progression following radiological assessment as determined by [CONTACT_1275] (per modified RECIST  1.1 criteria).  
• Patient ’s withdrawal of consent for treatment . 
• Pregnancy 
• Investigator ’s decision for other reasons , with documentation  of reason(s) if not 
included in any of the above categories.  
NOTE:  Clinical progression must be confirmed radiologically before treatment 
discontinuation and patient withdrawal. 
• Sponsor ’s decision, including discontinuation of the study, with documentation of 
reason(s)  in the eCRF . 
The reason for withdrawal will be recorded in the e CRF.  
The EOT visit must be performed and documented within [ADDRESS_395248] dose of eryaspase 
or chemotherapy. AEs/SAEs and concomitant medications must be collected up to [ADDRESS_395249]. For 
details of the assessments to be performed , refer to the Schedule of Events ( SOE ), Table 1. 
6.2 PARTICIPANT WITHDRAWAL FROM THE S TUDY  
A patient may be withdrawn from the study  for the following reasons:  
• Patient ’s withdrawal of consent for the study. 
• Loss to follow -up. 
• Death . 
• Sponsor ’s decision, including discontinuation of the study. 
The reason for withdrawal will be recorded in the e CRF.  
If a patient withdraws from the study  during treatment,  it is recommended that the EOT  visit be 
performed and documented within [ADDRESS_395250]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395251] make every effort to follow 
safety events to resolution, until the event s stabilize , or until the patient’s death.  
If the patient withdraws consent for disclosure of future information, the Sponsor may retain and 
continue to use any data collected before such a withdrawal of consent. 
If a patient withdraws from the study, he/she may request destruction of any samples that have 
been taken but  not yet  tested, and the Investigator must document this request in the site ’s study 
records and inform the Sponsor within [ADDRESS_395252] be taken if a participant fails to return to the clinic for a required study visit: 
• The site will attempt to contact [CONTACT_320200] , will counsel the patient on the importance of maintaining the assigned visit 
schedule, and will ascertain whether the patient wishes to and/or should continue in the 
study. 
• Before a patient is deemed lost to follow -up, the Investigator or designee must make 
every effort to regain contact [CONTACT_10970] (where possible, 3  telephone calls and, if 
necessary, a certified letter [or local equivalent] to the patient ’s last known mailing 
address). These contact [CONTACT_23526] ’s medical record or 
study file. 
• Should the patient continue to be unreachable, he or she will be considered to have withdrawn from the study with a primary reason of loss to follow -up. 
 
6.[ADDRESS_395253] igator will promptly inform study 
participants and the relevant IEC/IRB, and the Sponsor will provide the reason(s) for the termination or suspension to competent regulatory authorities. Study participants will be contact[CONTACT_320201]. 
The I nvestigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of an investigat ional site by [CONTACT_320202]:  
• Failure of the Investigator to comply with the protocol, the sponsor ’s procedures, or 
Good Clinical Practice ( GCP ) guidelines. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395254]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 79 of 119  • Inadequate recruitment of patients by [CONTACT_737]. 
• Discontinuation of further drug development. 
The Investigator will be responsible for completing all study close -out procedures as required by 
[CONTACT_1052]/or local regulatory authorities if a site is closed or the study is terminated  early.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395255]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 80 of 119  7 STUDY ASSESSMENTS AND PROCEDURES  
Screening and study procedures and their timings are summarized in the Schedule of Events 
(SOE) in Table 1. 
Adherence to the study requirements, including those specified in the SOE , is essential and 
required for study conduct. Protocol waivers or exemptions are not allowed (with the exception 
of those in response to immediate safety concerns).  
All screening evaluations must be completed within [ADDRESS_395256] (IRB)/Independent Eth ics 
Committee ( IEC)-approved Informed Consent Form  (ICF)  prior to any screening assessments.  
However, an evaluation conducted as part of the patient ’s routine clinical management (e.g., 
blood counts, disease evaluation) that is performed  before signature  [CONTACT_320228]- specified criteria 
and was  performed within the time frame defined in the SOE  (Table 1 ). Separate informed 
consent for the optional PGx assessment will be requested at the same time.  
For further information on the informed consent process,  please refer to Section  9.1.1. 
Eligibility criteria are to be evaluated within 3  weeks  prior to randomization, with confirmation 
that the patient continues to meet eligibi lity pre -dose on Cycle  1 Day  1. 
NOTE:  Screening period longer than 3 weeks may be allowed due to COVID-19 related 
restrictions  
Screening Assessments to Be Completed within  3 Weeks prior  to Randomization 
• Demography, including gender and date of birth. 
• Medical history , including cancer history and prior anticancer therapi[INVESTIGATOR_014] . 
• Complete physical exam, including height and weight (height to be collected at screening only). 
• Vital signs: temperature, heart rate, and blood pressure. 
• ECOG PS , and KPS if ECOG PS is 1  (see APPENDIX 2 and APPENDIX 3). 
• Laboratory assessments (to be completed within 14  days of randomization): hematology, 
clinical chemistry , and coagulation panel s will be completed at the local laboratory for 
the parameters defined in Table [ADDRESS_395257]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 81 of 119  NOTE:  Please see Table 12 in Section 7.8.3 for Minimum Safety Labs required during 
COVID-19. 
• Serum pregnancy test ( for patients of childbearing potential): a negative human chorionic 
gonadotropin test is required before the patient may receive any chemotherapy agent or 
eryaspase. 
• NOTE:  A woman is considered of childbearing potential unless post-menopausal or 
permanently sterile by [CONTACT_320203]: hysterectomy, bilateral salpi[INVESTIGATOR_15559]. A woman is considered postmenopausal in she has not had 
menses for 12  months without an alternative medical cause.  
• Collection of a paraffin -embedded tumor tissue block, or  a minimum of 10 unstained 
slides, obtained from an archived or newly obtained tumor tissue sample for biomarker 
analysis. 
• Whole blood sample for PGx assessment (optional) 
• 12-lead ECG . 
• Baseline disease assessments:  
− Radiologic al imaging studies : 
o Chest CT scans. 
o Abdomen CT scans. 
o Brain MRI is indicated in patients with known/ suspected brain metastasis at study 
entry . Brain scan s will be repeated during the study at 12-week intervals if 
clinically indicated . 
o Bone scan is indicated in  patients with known/ suspected bone metastasis at study 
entry . Bone scans will be repeated during the study at 12- week intervals if 
clinically indicated . 
• Additional imaging as clinically indicated . 
− In general, CT scan s are the preferred method of radiologic al assessment of the chest 
and abdomen; however, other techniques may be used (i.e., MRI ). 
o The s ame imaging technique must be used for a given patient throughout the 
study.  
o Radiological images must be collected in a de -identified manner, quality 
controlled, stored, and available for future review and reading as necessary.  
• Prior and c oncomitant medications:  record all medications the patient has received from 
14 days prior to randomization , as well as any and all  prior therap ies for the treatment of 
pancreatic cancer (or cancer -related events such as bone pain) , and any currently ongoing 
medications . 
• Collection of AEs and SAEs from the date of informed consent. 
Table [ADDRESS_395258] of Laboratory Assessments  
Cate gory  Parameter  
Hematology:  Hematocrit  
Hemoglobin 
Platelet count 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395259]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395260] of Laboratory Assessments  
Cate gory  Parameter  
RBC count  
White blood cell (WBC) count with differential  
Neutrophils  
Lymphocytes  
Eosinophils  
Monocytes  
Basophils  
Coagulation:  Fibrinogen  
Antithrombin  III (AT  III) 
 
Serum Chemistry and Tumor Markers:  Albumin  
Alkaline phosphatase 
Alanine aminotransferase (ALT) Ammonia  
Amylase  
Aspartate aminotransferase (AST)  
Bicarbonate  
Calcium  
Chloride  
Creatinine  
Gamma-glutamyl transferase (GGT)  
Glucose  
Lactate dehydrogenase (LDH)  
Lipase  
Potassium  
Sodium  
Total bilirubin Total cholesterol  
Triglycerides  
Urea  
Uric acid  
CA19 -9 
Other Laboratory Tests:  Blood phenotype, Rh factor, and ABO blood 
group, all done on two separate samples  
Irregular antibody screening test (IAST)  
Pregnancy test for women of childbearing 
potential (serum at screening and at End of 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395261]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395262] of Laboratory Assessments  
Cate gory  Parameter  
Treatment; urine on Cycle  1 Day  1 before 
treatment and as indicated during treatment for 
females of child -bearing potential ) 
 
7.[ADDRESS_395263] 5 days prior to Cycle  1 Day  1: 
− RBC phenotype (including D, C, E, c, e, K and other antigens  as per site practice ), 
ABO blood group status, and Rhesus factor , all assessed on [ADDRESS_395264] 
(Investigator or designee) , and the place and time of the delivery must be sent as soon as possible 
once the first infusion is scheduled (at the latest 5 working days before planned administration  ). 
7.3 TREATMENT PHASE  ASSESSMENTS AND PROCEDURES  
7.3.1 Assessments p rior to Initiation of Treatment on Cycle  1 Day 1 
The following assessments will be performed on Cycle  1 Day  1 prior to initiation of study 
treatment. Screening laboratory tests and procedures may be substituted for those on Cycle 1 
Day 1 if performed within 5  days prior to Cycle 1 Day  1. 
• Symptom-directed physical examination, including body weight. 
• Vital signs: temperature, heart rate, and blood pressure. 
• ECOG PS , and KPS if ECOG PS is 1  (see APPENDIX 2 and APPENDIX 3). 
• EORTC QLQ- C30. 
• Hematology, cli nical chemistry , and coagulation panel s and CA19-9, Table 10. 
• Urine pregnancy test for patients of childbearing potential. A negative test is required before administration of any chemotherapy agent or eryaspase. 
• Baseline blood and plasma samples for ph armacokinetic and pharmacodynamic analysis 
(for patients in the eryaspase arm) . 
• Baseline blood samples for immunogenicity (for patients in the eryaspase arm) . 
• Baseline blood and plasma samples for biomarker analysis  (both arms) , such as ctDNA, 
proteomics, and transcriptomics. 
Prior to administration  of the first infusion of eryaspase , (and each subsequent infusion during 
the treatment period) , an IAST and  complete compatibility (cross -match) test between the 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395265]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 84 of 119  patient’s blood and eryaspase should be performed using the removable segment tubes to 
confirm compatibility. In case a patient receives multiple bags of eryaspase to achieve the 
intended prescribed dose, a separate cross- match test must be performed with each eryaspase bag 
to confirm compatibility.  In case of incompatibility, an additional blood sample may be required 
for further investigations. Details of collection and shipment are provided in the IMP Manual.  
7.3.2 E fficacy Assessments During the Treatment Phase  
[IP_ADDRESS] RADIOLOGICAL DISEASE ASSESSMENTS  
CT/MRI of the chest and abdomen will be performed every 8 weeks (±3  days) calculated from 
the date of randomization until disease progression, patient’s withdrawal from study , or death. 
Every effort should be made to adhere to the assessment schedule, irrespective of any treatment delays or modifications . The same imaging technique must be utilized for a given 
patient throughout the study.  
Bone and/or brain scans are to be  repeated every 12  weeks if clinically indicated.  
[IP_ADDRESS] HEALTH OUTCOMES  
Patient -reported outcomes will be measured using a standardized instrument, the EORTC  
QLQ- C30. The self -administered questionnaires will be completed every 4 weeks during the  
treatment phase. 
[IP_ADDRESS] PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENTS  
For patients in the eryaspase arm , blood/plasma samples for pharmacokinetic and 
pharmacodynamic assessment will be collected , where possible, at the following time points of 
Cycles 1 and 3: 
• Day 1 prior to eryaspase  administration,  
• Day [ADDRESS_395266] - eryaspase infusion, 
• At 5-[ADDRESS_395267] -infusion (at the Investigator’s discretion), and  
• At Day 15 pre-dose. 
Samples will be analyzed for whole blood and plasma concentrations of ASNase  and amino 
acids. The sparse PK data will be combined with previous data as part of a Population PK 
(POP  PK) analysis.  To this effect, sample collection for PK and pharmacodynamics may be 
stopped based on the outcome of the evaluation of sample results during the course of the trial. 
The date and clock time for collection of each blood sample and for sample processing  (e.g., 
time placed on ice, time of centrifugation, etc.) will be documented. Further details will be 
provided in the lab manual. 
[IP_ADDRESS] IMMUNOGENICITY  
For patients in the eryaspase arm, samples for assessment of anti -ASNas e antibodies and 
neutralizing antibodies will be collected pre -dose at Cycle  1 Day  1, and Day  15 and at Day 1 of 
every second cycle thereafter (i.e., at Cycle  3 Day  1, Cycle 5 Day  1, and so on), and upon 
determination of disease progression, and EOT, whichever is sooner. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395268]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 85 of 119  [IP_ADDRESS] BIOMARKER ASSESSMENTS  
Plasma Samples  
Plasma samples for b iomarker analys is will be collected pre-dose on Cycle  1 Day  1 and Day  15 
and at Day  1 of every second cycle thereafter ( i.e., at Cycle 3 Day  1, Cycle 5 Day  1, and so on), 
upon determination of disease progression, and EOT, whichever is sooner. 
Pharmacogenetic Sample  
An optional blood sample for pharmacogenetic (PGx)  analysis will be obtained once during the 
study, preferably during the screening phase.  A separate informed consent must be signed before 
the sample  is obtained . 
7.3.3 S afety Assessments during the Treatment Phase  
The following safety assessments will be perfor med pre-dose for all patients on Day  1, and 
Day 15, unless otherwise specified . 
• Hematology, clinical chemistry, and coagulation panel s and CA19-9. 
• For patients under eryaspase arm, in addition to regular evaluation of liver function tests 
before treatment administration, patients will be monitored on weekly basis in the event 
of occurrence of ≥Grade 2 elevation of liver enzymes and bilirubin levels.  
• For women of childbearing potential, additional pregnancy testing should be performed 
in case of delayed menstrual period and is recommended to be performed monthly and 
until the end of treatment exposure extended by 30 days, in case of sexual activity .  
• Vital signs: temperature, heart rate, and blood pressure. 
• Symptom-directed physical examination, including body weight. 
• ECOG PS  (see APPENDIX 2). 
• 12-lead ECG: as clinically indicated.  
• Collection of AEs : from time of informed consent until [ADDRESS_395269] study 
treatment or start of new anti -cancer treatment, whichever is sooner . 
• Review/record ing of all concomitant medications added and/or changed from [ADDRESS_395270] study treatment  or start of new 
anti-cancer treatment, whichever is sooner . 
7.4 END OF TREATMENT VISIT 
The End of Treatment ( EOT ) visit should be conducted as soon as possible (but no later than 
30 days ) after the patient ’s discontinuation of the study drug, and will include the following 
assessments:  
• Hematology, clinical chemistry, and coagulation panel s and CA19-9. 
• Serum pregnancy test for patients  of childbearing potential . 
• Vital signs: temperature, heart rate, and BP. 
• Symptom- directed physical exam , including body weight. 
• ECOG PS  (see APPENDIX 2). 
• EORTC QLQ- C30. 
• Review of AEs and concomitant medications. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395271]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 86 of 119  • Samples for immunogenicity (for patients in the eryaspase arm) and biomarker analysis  
(both arms). 
7.5 FOLLOW -UP PHASE ASSESSMENTS AND PROCEDURES  
During the follow-up phase, the extent of efficacy evaluation will depend on the disease status: 
• In the absence of disease progression or starting new anti- cancer therapy  
− Radiological imaging of Tumor lesions to be carried out every 8 weeks until disease 
progression, 
− And then OS follow up every [ADDRESS_395272] for follow up or withdrawal 
from study  
• In the presence of objective disease progression or start of anticancer therapy  
−  OS follow up every [ADDRESS_395273]-Study Subsequent Cancer Therapy  
Information will be collected about any subsequent cancer therapy  given after discontinuation of 
study drug (s) , including both medications and procedures.  
7.5.2 S urvival Follow- Up 
Survival information will be collected by [CONTACT_648], follow- up visit, or from medical records  
approximately every 8 weeks from the date of the EOT visi t until the patient’s  death, until the 
patient is lost to follow -up, or until study closure. Survival follow -up will include collection of 
information about any subsequent anticancer therapy received after discontinuation of study 
drug. 
If a patient fails to return for scheduled visits or is unreachable for survival follow -up, the 
following efforts should be made to contact [CONTACT_12552]/her: 3 phone attempts, including the date and 
time, should be documented in the patient ’s chart.  If there is no response to the phone calls, a 
certified letter or local equivalent should be sent. After these efforts have been exhausted with no 
response, a patient should be considered as lost to follow-up. 
7.[ADDRESS_395274]/MRI scans of the chest and abdomen will be performed every [ADDRESS_395275]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395276] Comm ittee, version 1.1  (RECIST  1.1). The 
modifications to RECIST  1.[ADDRESS_395277] 1.1. These modifications are indicated  
below in italics . 
[IP_ADDRESS] KEY D EFINITIONS  
[IP_ADDRESS].1 MEASURABLE DISEASE  
• Measurable non -nodal lesions:  those that can be accurately measured in at least [ADDRESS_395278] diameter (LD) to be recorded as ≥[ADDRESS_395279] scan (CT slice thickness no greater than 5  mm).  
• Malignant lymph nodes:  to be considered pathologically enlarged and measurable, a 
lymph node must measure ≥15 mm in the short axis (SA) when assessed by [CONTACT_3610] (CT slice thickness recommended to be no greater than 5  mm).  
• It is recommended that slice gaps not be utilized for th e image acquisition procedures.  
• All radiographic measurements should be taken and recorded in millimeters utilizing an electronic measurement method based on lesion boundary definition. 
• Lesions on chest X -ray will not be considered measurable.  
[IP_ADDRESS].2 NON- MEASURABLE DISEASE  
• All other lesions (or sites of disease), including small lesions (LD <10  mm or 
pathological lymph nodes ≥10 mm to <15  mm in the SA) as well as truly non -measurable 
lesions, are considered non -measurable disease. Lesions considered truly non -measurable 
include leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic involvement of skin or lung, and masses or abdominal organomegaly identified by [CONTACT_320204] e 
imaging techniques. 
[IP_ADDRESS].3 TARGET LESIONS  
• Target lesions must be measurable lesions.  
• All lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, will be identified as target lesions, recorded and measured a t baseline, and followed consistently throughout the study . 
• Target lesions should be selected on the basis of their size (based on LD for non-nodal lesions or SA for lymph nodes), their suitability for accurate repeated measurements, and on their being most representative of the patient’s tumor burden.  
• A sum of the diameters for all target lesions will be calculated and reported for each time 
point. The baseline sum of diameters will be used as a reference according to  which the 
objective tumor response will be characterized.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395280]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 88 of 119  [IP_ADDRESS].4 NON-T ARGET LESIONS  
• All other lesions (or sites of disease, including any measurable lesions that were not 
selected as target lesions) will be identified as non -target  lesions and indicated as present 
at baseline.  
• It is possible to record multiple non -target lesions involving the same  organ as a single 
item (e.g., multiple enlarged pelvic lymph nodes or multiple liver metastases).  
• Measurements of these non -target lesions will not be performed, but the presence, 
absence, or unequivocal progression of these lesions should be noted for su bsequent 
assessments.  
[IP_ADDRESS].5 NEW LESIONS  
• A separate assessment category of “ new lesions” is defined as part of the independent 
reading. 
• The finding of a new lesion should be unequivocal (i.e., not attributable to differences in scanning technique, change in imagi ng modality, etc.).  
• If a new lesion is equivocal (i.e., because of its small size), and follow-up imaging 
confirms that it is definitely a new lesion, the n the lesion will be considered to have 
appeared on the date of the initial scan , indicating disease p rogression as of that date .  
• A lesion identified on a follow -up scan in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression.  
• A lesion that reappears at follow-up after a response of PR or  stable disease is not 
considered new . The lesion’s LD (or SA for lymph nodes) is added b ack into the sum of 
diameters.  
• A lesion that reappears at follow- up after a CR is automatically considered PD.  
[IP_ADDRESS].6 LYMPH NODES  
• At baseline, lymph nodes with tumor burden will be considered target lesions if the SA is 
≥15 mm.  
• At baseline, lymph nodes will be considered non- target lesions if the SA is ≥10 mm and 
<15 mm.  
• At baseline, lymph nodes will be considered normal if the SA is <10 mm.  
• At subsequent assessments, a lymph node must measure ≥10 mm along the SA to be considered a new lesion. 
• A lymph node that was identified as a target lesion  at baseline that falls below the 
measurable threshold at subsequent assessment  and then gets larger is not considered 
new if it follows  a PR or SD. The lymph node SA measurement is added back into the 
sum of diameters.  
• A lymph node that was identified as  a target lesion  at baseline that falls below the 
measurable threshold at subsequent assessment  and then gets larger following a CR is 
automatically considered PD . 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395281]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 89 of 119  [IP_ADDRESS] OTHER C ONSIDERATIONS  
[IP_ADDRESS].1 IRRADIATED LESIONS  
Previously irradiated lesions cannot be selected as target lesions. These lesions can be monitored 
to assess prog ression as non -target lesions.  
[IP_ADDRESS].2 HANDLING OF LESIONS THAT SPLIT  
When non- nodal and nodal lesions split or fragment, the individual diameters of the fragmented 
portions should be added together to calculate the target lesion sum. 
[IP_ADDRESS].[ADDRESS_395282] that they can no longer be separated by [CONTACT_320205], the LD or SA of the merged lesion should be measured . 
[IP_ADDRESS] MEASUREMENT OF SMALL LESIONS ON F OLLOW -UP SCANS  
[IP_ADDRESS].1 NON- NODAL LESIONS  
A non- nodal target lesion that is present but too small to measure accurately  at evaluations after 
baseline (<5  mm but greater than 0  mm in unilateral dimension) will be classified as Too small 
to measure  and will be assigned a value of 5 mm for the purposes of determining the sum of 
diameters. All other lesions (i.e., ≥5 mm) will have actual size recorded.  
[IP_ADDRESS].[ADDRESS_395283] the actual SA  measurement recorded, even if the lymph 
node regresses to <10  mm on study. This means that when lymph nodes are included as target 
lesions, the sum of diameters may not be zero even if CR criteria are met, since a normal lymph node is defined as having an SA of <10 mm. 
[IP_ADDRESS] RESPONSE C RITERIA 
[IP_ADDRESS].1 TARGET LESION RESPONSE CRITERIA  
• Complete response (CR): Disappearance (or normal ization) of all target lesions.  
− Any pathological lymph nodes (whether target or non- target) must have reduction in 
SA to <10 mm.  
• Partial response (PR): At least 30% decrease in the sum of diameters of target lesions , 
taking as reference the baseline sum of diameters.  
• Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest su m of diameters while on study. 
• Progressive disease (PD): At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum of diameters on study (this incl udes the 
baseline sum if t hat is the smallest on study). In addition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least [ADDRESS_395284]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 90 of 119  • Non-evaluable (NE): Patient time points that have inadequate or missing images, 
including the inability to visualize >25% of target disease . 
[IP_ADDRESS].2 NON-T ARGET LESION RESPONSE CRITERIA  
• CR: Disappearance (or normalization) of all non -target  lesions.  
• All lymph nodes must be non-pathological in size (<10 mm SA).  
• Non-complete response, non-progressi ve disease (Non -CR/Non -PD): Persistence of 1 or 
more non- target lesion(s).  
• PD: Unequivocal progression of existing non- target lesions.  
• NE: Patient time points that have inadequate or missing images, including the inability to 
visualize >50% of non-target disease . 
• No disease (ND): No non -target disease noted. The absence of non -target lesions at 
follow -up time points is designated as ND and not SD when there is no non-target 
disease noted at baseline. 
[IP_ADDRESS].[ADDRESS_395285] progressive disease overall.  
[IP_ADDRESS].4 RESPONSE ASSESSMENT IN CASE OF MISSING OR 
TECHNICALLY INADEQUATE SCANS  
If no lesions were identified at baseline in a specific body region (e.g., chest or abdomen) and the scan of that body region is unavailable at follow- up, then the response assessment will be based 
on the scans of the other regions. 
[IP_ADDRESS] DETERMINATION OF R ADIOLOGICAL B EST O VERALL RESPONSE  
Best overall response ( BOR) is the best response recorded from the start of treatment until the 
end of treatment (taking as reference for PD the smallest measurement recorded since the start of 
treatment). 
7.6.2 He
 alth Outcomes  
Patient -reported outcomes will be measured using  a standardized instrument, the EORTC 
QLQ- C30, at the following time points : 
• Cycle  1 Day  1 before treatment. 
• Every 4 weeks  during the treatment phase, Day 1 of each cycle before treatment . 
• At the End of Treatment visit.  
• Every 8 weeks  during the follow-up phase until end of study. 
The following scores will be calculated: 5 functional scales, 3 symptom scales, a global health 
status/ quality of life (QoL ) scale, and 6 single items  (Table 11). 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395286]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 91 of 119  Table 11 EORTC QLQ -30 Scales and Items [43]  
 Scale  Number 
of Items  Item 
Range* Version  3.0 
Item Numbers  Function 
Scales  
Global health 
status/QoL  QL2 2 6 29, 30  
Functional scales  
Physical functioning 
(revised)†  PF2 5 3 1 to 5 F 
Role functioning (revised)†  RF2 2 3 6, 7 F 
Emotional functioning EF 4 3 21 to 24 F 
Cognitive functioning  CF 2 3 20, 25 F 
Social functioning  SF 2 3 26, 27  F 
Symptom scales/items  
Fatigue FA 3 3 10, 12, 18  
Nausea and vomiting  NV 2 3 14, 15   
Pain PA 2 3 9, 19  
Dyspnoea DY 1 3 8  
Insomnia SL 1 3 11  
Appetite loss  AP 1 3 13  
Constipation CO 1 3 16  
Diarrhoea  DI 1 3 17  
Financial difficulties  FI 1 3 28  
*Item range  is the difference between the possible maximum and the minimum response to individual items; 
most items take values from 1 to 4, giving range  = 3. 
†(revised) scales are those that have been changed since version 1.0, and their short names are indicated by  a 
suffix “2” – for example, PF2.  
7.6.[ADDRESS_395287]  of eryaspase on amino acid 
levels will also be evaluated.  
For all patients who provide samples, PK and pharmacodynamics of eryaspase will be assessed at each meas urement  in terms  of: 
• Total ASNase  activity (U/L) , 
• Plasma ASNase  activity (U/L), 
• Plasma concentrations of asparagine (µmol/L) , and  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395288]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 92 of 119  • Plasma concentrations of glutamine (µmol/L). 
See Section 7.8.[ADDRESS_395289] samples for biomarker assessments in all patients. Sample types collected 
include tumor samples, whole blood samples and plasma samples. Biomarkers will be tested 
prospectively and summarized at baseline and, where applicable, at subsequent as sessments. 
These assays will be performed at  central laboratories.  In addition, biomarkers identified in other 
clinical studies may also be assessed in the biomarker samples collected from patients enrolled in this study. Detailed instructions for processing, storage, and shippi[INVESTIGATOR_169162]  
[IP_ADDRESS] ANALYSIS OF TUMOR TISSUES  
A paraffin -embedded tissue block (FFPE) , or a minimum of 10  unstained slides, obtained from 
an archived or newly obtained tumor tissue sample (primary tumor or metastatic lesion) will be 
required.  
All tumor samples may be used to assess the effects of eryaspase and tumor -relevant pathway 
dysregulation (such as mutations, amplifica tions) that may be important in the development of 
progression of cancer as well as for the potential use in diagnostic development. Assays to 
evaluate biomarkers that may correlate with clinical outcome may be performed at central 
laboratories, such as: 
• Mutational analyses and detection of gene amplification of relevant oncogenes (e.g., KRAS, MYC, PI3KCA, and FGFR ) and genes involved in activated pathways of survival 
and proliferation (e.g., Erk1/2, STAT3, AKT, and MAPK). 
• Expression profiling may be done by [CONTACT_320206] ( RNA) extracted from 
tissue. 
• Depending on tissue availability, additional assays including immunohistochemistry  
(IHC), gene expression profiling, or protein activation may be performed. 
• If applicable, mechanisms of resistance to eryaspase treatment will be evaluated.  
 
 
[IP_ADDRESS] ANALYSIS OF PLASMA SAMPLES  
Plasma samples will be collected for the following biomarker analyses : 
• Circulating tumor DNA (ctDNA) may  be analyzed in plasma samples to identify 
plasma-borne somatic mutations as predictors of clinical outcome with eryaspase . 
• Proteomic and transcriptomic analyses of biomarker samples may be conducted to 
identify profiles that can be related to treatment response.  Examination of pre - and 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395290]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395291]- treatment protein and trans cript profiles may uncover novel blood- borne candidate 
biomarkers/profiles  that could be used to predict response to eryaspase. 
• Markers of  immunological response may be evaluated for correlation with response. 
[IP_ADDRESS] PHARMACOGENETIC A NALYSIS  
Pharmacogenetic analy sis is the study of the variability in drug response due to hereditary 
factors. Individual genetic composition (genotype) may have an impact on the PK  and the 
pharmacodynamic effects of the drug. Examples of pharmacogenetic analyses include 
genotypi[INVESTIGATOR_31081] m etabolizing enzymes such as uridine 5'-diphosphate glucuronosyltransferases 
(UGTs ) and transports, evaluation of a whole- genome single nucleotide polymorphism (SNP), or 
other genetic marker sets. The information obtained is solely used to further characterize drug 
effects and does not have clinical, diagnostic, or therapeutic implications for the individual patients. This PGx research is not designed to determine whether other members of the patien t’s 
family are at risk of developi[INVESTIGATOR_320168].  The Sponsor will be blinded as to the 
subject’s identity and since the analysis is done for research purposes only, individual results will not be shared with the I nvestigator and/or subject or the subject’s relatives. Any information 
obtained is not intended for inclusion in the medical record. This research will not change the care the subject receives in this study . 
A whole blood sample (5 mL) will be drawn using a tube containing ethylenediaminetet raacetic 
acid ( EDTA ) from patients who provide separate written informed consent for this optional 
procedure. Patient participation in the PGx analysis is voluntary, and refusal of consent will not disqualify the patient from participating in the study. Furthermore, a patient can withdraw consent for  the PGx analysis at any time during the study. 
[IP_ADDRESS] SAMPLE COLLECTION, STORAGE, AND SHIPPI[INVESTIGATOR_320169], processing, handling, storage, and shipment of samples for central laboratory analysis (PK, pharmacodynamics, immunogenicity, biomarkers, and PGx) will be provided in the Laboratory Manual. 
[IP_ADDRESS] BIOANALYSIS  
Samples will be analyzed using validated, where applicable, analytical methods. A description of 
the assays and validation data will be provided in separate  analytical  reports.  
[IP_ADDRESS] STORAGE  OF BIOLOGICAL SAMPLES FOR POTENTIAL FUTURE 
ANALYSIS  
After the end of the study, b iological samples or derivatives (such as DNA, RNA, and protein) 
will be stored  at a central repository for the maximum number of years defined per local 
regulatory requirements to allow scientific research to be conducted in the future as new discoveries are made.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395292]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 94 of 119  7.7 ADVERSE EVENTS AND SERIOUS A DVERSE E VENTS  
The Investigator is required to report to the S ponsor or its representativ e all AEs occurring 
during the clinical study (Title  21 Code of Federal Regulations [ CFR] Part  312.64[b] and 
International Council for Harmonization [ICH] E6 [R2]).   
7.7.1 D efinition of Adverse Events  
An adverse event ( AE) is any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which  does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
7.7.2 D
 efinition of Serious Adverse Events 
A serious adverse event ( SAE)  is any untoward medical occurrence that at any dose: 
1. Results in death , 
2. Is life -threatening, 
3. Requires inpatient hospi[INVESTIGATOR_1081] , 
4. Results in persistent or significant disability/incapacity , 
5. Is a congenital ano maly /birth defect, or  
6. Is otherwise medically significant (any event not meeting the above criteria that , based 
upon medical judgment, jeopardizes the patient, and may require medical or surgical 
intervention to prevent one of the other outcomes listed in the definition of a n SAE ). 
NOTE:  If the standard of care or institutional practice require s hospi[INVESTIGATOR_320170], then such hospi[INVESTIGATOR_320171]. However, should an SAE develop during such a hospi[INVESTIGATOR_059], it will be considered serious and reported as such. 
NOTE:  Disease progression should not be reported as an SAE for the purposes of this study. 
NOTE: in instances, where an adverse event changes to serious event; this date should be the 
onset date of the SAE. 
7.7.3 C
 lassification of Adverse E vents 
[IP_ADDRESS] SEVERITY  GRADING  
The severity of AEs is to be graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE ) version 5.0. For AEs not listed in the 
CTCAE scale, the following definitions should be used: 
• Mild ( Grade  1): The AE is  noticeable to the patient but does not disrupt normal daily 
activities; it does not require discontinuation of the study drug, but may require additional 
therapy. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395293]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 95 of 119  • Moderate ( Grade  2): The AE is moderately uncomfortable and interferes with the 
patient ’s daily activities; it does not require discontinuation of the study drug but may 
require additional therapy. 
• Severe ( Grade  3): The AE is intolerable and disrupts normal daily activities, and may 
require additional therapy or hospi[INVESTIGATOR_5478]/or discontinuation of the study drug. 
• Life-threatening ( Grade  4): The AE exposes the patient to risk of death at the time of 
the event; this  does not refer to an event that might  have caused death if it had been more 
severe. Any event which is considered life- threatening  is considered to be serious, and 
must be reported as described in Section  7.7.6. 
• Death related to AE ( Grade  5): An event that results in death is considered a Grade  [ADDRESS_395294] be reported as 
described in Section  7.7.6. 
[IP_ADDRESS] CA[LOCATION_003]LITY ASSESSMENT  
An Investigator who is qualified in medicine must assess the causal  relationship between 
eryaspase, chemotherapy, or both and each occurrence of each AE/SAE. The Investigator should decide whether, in his/her medi cal judgment, there is a “reasonable possibility” that the event 
may have been caused by [CONTACT_5257] (IMP and non- IMP background treatment) . 
• If no valid reason exists for suggesting a causal relationship between the study drug (IMP or non- IMP background treatment) and the occurrence of the AE , then the AE should be 
classified as “unrelated.”  
• If there is any valid reason  for suspecting a possible causal  relationship between the study 
drug (IMP and non- IMP background treatment) and the occurrence of the AE, then the 
AE should be considered “related.” 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study treatment administration , should be 
considered and investigated. The I nvestigator should also consult the IB in making his/her 
assessment.  
There may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report to the Sponsor. However, it is critical that the Investigator provide an assessment of causal relationship  for every event before the initial 
transmission of the SAE report to the Sponsor, as it is one of the criteria used when determining 
regulatory reporting requirements.  
The Investigator may  change his/her opi[INVESTIGATOR_9242]-up information ; in 
this case an SAE follow -up report should be sent with the updated causal relationship  
assessment.  
Definitions of the causal relationship of an AE to the use of the study medication are as follows:  
• Related:  There is a reasonable possibility of a causal relationship between the 
administration of the study drug (IMP and non-IMP background treatment) and the adverse event emergence.  “Reasonable possibility ” means there is evidence to suggest a 
causal relationship , e.g. temporal relationship, biological plausibility, between study 
intervention and the AE. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395295]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 96 of 119  • Not Related: There is no reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study 
intervention and the event onset, or an alternate etiology has been established.  
[IP_ADDRESS] EXPECTEDNESS  
The drug safety group will be responsible for determining whether an AE is expected or unexpected, based on available reference safety information in the IB . An AE will be considered 
unexpected if its nature, severity, or frequency is not consistent with the reference safety 
information described for eryaspase in the IB. 
7.7.[ADDRESS_395296] medical terminology. For each event, the Investigator will evaluate and 
report the onset date, resolution date, severity , causality, action taken, seriousness, outcome (if 
applicable), and whether or not it caused any change in study drug administration (dose delay , 
dose reduction, or study treatment discontinuation).  Changes in the severity of an AE must be 
documented to allow the duration of the event at each level of severity to be assessed. AEs 
characterized as intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. 
Whenever possible, diagnoses should be provided when signs and symptoms represent a 
common etiology (e.g., cough, runny nose, sneezing, sore throat, and head congestion should be reported as “upper respi[INVESTIGATOR_4416]”). A specific disease or syndrome, rather than individual associated signs and symptoms, should be identified whenever possible. Where there is no link between different clinical symptoms occurring at the same time, each sign should be recorded as a separate AE. All reported information must be in English. 
When an AE occurs, it is the Investigator ’s responsibility  to review all documentation related to 
the event (e.g., hospi[INVESTIGATOR_1088], laboratory and diagnostics reports). The Investigator will 
then record all relevant AE information in the e CRF.  It is not acceptable for the I nvestigator to 
send photocopi[INVESTIGATOR_113502]’s medical records to the Sponsor in lieu of completion of the 
eCRF AE pages. 
In some instances, the S ponsor may request copi[INVESTIGATOR_320172]. 
Should this occur , all patient identifiers, with the exception of the patient’s  study identification 
number, will be redacted on the copi[INVESTIGATOR_47957]. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395297]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 97 of 119  7.7.6 S erious Adverse Event Reporting  
[IP_ADDRESS] INVESTIGATOR REPORTING RESPONSIBILITIES FOR SERIOUS 
ADVERSE EVENTS  
If an AE meets the definition of “serious,” the I nvestigator must report it immediately (within a 
maximum of 24  hours from knowledge of the event), r egardless of its  presumed relationship to 
the IMP . To do so, the I nvestigator  must complete the SAE Form , and forward it to 
PrimeVigilance , mandated by [CONTACT_320207], at: 
Email: [EMAIL_3589]  
eFax (US): +1(0) [PHONE_6696]  
eFax (EU): +44(0) [PHONE_6697] 
All reported information must be submitted in English.  It is not acceptable for the Investigator to 
send photocopi[INVESTIGATOR_113502]’s medical records to the Sponsor in l ieu of completion of the 
SAE form.  
If necessary, the Investigator will be asked for additional information which may include hospi[INVESTIGATOR_2553], laboratory reports, or other test results.  
SAEs must be followed until they resolve, or are determined to be perm anent at the EOT visit, or 
until the patient dies or is lost to follow -up. The I nvestigator must forward any relevant 
follow -up information for SAEs (including outcome and diagnosis) in the same manner as the 
initial report within 24  hours of obtaining the information.  
[IP_ADDRESS] EXPEDITED REPORTING AND INVESTIGATOR SAFETY REPORTS  
The Sponsor is responsible for submitting all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) related to the IMP to Competent Authorities (and IECs/IRBs  as required ) and to  
Investiga tors in accordance with ICH Guidelines and/or local regulatory requirements, as 
applicable. 
It is the Investigator’s responsibility to notify the local IEC/IRB of all suspected unexpected 
serious adverse reactions or other specific safety information ( e.g., summary or listing of SAEs ) 
involving risk to human subjects as appropriate according to local requirements. 
The I nvestigator will acknowledge and file all safety updates received from the sponsor along 
with the IB  in the Investigator’s Site File.  
7.7.[ADDRESS_395298]:  
• Venous thrombotic events, 
• Hepatic toxicity,  
• Pancreatitis , and  
• Transfusion- related events. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395299]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395300] immediately report any pregnancy occurring 
during the trial to ERYTECH Pharma  by [CONTACT_63412] “Exposure during pregnancy case report 
form” and forward it to PrimeVigilance , mandated by [CONTACT_320207], at: 
Email: [EMAIL_3589]  
eFax (US): +1(0) [PHONE_6696]  
eFax (EU) : +44(0) [PHONE_6697] 
Patients will give consent upon enrollment for this reporting of any pregnancy during the trial as well as information about the delivery and about the baby’s health until the age of [ADDRESS_395301] be recorded as AEs. If the infant has a congenital anomaly/birth 
defect, this must be reported and followed as an SAE.  
 
7.8 CHANGES IN P ROTOCOL DUE TO COVID-19  
7.8.1 BACKGROUND  
There is currently an outbreak of respi[INVESTIGATOR_19538] a novel coronavirus. The virus 
has been  named “SARS -CoV- 2” and the disease it causes has been named “Coronavirus Disease  
2019” (COVID-19). On January 31, 2020, Health and Human Services (HHS) issued a 
declaration of a public health emergency related to COVID -[ADDRESS_395302] of clinical trials and 
challenges may arise due to issues such as quarantines, site closures, travel limitations, or interruptions to the supply chain of investigational products.  These challenges may lead to difficulties in meeting protocol-specified procedures, including administering or the use of investigational products or adhering to protocol-mandated visits and laboratory/diagnostic testing.   
Regulatory authorities  in the EU and the US have provided guidance on how to handle the 
potential impacts of the COVID -19 pandemic when conducting clinical studies.  In the US, the 
Food and Drug Administration (FDA) published “FDA Guidance on Conduct of Clinical Trials 
of Medical Products during the COVID-19 Public Health Emergency”, and in the EU, the European Medicines Agency (EMA) published  “Guidance on the Management of Clinical Trials during the COVID- 19 (coronavirus) pandemic”.  
Erytech followed the guidance in these docum ents and conducted a Risk Assessment of the 
COVID-[ADDRESS_395303]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395304] of COVID -19 Minimum Safety Assessments that 
are to be completed.    
Inclusion criteria number 7 (requirement for archival or fresh tumor tissue)  will be waived if 
archive tissue is not available and an elective biopsy cannot be scheduled due to COVID.  
 
7.8.[ADDRESS_395305] Be 
Performed  
Hematology: (no waivers)  Hematocrit  
Hemoglobin 
Platelet count RBC count White blood cell (WBC) count with differential  
Neutrophils  
Lymphocytes  
Eosinophils  
Monocytes  
Basophils  X 
X X X X X 
X 
X X X X 
 
 
Coagulation:   
Fibrinogen  
Antithrombin  III (AT  III) 
  
X 
X 
 
Serum Chemistry and 
Tumor Markers:  Albumin  X 
Alkaline phosphatase  waived  
Alanine aminotransferase (ALT)  X 
Ammonia  waived  
Amylase  X 
Aspartate aminotransferase (AST)  X 
Bicarbonate  waived  
Calcium  X 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395306]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395307] Be 
Performed  
Chloride  X 
Creatinine  X 
Gamma -glutamyl transferase (GGT)  X 
Glucose  X 
Lactate dehydrogenase (LDH)  waived  
Lipase  X 
Potassium  X 
Sodium  X 
Total bilirubin  X 
Total cholesterol  waived  
Triglycerides  waived  
Urea  waived  
Uric acid  waived  
CA19 -9 waived  
Other Laboratory Tests: 
(no waivers)  Blood phenotype, Rh factor, and ABO blood 
group, all done on two separate samples  
Irregular antibody screening test (IAST) 
 
Pregnancy test for women of childbearing 
potential (serum at screening and at End of Treatment; urine on Cycle  1 Day  1 before 
treatment and as indicated during treatment for females of child -bearing potential)  X 
X 
 
X 
 
X 
  
7.8.4  ON-SITE VISIT SCHEDULES  
Investigators should make every attempt to maintain patient’s treatment administration as 
planned for each treatment arm per protocol and patient assessments as outlined in the Schedule of Events.  Given the need to quarantine, travel restrictions and site closures, patients may be evaluated outside of the protocol parameters,  including having laboratory or radiological 
assessments performed at another location.  
Disease assessments, particularly CT/MRI scans should be performed every 8 weeks [+ 3 days] from randomization per protocol, when possible.  Local imaging centers should be used if possible.   
 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395308]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 101 of 119 7.8.5  PHARMACODYNAMIC SAMPLES  
The laboratory that supplied the sulphosalicylic acid (SSA) vacutainer tubes for collecting 
pharmacodynamic (PD) samples was closed  due to COVID-19.  All remaining SSA tubes were 
supplied to active sites.   A determination was made that no further PD samples would be 
obtained after SSA vacutainer supplies were exhausted.  
     
 
7.8.6 PROTOCOL DEVIATIONS  
 
Investigators will apply due diligence to avoid protocol deviations if possible.  All protocol 
deviations due to delayed or missed visits and protocol required assessments or treatments 
related to COVID -19 will be collected on the COVID -19 Related Deviation Log ( APPENDIX 
4).  This log will serve as source documentation for entry into the COVID -19 eCRF form within 
the electronic data capture system.  
 
7.8.7 CLINICAL MONITORING  
 
On-site monitoring visits may be converted to remote monitoring visits according  to the 
Monitoring Plan if on-site visits cannot be conducted due to COVID- 19 restrictions on site 
closures, limited access to study staff and travel restrictions.  Access to source documents 
(medical records) may be provided electronically or other secure  method to comply with 
applicable privacy and security laws for the use and disclosure of information related to the 
research set forth in this protocol if authorized by [CONTACT_320208] .   
 Remote monitoring visits will be converted back to on- site visits upon a site’s availability to 
reopen safety. 
 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395309]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 102 of 119 8 STATISTICAL CONSIDERATIONS  
8.1 STATISTICAL HYPOTHESES  
The primary efficacy endpoint is Overall Survival (OS) and the study is designed to test the 
superiority of eryaspase plus chemotherapy over c hemotherapy alone. The primary analysis will 
test the following hypotheses: 
• Null Hypothesis: The hazard ratio for OS between eryaspase plus chemotherapy and chemotherapy alone is equal to one 
• Alternative Hypothesis: The hazard ratio for OS between eryaspase plus chemotherapy and chemotherapy alone is less than one 
The key secondary efficacy endpoints are Progression -free Survival (PFS), Objective Response, 
Duration of Response (DoR) and Disease Control Rate (DCR) . 
The null and alternative hypotheses for PFS will be as for OS 
The primary analyses of the endpoints objective response and disease control will test the 
following hypotheses: 
• Null Hypothesis: The Objective Response Rate (ORR)/Disease C ontrol Rate (DCR) in 
the eryaspase plus chemotherapy group is equal to the Objective Response Rate (ORR)/Disease Control Rate (DCR) in the chemotherapy alone group  
• Alternative Hypothesis: The Objective Response Rate (ORR)/Disease Control Rate 
(DCR) is grea ter in the eryaspase plus chemotherapy group versus the chemotherapy 
alone group 
There will be no formal statistical testing for DoR as this is not a randomized comparison and 
these data will be evaluated through the presentation of descriptive statistics 
All statistical testing will be undertaken based on a one- sided 2½% significance level subject to 
adjustments for interim analysis . 
8.2 SAMPLE SIZE DETERMINATION 
With a power of 88.4% and  an overall one-sided type I error of 2.5%, and including one interim 
analysis for efficacy with an O’Brien -Fleming type stoppi[INVESTIGATOR_1877], a total of [ADDRESS_395310] ratio in the Phase 2 study for eryaspase was 0.63 (95% CI: 0.39 to 1.10), and 0.[ADDRESS_395311] once 261 (67%) events have been observed.  
Assuming a recruitment period of 26 months, a median overall survival in the control group of 
6.0 months , a 10% probability of droppi[INVESTIGATOR_320150], and a minimum 
follow -up of [ADDRESS_395312]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 103 of 119 8.3 ANALYSIS POPULATIONS  
Intent to Treat population (ITT): All patients randomized , irrespective of whether they 
received study medication. 
Safety population (SP): All randomized patients who receive at least one dose of study 
medication (eryasp ase or chemotherapy). 
Per Protocol population (PP):  The PP population is a subset of the ITT population, and consists 
of all randomized patients who meet the major inclusion  criteria and none of the major exclusion 
criteria and who receive at least one cyc le of treatment. The major inclusion/exclusion criteria 
that are to be considered here will be defined in the Statistical Analysis Plan ( SAP). 
8.[ADDRESS_395313], with stratification factors as used in the 
randomization. Data will be summarized in Kaplan -Meier curves together with m edians and 
95% confidence intervals for those medians. The Cox Proportional Hazards model, stratified for the randomization factors, will be used to obtain a hazard ratio together with its 95% confidence interval.  
8.4.2 A
 nalysis of the Secondary Endpoints  
PFS wi ll be compared between  the two treatment arms using the same methods of analysis as for 
OS. 
The following efficacy analysis will also be performed in the ITT population: 
• ORR, defined as the proportion of patients who achieve objective tumor response (CR or  
PR) per RECIST  1.1. Each patient ’s BOR will be summarized (CR, PR, SD, PD, or 
unknown). This comparison will be based on the Cochran- Mantel -Haenszel test , with 
stratification factors as for the analysis of OS and PFS. Results will be reported in terms of an odds ratio and associated 95% confidence interval. 
• DCR (disease control rate), defined as the proportion of patients who achieve CR, PR and 
SD, 
• DoR will be evaluated in patients who achieve CR/PR.  It will be measured from the time 
CR/PR (whichever is first recorded) is first met until the first date that recurrence or PD 
is objectively documented. Kaplan- Meier curves will be provided in association with this 
analysis; however, there will be no p -value calculations, as this is n ot a randomized 
comparison. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395314]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 104 of 119 • Extensive evaluation of the consistency of treatment effect for OS and PFS across the 
population as a whole will be undertaken by [CONTACT_320183], with displays in forest plots and p- values for treatment by [CONTACT_320209]. 
8.4.[ADDRESS_395315] 16 weeks  respectively. These analyses will follow the 
methodology for DCR outlined in Section 8.4.2. 
All primary and secondary efficacy analyses will be repeated in the PP population. Confirmatory testing for the primary and secondary efficacy endpoints will be performed 
hierarchically  (OS followed by [CONTACT_320210]) in order to account for 
multiplicity. Any statistically significant findings occurring below a non- significant result in the 
hierarchy will be considered as exploratory findings
. 
8.4.[ADDRESS_395316] an  event- driven  interim analysis for OS, based on O’Brien- Fleming 
boundaries . The interim analysis  for OS  will take place following [ADDRESS_395317] ratios and 95% confidence intervals will be calculated for OS within subgroups using the 
unadjusted Cox proportional hazards model in order to evaluate the consistency of treatment 
effect. These subgroups will include those defined by [CONTACT_83353]. Other subgroups 
may also be considered, with a full list being set down in the SAP. 
Subgroup analyses of PFS will be performed  in a similar way. ORR and DCR will also be 
evaluated within these same subgroups, based on the calculation of unadjusted odds ratios and 
corresponding 95% confidence intervals. 
8.4.6 I ndependent Data Monitoring Committee (IDMC) 
An IDMC, composed of at least two oncologists (at least one of whom specializes in pancreatic 
cancer) and a statistician, will be set up to  review the safety of eryaspase during the study and to 
review the interim analysis for efficacy. The IDMC will develop and follow an IDMC plan and 
charter.  
The IDMC will review the safety of eryaspase in combination with irinotecan -based therapy or 
gemcit abine/A braxane regimen after [ADDRESS_395318]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395319]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 106 of 119 9 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
9.1 REGULATORY, E THICAL , AND STUDY OVERSIGHT C ONSIDERATIONS  
9.1.1 Informed Consent Process  
Participation  in the study is voluntary; each patient must indicate his/her agreement and 
willingness to participate by [CONTACT_320211]-related procedures. 
The Sponsor or designee will provide an Informed Consent Form to I nvestigators in a separate 
document. The consent forms that are used , including the separate consent form for PGx, must 
be approved both by [CONTACT_320212]/IRBs. 
The ICF  should be in accordance with the principles originating in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory requirements, and Sponsor policy. Prior to the start of any protocol-specific evaluations or screening procedures, the I nvestigator 
(or designated staff) will explain the nature of the study and its risks and benefits to the patient. 
Each patient will receive a copy of the ICF , which includes  patient information. Patients should 
be given ample time to read the information and the opportunity to ask questions. One copy of the signed ICF  will be given to the patient, and another will be retained with the study records by 
[CONTACT_737]. The process of obtaining informed consent should be documented in the patient ’s medical file.  
9.1.2 I
ndependent Ethics Committees and Regulatory Authorities  
This clinical study will be conducted in accordance with the current ICH GCP Guidelines, as well as the ethical principles founded in the Declaration of Helsinki and applicable local laws 
and regulations (including European Directive 2001/20/EC, EU Regulation No. 536/2014, and US Code of Federal Regulations (CFR) 21). 
Before the start of the study, the Sponsor or th e Sponsor’s designee will submit the clinical study 
protocol, ICF , and any other appropriate documents to regulatory authorities in accordance with 
local legal requirements. All required documents will also be submitted to the relevant 
IECs/IRBs by [CONTACT_1034], the Sponsor’s designee, or the investigative site s, as applicable. As 
required by [CONTACT_320213]/IRBs, the Sponsor or I nvestigator will also submit 
the financial arrangements for the study and/ or other financial interests of the Investigator or 
applicable site staff in the investigational drug or the Sponsor company. 
The study will only be conducted at sites where IEC/IRB and regulatory authority approval has 
been obtained as required . 
All substantial amendments to the study protocol will also be submitted to the IECs/IRBs and authorities in accordance with local legal requirements. Amendments must be evaluated to determine whether the ICF should also be revised. Protocol amendments must not be 
implemented without prior IEC/IRB and regulatory approval, except where necessary to eliminate immediate hazards to the subjects or when the changes involve only logistical or administrative aspects of the study (e.g., change in Sponsor contacts or telephone numbers). 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395320]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395321] of all communication with the IECs/IRBs and if applicable, 
between a national coordinating i nvestigator and the IECs/IRBs. This also applies to any 
communication between the investigator (or sub -inve stigator, if applicable) and regulatory  
authorities. 
9.1.[ADDRESS_395322] patient at his/her 
site and submit all eCRFs to the Sponsor (or designee) in satisfactory compliance with the 
protocol within the time  frame specified in the Clinical Trial Agreement. 
This study may be pr ematurely terminated if there is sufficient reasonable cause.  If the study is 
prematurely terminated or suspended, the I nvestigator will promptly inform study participants  
and the relevant IEC/IRB , and the Sponsor will provide the reason(s) for the termination or 
suspension to competent regulatory authorities. Study participants will be contact[CONTACT_164292] , and will be informed of any changes to the study visit schedule.  
Circumstances that may warrant termination or suspension of the study include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants, 
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007] , 
• Determination that the primary endpoint has been met, 
• Determination of futility , and 
• Sponsor decision to stop development of the IMP. 
The s tudy may resume once concerns about safety, protocol compliance, and data quality have 
been  addressed  to the satisfaction of  the Sponsor , IEC/IRB, and/or the applicable regul atory 
agency . 
Following study completion or termination , the Investigator will provide the Sponsor, the 
IEC/IRB, and the applicable regulatory agency with final reports and summaries as required by [CONTACT_427] (e.g., for Investigational New Drug ( IND) studies, the I nvestigator must submit 
a written report to the Sponsor and the Ethics Committee within 3  months after the completion or 
termination of the study). 
9.1.[ADDRESS_395323] any additional procedures for any research-related purpose. 
Investigators will apply due diligence to avoid protocol deviations. All protocol deviations identified via monitoring and data review will be tracked, and all 
significant protocol deviations  (i.e., major deviations that would exclude a patient from the PP 
population; to be defined in the SAP) will be reported in the Clinical Study Report (CSR).  
See Section 7.8.[ADDRESS_395324]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 108 of 119 9.1.5 D efinition of Source Data  
Source data are defined as data contained in original documents or certified copi[INVESTIGATOR_320173]’s medical file  (source documents), including but not limited to hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, pharmacy records, recorded 
data from automated instruments, X -rays, consultant letters and correspondence, and nurse’s 
notes. 
NOTE:  Each patient ’s involvement in the study should be clearly documented in his/her medical 
file; details should include the study protocol number, the patient ’s study identification number, 
the patient ’s consent to take part in the study (with the date of consent), and the dates of all study 
visits. Such essential documents must be retained by [CONTACT_941] I nvestigator in accordance with local 
regulations. 
9.1.[ADDRESS_395325] access to his/her 
personal data during and after the study to ensure the quality of data recorded for  study purposes. 
By [CONTACT_320214], the Investigator agrees to give full and direct 
access to all records (including electronic records) for patients enrolled in the study to the Sponsor or its representatives at the time of each monitoring visit or audit . The records will also 
be available for direct inspection, verification , and copying, as required by [CONTACT_198990], by [CONTACT_320215] (FDA, Agence nationale de sécurité du médicament et  des produits de santé  [ANSM ], EMA , and others) and IECs/IRBs . 
The I nvestigator will comply with applicable privacy and security laws for the use and disclosure 
of information related to the research set forth in this protocol.  
9.1.[ADDRESS_395326] transmission of clinical laboratory data from the central laboratory to the Sponsor’s database. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395327]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395328] all observations and other data pertinent to the study for each study 
participant. Study data for each enrolled patient will be entered into an eCRF by [CONTACT_320216] a secure, validated web -based electron ic data capture (EDC) application. A ll 
users will be required to complete EDC training  before they are given access to the system . 
Instances of missing, discrepant, or uninterpretable data will be queried  to the Investigator for 
resolution , via auto-queries generated by [CONTACT_320217]/or data managers. Any changes to the study data will be made in  the e CRF ; 
the EDC system will document these changes in an audit trail, which will be maintained within the clinical database.  
9.1.9 e
CRF  Completion using Electronic Data Capture  
Guidelines for eCRF completion will be provided and will be reviewed with study personnel before the start of the study , and as needed during the study. 
It is the I nvestigator’s res ponsibility to ensure the accuracy, completeness, clarity, and timeliness 
of the data reported in the patient’s eCRF. All data entered in the eCRFs must be supported by [CONTACT_112099]. The Investigator or designee must  complete eCRFs within 5  days after data are  
collected . 
The Sponsor or designee will review eCRF data for accuracy and completeness during on -site 
monitoring visits and after transmission of data to the Sponsor or designee; any discrepancies 
will be resolved with the I nvestigator or designee, as appropriate. After the data are uploaded  
into the clinical study database, they will be verified for accuracy. The I nvestigator must  answer 
all queries as soon as possible.  
The Investigator will provide formal approval of all information in the eCRFs, including any 
changes made to the eCRFs, to endorse the final submitted data for patients for whom he or she 
is responsible.  
A copy of the final archival eCRF in the form of a compac t disc (CD) or PDF will be provided to 
the Investigator for filing in his/her study file.  The S ponsor will retain the eCRF data.  
9.1.[ADDRESS_395329] research organization (CRO), imaging management vendors, central labs, and statistical firms to perform the operational aspects of the trial. The S ponsor will supervise 
and practice oversight on all outsourced activities. All structures a nd associated procedures will 
be described in the Oversight Plan, which will include information about IMP, quality assurance, and vendor management.  
The Sponsor Medical Monitors will support the Investigators during the conduct of the study, 
and the S ponsor site monitor will support the site personnel and will provide the necessary 
protocol training, RECIST 1.[ADDRESS_395330]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 110 of 119 9.1.11 S afety O versight  
The Sponsor’s Global Drug Safety departm ent or its designated representative will oversee, 
monitor and report AEs  and SAEs to all relevant parties as required by [CONTACT_320218]. Continuous safety monitoring will be performed by I nvestigators and site 
clinicians. An IDMC will be appointed and will meet in  regular intervals to monitor the safety of 
the study participants  and provide recommendations to the Sponsor. 
9.1.[ADDRESS_395331] Research Organization (CRO) and approved by [CONTACT_1034]. 
The S ponsor or its designee will perform on -site monitoring visits as frequently as necessary and 
according to the Monitoring Plan developed for the study to ensure that the investigation is 
conducted according to the protocol design and regulatory requirements. The monitor will cross- check the data entered into the eCRFs and SAE Forms  with the hospi[INVESTIGATOR_40961] 
(source documents) for completeness and clarity. Data queries will be raised in the EDC system , 
findings from this review of eCRFs and source documents will be discussed with the investigational staff , and administrativ e matters will be clarified.  
At site initiation visits, the nature and location of all source documents will be identified to ensure that all sources of original data required to complete the eCRF are known to the Sponsor and investigational staff and are accessible for verification by [CONTACT_320219]. If electronic records are maintained at the investigational site, access to these records and method s 
of verification must be discussed with the investigational staff. 
Direct access to source documents  (medical records) must be allowed for the purpose of 
verifying that the data in the eCRF are consistent with the original source data. It is expected that 
during monitoring visits the relevant investigational staff will be available, the source 
document ation will be accessible, and a suitable environment will be provided for review of 
study- related documents. The monitors will meet with the Investigator on a regular basis during 
the study to provide feedback on study conduct. 
See Section 7.8.7 for further information regarding Clinical Monitoring related to COVID -19. 
9.1.13 Si
 te Audits and Inspections  
The S ponsor is responsible for implementing and maintaining quality assurance (QA) and quality 
control (QC) systems, and for performing systematic and independent auditing of study conduct, 
data generation, documentation, analysis, and reporting to determine whether the evaluated activities are being  performed in compliance with the protocol, the S ponsor’s standard operating 
procedures, GCP, and applicable lo cal regulatory requirements.  
Representatives of the Sponsor ’s clinical QA department or designee may visit the site at any 
time during or after completion of the study to conduct an audit of the study in compliance with regulatory guidelines and company policy. Similar auditing procedures may also be conducted by [CONTACT_320220]/IEC or regulatory body, either as part of a national GCP compliance program or to review the results of this study in support of a regulatory submission. The 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395332]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 111 of 119 Investigator should immediately notify the Sponsor if he or she is contact[CONTACT_426] a regulatory 
agency concerning an upcoming inspection. 
The I nvestigator/institution will ensure direct access to all source data/documents and reports 
(including but not limited to written, electronic, magnetic , and optical records) for the purpose of 
monitoring , auditing, and inspection by [CONTACT_1201]/IEC or regulatory authorities. All parties will 
take reasonable precautions to maintain patient privacy. The I nvestigator and staff are also 
responsible for being present and available for consultation during routi nely scheduled site audit 
visits conducted by [CONTACT_320221] . 
9.1.[ADDRESS_395333]  Keepi[INVESTIGATOR_007]  
[IP_ADDRESS] DATA COLLECTION AND MA NAGEMENT RESPONSIBILITIES  
Patient data will be collected by [CONTACT_941] I nvestigator or designee using the eCRF provided by 
[CONTACT_320222].  
It is the Investigator’s responsibility to ensure the accuracy, completeness, clarity, and timeliness 
of the data reported in the eCRFs. 
All data entered in the eCRFs must be sup ported by [CONTACT_320223], and any 
discrepancies must be explained . 
The I nvestigator or designee will complete eCRFs within 5  days after data are  collected . 
The I nvestigator will provide formal approval of all information in the eCRFs, including any 
changes made to the eCRFs, to endorse the final submitted data for patients for whom the 
Investigator is responsible.  
Patient data necessary for analysis and reporting will be entered into a validated database system. Clinical data management will be performed in accordance with ERYTECH standards and data cleaning procedures.  
[IP_ADDRESS] STUDY RECORD RETENTION 
In compliance with the ICH  GCP guidelines, the I nvestigator/institution will maintain all eCRFs 
(provided at the end of the study on electronic media for site records), source documents that 
support the data collected from each patient, and other study documents as specified in ICH GCP 
Section  8 (Essential Documents for the Conduct of a Clinical Trial ) and applicable regulatory 
requirements. The I nvestigator/institution will take measures to prevent accidental or premature 
destruction of these documents. 
All documents must be retained by [CONTACT_941] I nvestigator for a minimum of two  years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region , or until at least two  years have elapsed 
since the formal discontinuation of clinical development of the investigational p roduct. At the 
end of the two -year period, the Sponsor or its designee must be consulted prior to the destruction 
of study documents. These documents will be retained per country regulation s. It is the 
Sponsor’s responsibility to inform the Investigator/institution as to when these documents no 
longer need to be retained. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395334]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395335] party without the Sponsor’s permission except to Investigator ’s employees and staff 
who have been made aware that the information is confidential and who are bound to treat it as such. 
The Investigator understands that the information developed from this clinical study will be used 
by [CONTACT_320224] s, business partners and associates, and 
government agencies. The Investigator understands that to allow use of the information derived from the clinical study, the Investigator has the obligation to provide the Sponsor with complete 
test re sults and all data developed in the study. 
The S ponsor or designee will list this study on the public databases of clinical studies . 
www.clinicaltrials.gov  and www.clinicaltrialsregister.eu . A clinical study  report of the study will 
be made available after the conclusion of the study. The final report may be submitted to relevant 
regulatory authorities to support a request for product registration. It is the intention of the 
Sponsor to publish the results of this study in a peer- reviewed journal.  
No publication or disclosure of study results will be permitted except under the terms and co
nditions defined in a separate written agreement between the Sponsor and the Investigator 
and/or the Investigator’s institut ion. 
9.2 PROTOCOL A MENDMENT H ISTORY  
Version  Date  Description  
0 05th March 2018  GRASPANC  2018 -01 Study Protocol  
(Original)  
1.0 05th September 2019  GRASPANC 2018 -01 Study Protocol 1.0 
(Global Amendment) 
2.0 14th December 2020  GRASPANC 2018 -01 Study Protocol 2.0 
(Global Amendment) 
.
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395336]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 113 of 119 10 REFERENCES  
1. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision 
of the Atlanta classification and definitions by [CONTACT_5757]. Gut 
2012; 62(1):102  
2. GLOBOCAN. Mortality Tables by [CONTACT_320225]. Available from: http://globocan.iarc.fr/Default.aspx  
Accessed: 04 January 2018 2018  
3. Ferlay J, Soerjomataram I, Dikshit R, et al.  Cancer incidence and mortality worldwide: 
sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5):E359-86 doi: 10.1002/ijc.[ZIP_CODE][published Online First: Epub Date]|. 
4. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to  treat? Therap Adv 
Gastroenterol 2013; 6(4):321-37 doi: 10.1177/1756283X13478680[published Online 
First: Epub Date]|.  
5. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow -up. Ann Oncol 2015; [ADDRESS_395337] 5 :v56-68 
doi: 10.1093/annonc/mdv295[published Online First: Epub Date]|. 
6. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit 
with gemcitabine as first -line therapy for patients with advan ced pancreas cancer: a 
randomized trial. J Clin Oncol 1997; 15(6):2403-13 doi: 
10.1200/JCO.1997.15.6.2403[published Online First: Epub Date]|.  
7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic 
pancreatic cancer. N Engl J Med 2011; 364(19):1817-25 doi: 
10.1056/NEJMoa1011923[published Online First: Epub Date]|. 
8. NCCN. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. 
Available from: 
https://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf  Accessed: 16 
January 2018 2017  
9. ESMO. Guidelines Committee eUpdate Published 20 June 2017 Available from: 
http://www.esmo.org/Guidelines/Gastrointestinal- Cancers/Cancer -of-the-Pancreas/eUpdate- Treatment -
Recommendations . Accessed 03 January 2018 2017  
10. Wang- Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and 
folinic acid in metastatic pancreatic cancer after previous gemcitabine -based therapy 
(NAPOLI -1): a global, randomised, open- label, phase 3 trial. Lancet 
2016; 387([ZIP_CODE]):545-57 doi: 10.1016/S0140-6736(15)[ZIP_CODE]-1[published Online First: 
Epub Date]|. 
11. Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C.  Use of 
gemcitabine as a second -line treatment following chemotherapy with folfirinox for 
metastatic pancreatic adenocarcinoma. Oncol Lett 2017; 13(6):4917- 24 doi: 
10.3892/ol.2017.6061[published Online First: Epub Date]|. 
12. Perera RM, Bardeesy N. Pancreat ic Cancer Metabolism: Breaking It Down to Build It Back 
Up. Cancer Discov 2015; 5(12):1247-61 doi: 10.1158/2159-8290.CD-15-0671[published 
Online First: Epub Date]|.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395338]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 114 of 119 13. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers 
revealed by [CONTACT_483]. Science 2008; 321(5897):1801-6 doi: 
10.1126/science.1164368[published Online First: Epub Date]|. 
14. Ji Z, Mei FC, Xie J, Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in 
pancreatic cancer cells. J Biol C hem 2007; 282(19):[ZIP_CODE]-55 doi: 
10.1074/jbc.M611089200[published Online First: Epub Date]|. 
15. Collins MA, Bednar F, Zhang Y, et al. Oncogenic Kras is required for both the initiation and 
maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122(2):639-53 doi: 
10.1172/JCI59227[published Online First: Epub Date]|.  
16. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a 
KRAS -regulated metabolic pathway. Nature 2013; 496(7443):101-5 doi: 
10.1038/nature12040[published Online First: Epub Date]|. 
17. Gaglio D, Metallo CM, Gameiro PA, et al. Oncogenic K- Ras decouples glucose and 
glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011;7:523 doi: 
10.1038/msb.2011.56[published Online First: Epub Date]|. 
18. Hosios AM, Hecht VC, Danai LV, et al. Amino Acids Rather than Glucose Account for the 
Majority of Cell Mass in Proliferating Mammalian Cells. Dev Cell 2016;36 (5):540-9 doi: 
10.1016/j.devcel.2016.02.012[published Online First: Epub Date]|.  
19. Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropi[INVESTIGATOR_320174]- transformed cells. Nature 2013; 497(7451):633-7 doi: 
10.1038/nature12138[published Online First: Epub Date]|. 
20. Shrivastava A, Khan AA, Khurshid M, Kalam MA, Jain SK, Singhal PK. Recent 
developments in L- asparaginase discovery and its potential as anticancer agent. Crit Rev 
Oncol Hematol 2016; 100:1-10 doi: 10.1016/j.critrevonc.2015.01.002[published Online 
First: Epub Date]|.  
21. Cui H, Darmanin S, Natsui saka M, et al. Enhanced expression of asparagine synthetase under 
glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by [CONTACT_320226]. Cancer Res 2007; 67(7):3345-55 doi: 10.1158/0008-
5472.CAN-06-2519[published Online First: Epub Date]|. 
22. Gwinn DM, Lee AG, Briones- Martin -Del-Campo M, et al. Oncogenic KRAS Regulates 
Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase. Cancer Cell 2018; 33(1):91-107 e6 doi: 
10.1016/j.ccell.2017.12.003[published Online First: Epub Date]|. 
23. Ueno T, Ohtawa K, Mitsui K, et al. Cell cycle arrest and apoptosis of leukemia cells induced 
by L- asparaginase. Leukemia 1997; 11(11):1858-61  
24. Miller HK, Balis ME. Glutaminase activity  of L -asparagine amidohydrolase. Biochem 
Pharmacol 1969; 18(9):2225-[ADDRESS_395339]. Biochem Biophys Res Commun 1999; 260(2):534-9 doi: 
10.1006/bbrc.1999.0920[published Online First: Epub Date]|. 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395340]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 115 of 119 26. Wu MC, Arimura GK, Yunis AA. Mechanism of sensitivity of cultured pancreatic carcinoma 
to asparaginase. Int J Cancer 1978; 22(6):728-33  
27. Dufour E, Gay F, Aguera K, et al. Pancreatic tumor sensitivity to plasma L -asparagine 
starvation. Pancreas 2012; 41(6):940-8 doi: 10.1097/MPA.0b013e318247d903[published 
Online First: Epub Date]|.  
28. Lessner HE, Valenstein S, Kaplan R, DeSimone P, Yunis A. Phase II study of L-
asparaginase in the treatment of  pancreatic carcinoma. Cancer Treat Rep 
1980; 64(12):1359-61  
29. Hays JL, Kim G, Walker A, et al. A phase II clinical trial of polyethylene glycol-conjugated 
L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. Mol 
Clin Oncol 2013; 1(3):565-69 doi: 10.3892/mco.2013.99[published Online First: Epub 
Date]|.  
30. Agrawal NR, Bukowski RM, Rybicki LA, Kurtzberg J, Cohen LJ, Hussein MA. A Phase I- II 
trial of polyethylene glycol-conjugated L- asparaginase in patients with multiple 
myeloma . Cancer 2003; 98(1):94 -9 doi: 10.1002/cncr.[ZIP_CODE][published Online First: Epub 
Date]|.  
31. Borad MJ, Babiker HM, Anthony S, et al. A multicenter, open-label, phase [ADDRESS_395341] 2015; 33(5):172-9 doi: 
10.3109/07357907.2015.1019677[published Online First: Epub Date]|. 
32. Domenech C, Thomas X, Chabaud S, et al. l- asparaginase loaded red blood cells in refractory 
or relapsing acute lymphoblastic leukaemia in children and adults: results of the 
GRASPALL 2005 -01 randomized trial. Br J Haematol 2011; 153(1):58-65 doi: 
10.1111/j.1365-2141.2011.[ZIP_CODE].x[published Online First: Epub Date]|. 
33. Ataullakhanov FI, Vitvitskii VM, Zhabotinskii AM, Pi[INVESTIGATOR_320175]. [Permeability of human 
erythrocytes to asparagine]. Biokhimiia 1985; 50(10):1733-7  
34. Bachet JB, Gay F, Marechal R, et al. Asparagine Synthetase Expression and Phase I Study 
With L -Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic 
Adenocarcinoma. Pancreas 2015; 44(7):1141-7 doi: 
10.1097/mpa.0000000000000394[published Online First: Epub Date]|. 
35. Hunault-Berger M, Leguay T, Huguet F, et al. A Phase 2 study of L- asparaginase 
encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL -SA2-2008 study. Am J 
Hematol 2015; 90(9):811-8 doi: 10.1002/ajh.[ZIP_CODE][published Online First: Epub Date]|. 
36. Wang-Gillam A, CP L, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and 
folinic acid in metastatic pancreatic cancer after previous gemcitabine -based therapy 
(NAPOLI -1): A global, randomised, open- label, phase 3 trial. Lancet Journal Translated 
Name [CONTACT_320229] 2016; 387([ZIP_CODE]):545-57 doi: 
http://dx.doi.org/10.1016/S0140 -
6736%2815%2900986 -1[published  Online First: Epub Date]|.  
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395342]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 116 of 119 37. Godfrin Y, Liens D, Andre T, Adenis A, Joly F. L- asparaginase loaded red blood cells (RBC) 
in pancreatic cancer: A phase i clinical study. Pancreas 2011; 40(8):1323 doi: 
http://dx.doi.org/10.1097/MPA.0b013e318232ea83[published  Online First: Epub Date]|. 
38. Delaney M, Taune-Wikman A, Van De Watering LM, et al. Red blood cell transfusion 
antigen matching influence on gestational outcomes (AMIGO) study. Transfusion 
2015; 55:25A  
39. Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and 
treatment. The Lancet 2016; 388([ZIP_CODE]):2825-36 doi: http://dx.doi.org/10.1016/S0140 -
6736(15)[ZIP_CODE] -6[published  Online First: Epub Date]|.  
40. Roselló S, Blasco I, Garc ía Fabregat L, Cervantes A, Jordan K. Management of infusion 
reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines†. Annals of Oncology 2017; 28(suppl_4):iv100-iv18 doi: 10.1093/annonc/mdx216[published Online 
First: Epub Date]|.  
41. Simons FER, Ardusso LRF, Bilò MB, et al. World Allergy Organization Guidelines for the 
Assessment and Management of Anaphylaxis. The World Allergy Organization Journal 2011; 4(2):13 -37 doi: 10.1097/WOX.0b013e318211496c[published Online First: Epub 
Date]|.  
42. 2006 Update of ASCO Practice Guideline Recommendations for the Use of White Blood 
Cell Growth Factors: Guideline Summary. J. Oncol. Pract. Journal Translated Name [CONTACT_320230] 2006; 2(4):196- 201 doi: 
10.1200/jop.2006.2.4.196[published Online First: Epub Date]|. 
43. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and 
Treatment of Cancer QLQ -C30: a quality-of- life instrument for use in intern ational 
clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-76  
44. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 
70:659--663.  
 
ERYTECH Pharma  Amended Protocol GRASPANC [ADDRESS_395343]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page [ADDRESS_395344]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 118 of 119 APPENDIX 2 PERFORMANCE STATUS (ECOG GRADING SCALE)  
Grade  ECOG*  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g. light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up 
and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking 
hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
*ECOG, Robert Comis, MD, Group Chair.  
Reference: Oken MM, Creech RH, Tormey DC et -al. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group. Am. J. Clin. Oncol. 1983;5 (6): 649 -55. 
 
APPENDIX 3 KARNOFSKY PERFORMANCE STATUS  
Definition  Rating  Description  
Able to carry on normal 
activity and to work; no special care needed.  100 Normal ; no complaints; no evidence of disease.  
90 Able to carry on normal activity; minor signs or symptoms 
of disease.  
80 Normal activity with effort; some signs or symptoms of 
disease.  
Unable to work; able to live at 
home and care for most 
personal needs; varying amount of assistance needed.  70 Cares for self; unable to carry on normal activity or to do 
active work.  
[ADDRESS_395345] 
of his personal needs.  
50 Requires considerable assistance and frequent medical 
care.  
Unable to care for self; requires equivalent of institutional or hospi[INVESTIGATOR_10422]; disease may be progressing rapi[INVESTIGATOR_375].  40 Disabled; requires special care and assistance.  
30 Severely disabled; hospi[INVESTIGATOR_320176].  
20 Very sick; hospi[INVESTIGATOR_3115]; active supportive 
treatment necessary.  
10 Moribund; fatal processes progressing rapi[INVESTIGATOR_375].  
[ADDRESS_395346]: Eryaspase  Version 2.0 ( 14th December  2020)  
CONFIDENTIAL AND PROPRIETARY   Page 119 of 119 APPENDIX 4 COVID- 19 RELATED PROTOCOL DEVIATION LOG  
 
